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-LINE ANTITUBERCULOSIS DOSING REGIMENS USING A 
POPULATION PHARMACOKINETIC APPROACH: FOOD EFFECTS, DRUG 
COMBINATIONS AND PHARMACOLOGICAL EFFECTS 
 
Simbarashe Peter Zvada – 2014 
The aim of this thesis was to evaluate optimal doses of 1
st
-line antituberculosis dosing regimens using a 
population pharmacokinetic approach, quantify food effects, drug combinations and pharmacological 
effects. The population pharmacokinetics of rifampicin, isoniazid and pyrazinamide in 76 children with 
tuberculosis were described using a population pharmacokinetic approach, and then Monte Carlo 
simulation were performed to evaluate adequacy of newly recommended weight band based doses in 
World Health Organisation (WHO) guidelines. Food effect (breakfast) was evaluated on rifapentine 
pharmacokinetic data in 35 healthy male volunteers. Effect of co-administered intermittent rifapentine 
on the pharmacokinetics of moxifloxacin was evaluated in 28 patients with pulmonary tuberculosis, 
who participated in a multicenter controlled clinical trial evaluating high dose rifapentine in 
combination with moxifloxacin. The moxifloxacin pharmacokinetic model, together with a previously 
published ofloxacin pharmacokinetic model, was used to evaluate the efficacy between moxifloxacin 
and ofloxacin. Furthermore, pharmacokinetic summary variables of rifapentine and moxifloxacin were 
evaluated as predictors of treatment outcome. 
Simulations based on the final models suggested that with the new guidelines, and utilizing available 
paediatric fixed dose combinations, children will receive adequate rifampicin exposures when 
compared to adults, but with a larger degree of variability. However, pyrazinamide and isoniazid 
exposures in many children will be lower than in adults. For food effect, all meals compared with the 
fasting state, high fat meal had the greatest effect on rifapentine oral bioavailability, increasing it by 
86%; bulky low-fat, bulky-high-fat, and chicken soup resulted in 33%, 46%, and 49% increases in 
rifapentine oral bioavailability, respectively. Similar trends were observed for the metabolite 25-
desacetyl rifapentine. For drug-resistant tuberculosis, using a target ratio of ≥100 for multidrug-resistant 
strains (without resistance to injectable agents or fluoroquinolones), the cumulative fraction of response 
(CFR) was 88% for moxifloxacin and only 43% for ofloxacin. The higher dose of 800 mg moxifloxacin 
was needed to achieve a CFR target of ≥90%. In terms of drug-interaction, rifapentine increased the 
clearance of moxifloxacin by 8% during antituberculosis treatment compared to that after treatment 
completion without rifapentine. Also, the effect moxifloxacin and rifapentine pharmacokinetics indices 
on outcome treatment outcome support that combined effect of longer treatment duration and higher 
rifapentine exposures are associated with better treatment response.  
In summary, the newer WHO doses for children may give lower pyrazinamide and isoniazid exposures 
in many children than in adults. Meals have a substantial impact on rifapentine exposure. Rifapentine 
did not result in a clinically significant change in moxifloxacin exposure.  Moxifloxacin is more 
efficacious than ofloxacin in the treatment of MDR-TB. The combined effect of longer treatment 
duration, higher rifapentine exposures are associated with better treatment outcome, but could not 
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1 INTRODUCTION AND LITERATURE REVIEW 
1.1 Tuberculosis  
Tuberculosis is a contagious, more frequently a chronic disease, caused by 
phenotypically  and genotypically diverse acid-fast tubercle bacillus (Jindani et al. 1980, 
Wayne & Hayes 1996) called Mycobacterium tuberculosis (M.tuberculosis). The disease 
burden is high amongst the poor especially those in Sub-Saharan Africa and across all 
age groups; human immunodeficiency virus (HIV) infection being an important risk 
factor (WHO 2013). Tuberculosis largely affects the lung parenchyma or the 
tracheobronchial tree in about 90% of the cases (Lawn & Zumla 2012), and in South 
Africa about 80% of cases are classified as pulmonary tuberculosis. The most common 
clinical features of active tuberculosis infection include chronic cough, sputum 
production, weight loss, fever, night sweats, and hemoptysis (Lawn & Zumla 2012). The 
recommended methods for M.tuberculosis diagnosis are sputum microscopy and culture 
in liquid or solid medium (solid more cost-effective in resource-limited settings), with 
consequent drug-susceptibility testing (DST), but treatment sometimes has to be started 
without a microbiological confirmation of M.tuberculosis especially in children. 
Treatment of tuberculosis requires administration of multiple antibiotics over a long 
period of time, and is may be complicated by emergence of drug-resistant strains, co-
infection with HIV, and severity of disease in children. Tuberculosis has existed for 





In the history of tuberculosis, pictures of people suffering from the disease were seen in 
Egyptian art and amplification of skeletal remains discovered in Egyptian tombs 
suggests that the disease existed for more 3000-2400 “Before Christ” (years BC) (Haas 
et al. 2000, Zink et al. 2003); making tuberculosis different from other diseases due to its 
long co-existence with humans. Tuberculosis spread to the rest of the world, surged in 
major epidemics and then subsided, similar to other infectious diseases. At that time 
death rates in cities like London, Stockholm, and Hamburg approached 800 - 1000 per 
100 000 population per year (Daniel 2006). A likely explanation for these figures is that 
tuberculosis transmission increased due to increased population density and crowded 
living conditions, while other risk factors, such as poor nutrition, increased the risk of 
progressing from latent to active disease (Lonnroth et al. 2009). In those early years, the 
discovery of the tubercle bacillus in 1882, and the discovery of X-rays by Wilhelm 
Konrad Röntgen in 1895 were two breakthrough events followed by the development of 
the Bacillus Calmette–Guérin vaccine in 1921 in France (Bonah 2005), as well as 
effective medical treatment. In 1923, the British Medical Research Council was 
established mainly focusing on tuberculosis research (Grig 1958). Improvements in 
public health began significantly reducing rates of tuberculosis by 90% even before the 
discovery of streptomycin and other antibiotics for treatment of tuberculosis. Since these 
early years, significant progress has been made with discovery of drugs for treatment of 
tuberculosis, and management of the disease. With this long history, the disease 
continues to be a major pandemic.  
1.1.1 Burden of tuberculosis 
In spite of falling incidence rates of tuberculosis in many countries, the annual incidence 
of tuberculosis remains high. In 2012 there were an estimated 8.6 million incident cases 
of tuberculosis and 1.3 million (320 000 had HIV) deaths from the disease. Among these 
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deaths, were an estimated 170 000 from multi-drug resistant tuberculosis (MDR-TB) 
(WHO 2012a). In children less than 15 years of age, there were an estimated 530 000 
new cases and 74 000 deaths among children who were HIV negative. The estimates of 
tuberculosis morbidity and mortality were estimated to be slightly higher than those 
reported in 2012 (WHO 2013).  
In 2012, it was estimated that there were 310 000 incident cases of MDR-TB. MDR-TB 
occurs when M.tuberculosis organisms became resistant to at least isoniazid and 
rifampin. More than 60% of these patients were in China, India, the Russian Federation, 
Pakistan, and South Africa  (WHO 2012a). A total of 84 countries have reported cases of 
Extensively drug-resistant tuberculosis (XDR-TB) tuberculosis, a subset of MDR-TB 
with added resistance to all fluoroquinolones plus any of the three injectable 
antituberculosis drugs, kanamycin, amikacin, and capreomycin (WHO 2012a).  
Worrying is the case of children, who are often neglected when optimizing therapeutic 
regimens but experience severe forms of tuberculosis. They comprise 10-20% of the 
total cases of tuberculosis in high burden areas (Marais et al. 2006, Walls & Shingadia 
2004). Thus, childhood tuberculosis represents a significant but still neglected clinical 
and public health problem. An additional complication is dissemination of drug 
resistance that may also occur in children,  and which may be facilitated by lack of 
optimised doses of first-line drugs in children (McIlleron et al. 2009, Schaaf et al. 2009b, 
Thee et al. 2008). 
 
1.1.2 Host and pathogen factors affecting disease progression/treatment 




Standards of living and nutrition  
An improved standard of living and nutrition is proposed to be among factors that were 
associated with declining mortality rates due to tuberculosis before chemotherapy was 
available in the mid-19
th
 century (Lonnroth et al. 2009). Improved working conditions 
and socioeconomic factors (Weber 1948), along with improved health care programs 
were among the factors. Also importantly,  ill patients were housed in sanitoria. These 
sanitoria prevented ill patients from spreading tuberculosis to others and the patients 
found them comforting and relieving. The first sanatorium devoted to treatment of 
tuberculosis was built in 1859 by Herman Brehmer, where rest, rich diet and supervised 
exercises was important components of the management of tuberculosis.  
 
Strains of M.tuberculosis 
The M.tuberculosis was first described by Robert Koch on 24 March 1882 (Sakula 
1982). M.tuberculosis is an aerobic, small, non-encapsulated, non-spore forming, and 
nonmotile bacillus characterised by high lipid content which probably results in its 
virulence and intrinsic resistance to antibiotics (Southwick 2007). Also, due to the high 
lipid-rich and mycolic acid content of the cell wall, M.tuberculosis does not retain any 
bacteriological stain hence Ziehl-Neelsen staining, or acid-fast staining, is used. In terms 
of multiplication, the mycobacterium divides at an extremely low rate (every 16-20 
hours) compared with other bacterium like Escherichia coli (every 20 minutes). This 
slow replication rate and ability to persist in a latent state leads to long durations of both 
drug therapies of tuberculosis and for preventive therapy in people with M.tuberculosis 
infection. M.tuberculosis is genetically diverse, and different strains of M.tuberculosis 
are associated with different geographic regions. Even though there are many strains, 
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studies of the phylogeny and biogeography of M.tuberculosis have discovered six main 
strain lineages that are linked with particular geographical regions (Gagneux & Small 
2007). It is speculated that, the Beijing family of strains originated in Asia.  This family 
of strains is distributed worldwide and is able to spread in large clonal clusters. Lineage 
of strains may affect outcomes of treatment of tuberculosis. A recent study in 2013 by 
Reiling et al., identified clade-specific virulence patterns in human primary macrophages 
and in mice infected by the aerosol route. The authors’ analysis identified 3 different 
pathogenic profiles: strains of the East Asian lineage lineage characterized by low 
uptake by macrophages, low cytokine induction, and a high replicative potential; strains 
of the Haarlem lineage by high uptake, high cytokine induction, and high growth rates; 
and East African Indian strains by low uptake, low cytokine induction, and a low 
replicative potential (Reiling et al. 2013). Furthermore, the characteristics of Beijing 
strain could be associated with relapse after treatment. A prospective study conducted 
among 1068 Vietnamese with tuberculosis (23 relapse cases), the Beijing strain was 
significantly associated with relapse (Huyen et al. 2013). These findings support are in 
agreement with a study by Visser et al which identified W-Beijing genotype as a 
moderate baseline predictor for sputum conversion (Visser et al. 2012).  
Immunity, cavitation and smoking 
The main sources of M.tuberculosis are patients with active pulmonary tuberculosis 
(PTB). After infection, progression to active tuberculosis does not immediately occur in 
the majority of immunocompetent people; in 95% of them, the immune system can 
successfully contain the M.tuberculosis but as asymptomatic latent infection (Long & 
Shwartzman 2007). The latent infection may persist in the host for years without 
symptoms or experiencing adverse effects. . However, risk of progression to active 
tuberculosis from latent stage was estimated to be 5% in 18 months from first infection 
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(Andrews et al. 2012). In the approximately 5% of immunocompetent individuals whose 
immune system cannot contain the infection, the probability of developing primary 
disease after infection is also much greater in immunocompromised individuals (Long & 
Shwartzman 2007).  
When M.tuberculosis reaches lungs, mostly by inhalation, it begins to multiply within 
alveolar macrophages. In response, cell-mediated and delayed type hypersensitivity 
immunity is activated by the host if the innate response is not capable of destroying the 
bacterium (Flynn 2006, Long & Shwartzman 2007).. The CD4+ T cells secrete mainly 
interferon-γ capable of inducing macrophages into inducing intracellular killing of 
mycobacteria. Thereafter, inflammatory response includes the formation of granulomas 
by the host immune system that work to limit the spread of infection. In the majority of 
infected individuals, the infection is contained and tuberculosis disease does not develop. 
Screenings for latent infection is therefore indicated in people at high risk, especially 
those living in regions with high disease burden. . The Mantoux tuberculin skin test 
(Escalante 2009) and Interferon gamma release assays (IGRAs) are recommended in 
those who tested positive Mantoux test. Because treatment is based upon diagnosis, it 
should be known that a false-positive Mantoux test can occur in those previously 
immunized while false-negative test may occur in those with malnutrition (Kumar et al. 
2007). 
Once the granuloma is formed, it assumes a solid caseous center surrounded by 
immature macrophages. The caseous material is not favourable for bacterial growth due 
to acidic pH, and low oxygen tension. Even though the mycobacterium cannot multiply, 
it can survive for years in this environment. Liquefaction and cavitation occurs as the 
disease progresses. Immunocompromised individuals and/or infants may be deficient in 
granuloma formation and thus are not efficient at containing the infection. Without the 
7 
 
formation of granulomas to control the bacteria, the infection cannot be contained (Flynn 
2006). Cavitation is a well-known risk factor associated with treatment failure or delayed 
sputum conversion (Telzak et al. 1997, Visser et al. 2012), and relapse (Benator et al. 
2002), possibly due to inability of the drugs to penetrate the cavities. Other factors such 
as high bacillary load, host immunity and bacterial physiology are other plausible 
explanations. Also M.tuberculosis can migrate to other extrapulmonary infection sites 
including the pleura, central nervous system, the lymphatic system, the genitourinary 
system, the bones and joints. In these areas, successful treatment may be limited by the 
ability of the drugs to penetrate to the infected sites. Failure of drugs to infiltrate to 
affected areas especially necrotic lesions may possibly result in localised monotherapy 
and emergency of drug resistance. 
Even though some studies show smoking as a risk factor to lack of sputum culture 
conversion, these findings are still conflicting. A study by Slama et al., failed to find 
sufficient evidence to support an association of smoking and delay, default, slower 
smear conversion, greater severity of disease or drug-resistant TB or of second-hand 
tobacco smoke exposure and infection (Slama et al. 2007). But a recent reported that, 
ever smokers had longer time-to-culture conversion than those who never smoked 
(Visser et al. 2012). Also, smokers have been shown to have cavitary more lesions, 
compared with non-smokers (Altet-Gômez et al. 2005). However, further studies may be 
needed to evaluate the relationship between smoking and time-to-culture conversion. 
Genetic variability of human leukocyte antigen 
Other contributors to susceptibility include polymorphisms in genes including human 
leukocyte antigen (HLA) alleles and other non-major histocompatibility complex genes 
(Yim & Selvaraj 2010). These polymorphisms may provide genetic markers to predict 
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an individual’s vulnerability to the development of tuberculosis. Work on genetic 
variability in relation to tuberculosis noted that immunological adaptations, specifically 
different forms of T-cell immune responses, in addition to socioeconomic factors may 
influence susceptibility to tuberculosis (Larcombe et al. 2005).  
Vitamin D deficiency 
There is growing interest in the link between susceptibility to tuberculosis and vitamin D 
deficiency; this has multiple effects on the immune system (Wang et al. 2004) including 
macrophage activation and induction of the antimycobacterial peptide LL37 (Martineau 
et al. 2011). A randomised clinical trial demonstrated that vitamin D supplementation 
was associated with more rapid sputum-culture conversion (from positive to negative) in 
a subset of individuals with specific vitamin D receptor polymorphisms even though 
further clinical trials of vitamin D supplementation in the treatment and prevention of 
tuberculosis are warranted (Martineau et al. 2011).  
 
Diagnosis of tuberculosis in resource-limited countries 
Importantly, in resource-constrained settings where there is a high burden of tuberculosis 
and HIV, an estimated 30% of all patients with tuberculosis and more than 90% of those 
with multidrug-resistant and extensively drug-resistant tuberculosis do not receive a 
diagnosis (WHO 2012b), which severely impacts on timely intervention with 
chemotherapy. Even though the new molecular diagnostic test called Xpert MTB/RIF 
has been developed, it is not readily available in resource limited countries. The Xpert In 
children, diagnosis often starts after presenting with signs and symptoms, with the 
likelihood of exposure at the forefront of predictive value of subsequent investigations. 
9 
 
Even though microscopical examination of sputum smears is the cornerstone of 
diagnosis in most countries, the paucibacillary nature of the disease disrupts its 
usefulness  in young children due to low expectorant capability, albeit gastric aspiration 
and sputum induction can improve diagnostic yield (Nicol & Zar 2011).  
1.2 Treatment of tuberculosis  
Treatment of tuberculosis and emergence of drug-resistant strains dates back to 1940s 
after the discovery of streptomycin by Albert Schatz (Schatz et al. 1944). Streptomycin 
was administered as monotherapy and resulted in a dramatic decrease in mortality (MRC 
1948). However, 5 years later it was increasingly evident that M.tuberculosis became 
resistant to streptomycin as patients on monotherapy died in similar proportions to those 
not on treatment (Fox et al. 1954), and combination with para-aminosalicylic acid (PAS) 
significantly reduced the emergence of streptomycin resistance (Fox et al. 1954). A year 
after the discovery of PAS, isoniazid emerged as a better drug due to tolerability in 
humans and low minimum inhibitory concentration. Therapy with streptomycin, PAS, 
and isoniazid prevented the selection of streptomycin-resistant mutants and resulted in 
the cure of patients with 18 months of treatment. During those times, the exploration of 
isoniazid monotherapy or combination with streptomycin and/or PAS continued, and led 
to the widely acceptable regimen of first 3 months streptomycin, PAS and isoniazid 
followed by 9 months of PAS and isoniazid. However, the regimen was only available in 
Europe due to the cost of PAS (Lonnroth et al. 2010). 
The issue of cutting treatment expenses in hospitals come to light in 1960 after a study 
under the direction of Fox which showed that domiciliary chemotherapy could be as 
effective as treatment in expensive hospitals or sanatoria (Andrews et al. 1960). The 
study resulted in finding ways to ensure regular drug taking during a year of domiciliary 
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treatment and led to establishment of the DOTS (Directly Observed Therapy Short 
course) strategy by WHO in 1995, DOTS was subsequently updated by the with the 
formulation of the Stop TB strategy (Lonnroth et al. 2010). Beginning in the 1970s, 
combination therapy with streptomycin, isoniazid, and PAS was progressively replaced 
by combinations that included isoniazid, rifampin, pyrazinamide, and ethambutol. 
Rifamycins and pyrazinamide played an important role in reducing the duration of 
treatment to 6 months. A remarkable number of well-controlled randomized clinical 
trials established the efficacy of “short-course” treatment regimens utilizing these agents 
(Fox et al. 1999). These short-course regimens are able to cure multibacillary forms of 
active tuberculosis after 6 months of administration and have become the standard of 
care throughout the world. This classical therapy for pulmonary tuberculosis consists of 
rifampicin, isoniazid, pyrazinamide and ethambutol for 2 months followed by a 
continuation phase of rifampicin and isoniazid. When adequately administered, the 
standard regimens are capable of relapse-free cure rates of 95% or more in patients with 
drug sensitive organisms (Fox et al. 1999, Jindani et al. 2004). Shortening the duration 
of tuberculosis  treatment or administering therapy intermittently (i.e., once weekly or 
even less frequently) without lowering efficacy is a plausible option in reducing the 
burden of supervised drug therapy and could improve treatment success. In the context 
of the HIV epidemic and emergency of drug resistance, new drugs and novel strategies 
to complement current efforts are desirable.   
1.2.1 Drug resistant tuberculosis 
Due to the limited number of randomized controlled clinical trials, the treatment of 
MDR-TB, on top of using data from large observational studies, is also based on expert 
opinion and requires the creation of combination drug regimens which are very costly 
and prolonged. However, successful outcomes for MDR-TB are achievable in about 
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two-thirds of patients, though for XDR-TB the outcomes are very heterogeneous 
(Orenstein et al. 2009). In most parts of the world, access to such therapy is very poor, 
with less than 2% of patients with MDR-TB worldwide treated according to WHO 
standards (WHO 2009). As part of treatment of MDR-TB, a fluoroquinolone (e.g., 
moxifloxacin) and an injectable agent (e.g., kanamycin or capreomycin) should routinely 
be included to provide a regimen with at least four second-line drugs that will have 
certain or nearly certain effectiveness, as well as pyrazinamide. Such therapy should be 
administered for at least 20 months in patients who have not received previous treatment 
for MDR-TB and for up to 30 months in those who have received previous treatment. 
Encouragingly, an observational study showed that a shorter regimen, with treatment 
given for 9 to 12 months (the so-called Bangladesh regimen), had acceptable efficacy 
with fewer adverse reactions (Van Deun et al. 2004) in a population with no previous 
exposure to second-line drugs. However, MDR-TB remains a cause of concerns leading 
to development of new drugs, development and optimization of novel regimens, and 
other therapeutic alternatives.  
1.2.2 Novel regimens in the treatment of tuberculosis   
Faced with these treatment option challenges, future successes in the control of 
tuberculosis will depend on the development of novel treatment strategies with regimens 
that are shorter, easier to deliver, safe, easy to monitor and low in cost. After decades of 
neglect, ten new drugs for the treatment of tuberculosis are in the clinical development 
pipeline of which six are being specifically developed for tuberculosis (Figure 1.1).  
The Novel regimens for the treatment of tuberculosis are aiming at reducing the duration 
of standard therapy from 6 months but without compromising the efficacy of the drugs.. 
Clinical trials involving rifapentine conducted in humans indicate that higher doses of 
rifapentine may be beneficial in preventing rifamycin resistance, and this is supported by 
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in vitro studies of rifamycin activity (Gumbo et al. 2007a). The trials demonstrated that 
in patients with HIV infection, severe or advanced tuberculosis (as evidenced by 
cavitations on chest x-ray), once weekly rifapentine plus isoniazid, at the currently used 
standard dosage of 600 mg (Blumberg et al. 2003), was inferior to the thrice-weekly 
rifampicin comparator (Benator et al. 2002, Tam et al. 2002). 
 
 
Figure 1.1: Illustration of time points at which drugs were developed and stages of those 
in developmental pipeline (adapted from Wong AB et al (Wong et al. 2013) 
 
In a study conducted in the United States of America (USA), emergence of acquired 
rifamycin monoresistance (ARR) was reported in four out of 5 HIV sero-positive 
patients who relapsed. The highly protein-bound nature of rifampicin (97%) is assumed 
to have played a role in relapse or failure since low unbound drug levels will be 
available for bactericidal activity (Mitchison 1998, Sirgel et al. 2005).  Low unbound 
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concentrations of rifapentine were thought to have led to a small pulse size and to the re-
growth of bacilli during the interval between doses when active levels are very low.   
Despite the fact that no association between low isoniazid concentration and failure rate 
was found in the Hong-Kong study (Tam et al. 1998), in Center for Disease Control 
(CDC) Study 22 (Weiner et al. 2005) where patients were on regimen of once weekly 
RFP plus isoniazid, an association was found between low isoniazid plasma 
concentrations and the occurrence of relapse suggesting that isoniazid might have been 
ineffective in preventing rifamycin resistance. Moxifloxacin which has demonstrated 
potent bactericidal and sterilizing activity in vitro and in mouse models (Ji et al. 1998, 
Yoshimatsu et al. 2002) could be a better potential companion drug for rifapentine 
regimen. Moxifloxacin has a long serum half-life (9-12 hours) in humans (Siefert et al. 
1999) giving a longer duration of drug activity and ultimately reduction in frequency of 
drug administration matching very well with rifapentine.  In support of moxifloxacin as 
a potential companion to rifapentine, a mouse study has led to the suggestion that the 
efficacy of the once weekly isoniazid plus rifapentine in the continuation phase can be 
increased by substituting moxifloxacin for isoniazid and by increasing the dose size of 
rifapentine to 15 mg/kg (Lounis et al. 2001).  
 
1.3 Pharmacology of drugs for treatment of tuberculosis 
The activity of anti-tuberculosis drugs either in combination or alone during the first 14 
days of treatment were widely studied by Jindani et al (Jindani et al. 1980, 2003). These 
early bactericidal (EBA) studies take into account the viable bacterium content of the 
sputum. Even with EBA studies extended to 14 days, their role in predicting treatment 
shortening potential is unclear. Another improvement in describing EBA results was 
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inclusion of calculation of the therapeutic margin, defined as the ratio between 
therapeutic dose and minimum effective dose (MED) correspondingly for each drug. 
The MED is determined as the lowest dose that failed to produce a kill, and for isoniazid 
the MED is 15 giving a therapeutic margin of 20 when a dose of 300 mg is given 
(Donald et al. 1997).  
 
1.3.1 Mechanism of action for drugs used for the treatment of tuberculosis   
The mechanism of action of rifampicin and rifapentine is through binding to and 
inhibition of the deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) 
polymerase beta  subunit (rpoB), thus preventing formation of new proteins (Wehrli 
1983). Therefore mutation in rpoB results in resistance to rifampicin. In terms of 
activity, rifampicin has a low therapeutic margin of only 4 (Sirgel et al. 2005) at the 
standard dose of 10 mg/kg presumably due to highly protein bound nature of rifampicin 
resulting in 20% unbound concentrations in lesions (Acocella 1978). Rifampicin gave an 
average rate of decline in the count of bacteria per mL of sputum per day of 0.17 log10 
colony-forming units (CFU) in the first two days when administered at standard doses 
(Jindani et al. 2003).. Isoniazid is important for actively diving bacteria (Jindani et al. 
2003). Nonetheless, rifampicin is an important drug throughout the entire course of 
treatment. Rifampicin is a key sterilizing drug and is important for shortening the 
duration of treatment.  
 
Importantly, complete sterilization takes 6 months for tuberculosis lesions in the lungs of 
patients, an occurrence which has been attributed to the presence of slowly replicating 
bacteria (persisters) particularly those in the stationary phase of growth (Mitchison & 
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Selkon 1956). Peak serum concentrations of rifampicin may be important in the 
sterilization of these persisters (Mitchison 2012). Only in vitro, persisters were reported 
to go through the non-replicating phases, nrp1 and nrp2, lasting approximately 3 weeks, 
when they acquire tolerance to isoniazid and minimally to rifampicin (Wayne & Hayes 
1996). Following further incubation for about 3 months, they become the bacilli of the 
Hu/Coates model (Hu et al. 2000) with a failure to grow on solid media and marked 
antibiotic tolerance.  
Bacilli which fail to grow on solid media are killed rapidly by pyrazinamide (Hu et al. 
2006).  There are different theories with regards to how pyrazinamide or pyrazinoic acid 
(pyrazinamide’s active moiety) exerts bacterial activity. Pyrazinamide is deaminated to 
pyrazinoic acid by the M.tuberculosis amidases-encoded by the pncA gene (Zhang & 
Mitchison 2003). Hence mutations in pncA result in drug resistant to pyrazinamide 
(Sreevatsan et al. 1997). Pyrazinoic acid is reabsorbed by passive diffusion (not 
requiring energy) in a highly pH-dependent manner once it reaches the exterior of 
bacilli. Pyrazinoic acid then accumulates inside the bacilli due to inefficient energy 
requiring efflux pump, acidifying the interior, and membrane damage or inhibition of 
trans-translation in persisting cells is probably how it kills the bacilli (Shi et al. 2011). 
With this mechanism, pyrazinamide is particularly effective in killing dormant bacilli.  
Isoniazid is most important for rapidly dividing bacilli. Isoniazid is activated to 
isonicotinyl-NAD by the bacterial catalase-peroxidase (katG). The activated Isoniazid 
irreversibly binds and inhibits the bacterial enoyl-acyl carrier protein reductase (inhA). 
inhA is the key bacterial enzyme responsible for fatty acid synthesis and production of 
cell wall mycolic acid (Lei et al. 2000). Resistance usually arises by mutation in katG 
most commonly at S315T, which confers partial loss of isoniazid activation and is 
associated with high-levels of resistance; whereas inhA  mutations lead to target 
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alteration in the gene product and altered affinity for isoniazid-NAD adducts (Almeida 
Da Silva & Palomino 2011, Warren et al. 2009). Unlike rifampicin, isoniazid has a high 
therapeutic margin of 20 (Donald et al. 1997), but has much slower action against non-
multiplying cells. From EBA studies, a typical curve in the log CFU counts is obtained 
which starts with a rapid fall and then levels off as an exponential kill from about day 7 
(Brindle et al. 2001). An alternative explanation for little or no activity of isoniazid 
could be selection or physiological changes in the baseline populations. The initial rapid 
part of the kill could be due to the action of isoniazid on an initially multiplying part of 
the bacterial population.  
The general mechanism of action of action of moxifloxacin on M.tuberculosis is 
inhibition of bacterial DNA gyrase (topoisomerase IV), which is essential for bacterial 
DNA replication and growth (Sato et al. 1986)(Sato et al. 1986). Resistance to 
fluoroquinolones is a result of mutations in the genes encoding for the DNA gyrase 
subunits A and B (gyrA and gyrB), particularly gyrA (Kocagoz et al. 1996). The best 
predictor of in vivo efficacy for this class of drugs is the area under curve 
(AUC/minimum inhibitory concentration (MIC) (Shandil et al. 2007). Several studies 
have shown that the optimal kill rates and low probability of development of resistance 
will occur when the AUC/MIC ratio for the fluoroquinolones is at least 100  (Ginsburg 
et al. 2003, Schentag et al. 2003a,b). The EBA of an 800 mg dose ofloxacin is reported 
to be about half that of a 300 mg dose of isoniazid (Sirgel et al. 2000).  Among 
fluoroquinolones, ofloxacin has been widely used in developing countries, and the use of 
moxifloxacin as a replacement is advised. Ofloxacin is known to be less potent than the 
other fluoroquinolones used for the treatment of tuberculosis both in vitro and in vivo 
(Hu et al. 2003, Rustomjee et al. 2008). In 2012, Chigutsa et al., demonstrated that 
ofloxacin might be ineffective even with doubled dose to 1600 mg daily (Chigutsa et al. 
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2012). Based on in vitro potency, it has been demonstrated that moxifloxacin  was more 
bactericidal against slowly growing bacilli and also had sterilizing activity against 
persisters that are tolerant of high rifampin concentrations (Hu et al. 2003), hence 
moxifloxacin might be superior to gatifloxacin. Moreover, levofloxacin is more 
promising among fluoroquinolones, its activity has been shown to be slightly lower than 
moxifloxacin (Ahmad et al. 2013), making moxifloxacin and levofloxacin as attractive 
candidates.  
 
1.3.2 Pharmacokinetics of drugs for the treatment of tuberculosis 
 
Rifampicin pharmacokinetics are influenced by polymorphisms in drug transporting 
enzymes (Chigutsa et al. 2011) and autoinduction of rifampicin systemic metabolism 
(Strolin Benedetti & Dostert 1994). Rifampicin induces the  majority of phase I and 
phase II drug metabolising enzymes and drug transporters such as p-glycoprotein (P-gp) 
through binding to and subsequent activation of the constitutive androstane receptor 
(CAR) and pregnane X receptor (PXR) (Chen & Raymond 2006, Rae et al. 2001), also 
inducing its own metabolism. The bioavailability of rifampicin has been reported to be 
93% after single administration of rifampicin but with chronic administration the 
bioavailability reduces to only 68% (Loos et al. 1985), which is a clear indication of 
autoinduction of first-pass metabolism as was described by (Smythe et al. 2012). Smythe 
et al. study determined that it takes 40 days for the autoinduction of rifampicin to reach 
its steady-state and causing more than 40% reduction in AUC (Smythe et al. 2012).  In 
vitro experiments using human hepatocytes determined that rifampicin has the highest 




Rifampicin pharmacokinetics is marked by high between subject variability (Wilkins et 
al. 2008), influenced by factors like age, weight, HIV infection, and nutrition, 
polymorphisms in drugs transporters, food, sex (detailed under section 1.3.3: Factors 
influencing drug pharmacokinetics). The absorption of rifampicin was reported to be 
quite variable (Wilkins et al. 2008) with two subgroups of  ‘fast absorbers’ and ‘slow 
absorbers’ reported previously (Peloquin et al. 1997). Rifampicin is rapidly absorbed 
with maximum time (Tmax) to reach peak concentrations (Cmax) within 2-3 hours 
(Table 1.1). In humans, rifampicin is about 80% bound mainly to albumin, and 
distributes well throughout the body and body fluids (Acocella 1978). About 50% of the 
rifampicin dose is eliminated unchanged through biliary, whilst the other 50% is found 
in the urine as a combination of unchanged drug (10%) and metabolites. Rifampicin is 
metabolized by arylacetamide deacetylase, AADAC (Nakajima et al. 2011), and its main 
metabolite is 25-desacety rifampicin, which is active against M.tuberculosis. The 
expected half-life, Cmax and area under concentration-time curve (AUC) are 
summarized in Table 1.1. Rifampicin elimination is dose-dependent. At doses higher 
than 450 mg daily, there is decreased elimination of rifampicin (Acocella 1978), which 
could be attributed to saturation of the biliary transport mechanisms (Acocella 1983). 
Also, sex difference has been shown to alter pharmacokinetics of rifampicin, males had 
19.3% (95% CI, 3.6, 35.1) lower AUC0-12 than females (McIlleron et al. 2012).  
 
The pharmacokinetics of rifapentine is similar and also different from that of rifampicin 
and some of the factors influencing its pharmacokinetics gave opposite effects when 
compared with rifampicin. Rifapentine pharmacokinetics is influenced by age, weight, 
HIV infection, and nutrition, polymorphisms in drugs transporters, food, and sex . 
Rifapentine is well absorbed and less rapid than rifampicin with Tmax reached within 5 
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h (Langdon et al. 2004).  The relative bioavailability reported after oral administration is 
70%. Rifapentine has a longer half-life than rifampicin, which is approximately 12 hours 
in humans (Burman et al. 2001, Keung et al. 1999). The primary metabolic pathways for 
rifapentine are deacetylation and nonenzymatic hydrolysis forming a main primary 
enzymatic metabolite, 25-desacetyl rifapentine, and two secondary nonenzymatic 
metabolites, 3-formyl rifapentine and 3-formyldesacetyl rifapentine (Reith et al. 1998). 
Protein binding of rifapentine was estimated to be 98% (mainly to albumin) and 93% for 
25-desacetyl rifapentine (Sirgel et al. 2005, Weiner et al. 2004). Even though  rifampicin 
has higher induction potential in vitro (Li et al. 1997), at clinically relevant doses 
encountered routinely, rifapentine had a higher induction potential on cytochrome P450 
subfamily 3A (CYP3A)  (Bliven-Sizemore et al. 2011). The autoinduction effect of 
rifapentine has been described, with the mean AUC0-48 after seven thrice-weekly doses 
decreased by 20.3% (p = 0.0035) compared to the AUC0-48 after the first dose, and the 
mean t1/2 decreased from 18.5 to 14.8 h (p = 0.0004). The mean AUC0-48 for the 25-
desacetyl-rifapentine metabolite diminished by 21% (Dooley et al. 2008).  
 
Pyrazinamide is rapidly absorbed following oral administration with Tmax reached with 
1 h (Table 1.2). The pharmacokinetics of pyrazinamide have been shown to be less 
variable than that for the other first-line drugs (McIlleron et al. 2006). Pyrazinamide is 
reported to have an oral clearance of about 3.4 L/h and a volume of distribution of about 
29 L (Wilkins et al. 2006) with relatively low protein binding of 10-20%. It is mainly 
eliminated through metabolism to pyrazinoic acid by a hepatic microsomal deamidase 
(Lacroix et al. 1989). Pyrazinoic acid is further metabolised to 5-hydroxy-pyrazinoic 
acid by xanthine oxidase (Lacroix et al. 1989). The main metabolite of pyrazinamide is 
pyrazinoic acid which is about 30% of the dose, whilst other metabolites and unchanged 
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drug account for the rest of its elimination from the body (Ellard 1969). Table 1.2 
summarises different studies and expected half-life and exposures of pyrazinamide. 
Pyrazinamide pharmacokinetics is marked by high between subject variability (Wilkins 
et al. 2006). Similar to rifampicin, males on pyrazinamide had 14.0% (95% CI, 5.6, 
22.4) lower AUC0-12 than females (McIlleron et al. 2012).  
 
Isoniazid pharmacokinetics is very variable with the major source of variability between 
subjects being contributed by NAT-2 genetic polymorphism (McIlleron et al. 2009). 
Isoniazid is rapidly absorbed with a Tmax of about 1 h (Peloquin et al. 1997) and 
distributes well into tissues. Table 1.3 summarises some of the recent studies where 
Cmax and AUC were reported for isoniazid. Isoniazid undergoes first pass metabolism 
in the liver and intestines (Back & Rogers 1987) which has been shown to occur to a 
greater extent in fast than in slow acetylators, thus giving rise to differences in 
bioavailability between the 2 subpopulations; hence slow acetylators have higher Cmax 
compared with fast acetylators (Peloquin et al. 1997). With a dose of 5 mg/kg/day, peak 
serum concentrations of 3-5 mg/L were observed in humans (Weber & Hein 1979). The 
half-life of isoniazid in South African tuberculosis patients has been reported to be 2.8 
hours (McIlleron et al. 2006) although up to 8 fold differences between patients has been 
observed.  
 
Moxifloxacin is rapidly absorbed and the major fraction of the dose reaches the systemic 
circulation within 2 h (Dooley et al. 2008, Siefert et al. 1999). It has a long half-life of 9-
12 hours in humans  (Dooley et al. 2008, Siefert et al. 1999) with moderate renal 
excretion of 6-20% of total elimination after intravenous administration (Siefert et al. 
1999). Moxifloxacin is widely distributed throughout the body, with tissue 
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concentrations often exceeding plasma concentrations. Moxifloxacin is a not substrate of 
cytochrome P450 enzyme but of the inducible drug-transporter p-glycoprotein (P-gp) , 
recently named ABCB1 (Brillault et al. 2009), sulfotransferases (Senggunprai et al. 
2009), and glucuronyltransferases (Tachibana et al. 2005). The pharmacokinetics of 
moxifloxacin are influenced by rifamycins (due to induction of metabolising enzymes) 
resulting in low exposures (Dooley et al. 2008). The sulfate conjugate (M1) accounts for 
approximately 38% of the dose, and is eliminated primarily in the faeces. Approximately 
14% of an oral or intravenous dose is converted to a glucuronide conjugate, which is 
excreted exclusively in the urine. Peak plasma concentrations of glucuronide conjugate 
are close to 40% those of the parent drug, while plasma concentrations of sulfate 
conjugate are generally less than 10% those of moxifloxacin.  
 
Ofloxacin is rapidly absorbed with peak concentrations reached within 2 h and with a 
half-life of 6 h, which is comparable between healthy volunteers (Yuk et al. 1991) and 
patients (Belousov et al. 1996). The primary route of elimination of ofloxacin is renal 
with only 4% being metabolized (Lode et al. 1987)  (Lode et al. 1987). Ofloxacin has 
been shown to have linear pharmacokinetics with concentrations reported to increase 
linearly with dose, but elimination of ofloxacin decreases with declining renal function 




Table 1.1:  Rifampicin pharmacokinetics (since year 2000) in adults with tuberculosis including those who are HIV positive (HIV+), where  













10.5 (6.9, 14.1) 13 2.4 (1.7, 3.1) 7.2 (5.5, 8.9) 33.0 (26.7, 39.4) (Gurumurth




10.7 (7.3, 19.6) 15 (HIV+) 3.6 (2.7, 4.5) 3.4 (2.7, 4) 16.5 (12.4, 20.6) 
9.6 (6.6, 14.7) 34  5.6 (2.0, 10.0) 5.5 (1.1, 11.2) 17.0 (3.7, 47.7) (Perlman et 
al. 2005)
c
 8.7 (6.1, 15.2) 21 (HIV+) 2.2 (2.0, 8.0) 5.44 (2.2, 14.0) 22.3 (4.6, 49.1)) 
10 58 (HIV+) 2.0 (1.8, 6.3) 5.6 (0, 13.7) 24.0 (7.0, 52.4) (Tappero et 
al. 2005)
d
 10 28  2.0 (1.8, 6.1) 6.0 (2.2, 14.6) 21.7 (7.1, 52.9) 
3 8 2.8 (±0.5) 1.5 (±0.4) 7.8 (±1.6) (Sirgel et 
al. 2005)
e
 6 8 3.4 (±0.5) 2.9 (±0.5) 15.5 (±2.6) 
12 8 2.1 (±0.6) 9.5 (±1.8) 65.2 (±9.6) 






 Sample size Median age 
(years) 
    
9.6 (±2.3) 21 
(HIV+) 




9.6 (±2.3) 33  4.05 1.7 (±0.9) 6.9 (±5.9) 18.1 (±12.5) 
Tmax, time to reach peak plasma concentrations. 
a
Area under concentration-time curve (AUC) and peak plasma concentration (Cmax) reported as median  
(interquartile range), mean (±standard deviation). 
b
AUC until 8-h time point.  
c
AUC calculated using 2-6 h concentrations. 
d
AUC until 6-h time point. 
 
e









Table 1.2: Pyrazinamide pharmacokinetics (since year 2000) in adults with tuberculosis including those who are HIV positive (HIV+), where  













 24 (HIV+) 2.7(±1.5) 52.8 (±17.6) 328  
(±92) 
30 or 50 59 (HIV+) 2.0 (2, 6.3) 48.7 (35.6, 
118.8) 
219 (156, 519) (Tappero et al. 2005)
c
 
30 or 50 28  2.0 (1.8, 6.3) 55.5 (36.7, 78.9) 241 (156, 372) 





 Sample size age (years)     




35.0 12 >5 3.3 47.9 (±17.7) 416 (±333) 
25 20 5 - 12 1.7 (0.2) 42.4 (±3.3) 453 (±67) (Gupta et al. 2008)
c
 
15 20 5 - 12 1.8 (0.1) 38.6 (±3.9) 385 (±43) 




Tmax, time to reach peak plasma concentrations. 
a
Area under concentration-time curve (AUC) and peak plasma concentration (Cmax) reported as  
median (interquartile range), or mean (±standard deviation). 
a




AUC until 6-h time point.   
d
AUC until 8-h time point. 
e







Table 1.3: Isoniazid pharmacokinetics (since year 2000) in adults and children with tuberculosis including those who are HIV positive (HIV+) 











 8 12.9 (10.6, 15.2) 61.1 (50.0, 72.3)  
(Gurumurthy et al. 2004b) 14.3 (9.7, 26.1)
a
 7 (HIV+) 10.1 (8.3, 11.8) 52.4 (44.9, 59.8) 
14.0 (9.2, 18.8)
b
 5 11.0 (7.6, 14.3)  39.0 (23.7, 54.4) 
14.0 (9.2, 18.8)
b
 8 (HIV+) 7.0 (5.5, 8.6) 22.9 (17.8, 28.0) 




 Sample size age (years)    
<4 7 1.27 (0.41, 5.1) 0.76 (0.69, 2.24) 2.93 (1.56, 7.2) (McIlleron et al. 2009)
f
 
4 - 6 30 3.58 (1.97, 5.51) 2.39 (1.59, 3.4) 5.97 (4.0, 9.39) 
>6 to <8 2 7.0 (2.04, 11.97) 5.85 (5.7, 6.0) 11.7 (11.0, 12.4) 
8 -12 15 4.07 (1.91, 6.43) 5.71 (4.74, 7.62) 14.1 (9.4, 28.4) 
5.01 (4.35, 9.24)
a
 20  4.05 (2.72, 5.74) 10.6 (8.7, 16.1) 
5.01 (4.35, 9.24)
c
 24  2.63 (1.6, 5.3) 6.5 (4.2, 13.3) 
5.01 (4.35, 9.24)
b
 8  1.54 (1.2, 4.1) 2.3 (1.8, 6.1) 
>12 2 0.81 (0.61, 1.01) 6.46 (5.92, 6.99) 19.74  
9.4 (6.9, 12.5) 17 1.0 - 3.0 3.3 (2.4, 4.6) 14.9 (7.2, 19.5) (Ramachandran et al. 2013)
e
 
10.1 (8.6, 11.4) 22 3.1 - 6.0 6.1 (3.1, 8.4) 26.7 (12.5, 40.7) 
10 (8.8, 10.7) 23 6.1- 9.0 6.3 (4.4, 9.0) 21.9 (15.0, 28.8) 








Area under concentration-time curve (AUC) and peak plasma concentration (Cmax) reported as median 
(interquartile range). 
e






1.3.3 Factors influencing drug pharmacokinetics 
Cure rates of more than 85% were reportedly achieved when rifampicin, isoniazid and 
pyrazinamide are administered optimally in adults (Fox et al. 1999, Jindani et al. 2004). 
Children still face the challenge of low exposures of rifampicin, pyrazinamide and 
isoniazid when compared to adults after standard doses (mg/kg), and children experience 
severe form of tuberculosis compared with adults. Recent systematic reviews on 
rifampicin (Donald et al. 2011) and pyrazinamide (Donald et al. 2012) have shown that 
the serum levels of rifampicin are low in patient infected with M.tuberculosis and 
children having the lowest concentrations when they receive similar mg/kg doses (Table 
1.1) when compared to health volunteers; although generally similar exposures are 
achieved in both adults and children with tuberculosis receiving similar mg/kg doses of 
pyrazinamide (Table 1.2).  Several factors such as HIV co-infection, weight, sex, 
formulation, age, pharmacogenetic and nutritional status influence the pharmacokinetics 
of anti-TB drugs and they needs to account for when describing the pharmacokinetics 
and pharmacodynamics of drugs. 
HIV infection 
The impact of HIV and consequently immune suppression has been shown to influence 
the pharmacokinetics of drugs in patients co-infected with tuberculosis  (Gurumurthy et 
al. 2004a).. Reductions in rifampin bioavailability of ranging from 32 to 50% have been 
ascribed to HIV infection (Chideya et al. 2009, Gurumurthy et al. 2004a, McIlleron et al. 
2006). However, since other studies found no effect of HIV status, this effect could be 
related to WHO stage, CD4 count and antiretroviral drugs used in the cohorts.  
Pyrazinamide concentrations may also be reduced among subjects with HIV, and similar 
trends have been described for isoniazid in association with diarrhea (Gurumurthy et al. 
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2004a). Decreased bioavailability of these drugs is thought to be linked to more 
extensive malabsorption due to HIV-mediated enteropathy and increased susceptibility 
to enteric infections.   
Other studies evaluating the effect of HIV infection were conducted following 
intermittent dosing. In general, intermittent dosing of anti-TB drugs is not recommended 
in patients with HIV co-infection, but studies have been conducted when intermittent 
short course regimens were administered and have shown that high mortalities and 
failures occur in people co-infected with HIV (Havlir & Barnes 1999). Poor treatment 
outcomes have been reported in children with tuberculosis in areas highly burdened with 
HIV, and HIV being the most import risk factor (Rekha & Swaminathan 2007). When 
rifampicin has been dosed daily for at least 6 months, better treatment outcomes were 
reportedly achieved in patient with tuberculosis (Khan et al. 2010). Other contrary 
reports have shown no effect of HIV on the pharmacokinetics of anti-tuberculosis drugs 
(Gurumurthy et al. 2004a). In South African children infected with both HIV and 
M.tuberculosis, low rifampicin levels have been reported in children irrespective of HIV 
status. The respective AUC0-6 (standard deviation) for rifampicin were 14.9 (7.4) and 
18.1 (12.5) mgh/L for HIV infected and HIV negative children with tuberculosis 
(Schaaf et al. 2009a). Similarly, in a study conducted in Malawi, pyrazinamide AUC0-24 
were not comparable between children with tuberculosis only and those infected with 
both HIV and tuberculosis, the respective  AUC (standard deviation) for rifampicin were 
411 (382) and 322 (240) mgh/L for HIV infected and HIV negative children with 
tuberculosis (Graham et al. 2006a). For rifapentine, studies of differences in 
pharmacokinetic parameters of in HIV-positive and -negative individuals have produced 
mixed results, with some groups showing significant differences (Peloquin et al. 1996) 
and others finding no clinically significant effect (Choudhri et al. 1997). A study 
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conducted in South Africa (Langdon et al. 2004) showed good absorption of rifapentine 
and no differences in pharmacokinetic parameters when compared to HIV-negative 
patients. Sex was not found to influence the pharmacokinetics of rifapentine (Reith et al. 
1998). Conversely, a study conducted in South Africa showed that females had low 
clearance of rifapentine, and  there was a good correlation between rifapentine 
pharmacokinetics and total body weight (Langdon et al. 2005); given that females in the 
study had generally lower body weight, the sex effect possible was not independent of 
body weight 
Dosage form  
Drug formulation plays an important role in the pharmacokinetics of drugs. A previous 
study by McIlleron et al in adults have showed important differences when patients were 
dosed with single drugs versus fixed dose combinations  (FDC) of rifampicin and 
isoniazid (McIlleron et al. 2006). Children often receive crushed or divided FDC tablets. 
Crushing and division of the FDCs may result in changes in biopharmaceutics and  loss 
of active drug, and has been shown to result in significantly lower concentrations 
especially of isoniazid (Notterman et al. 1986). Absorption of drugs in children can also 
be affected by gastric pH, gastrointestinal surface area (Kearns 2000, Kearns et al. 2003) 
and other factors experienced by children including ‘dislike’ of the taste of drugs.  
Age and body weight 
Children experience varied physiological changes during growth which may affect drug 
absorption, distribution and metabolism leading to significantly altered pharmacokinetic 
profiles which could impact drug efficacy. Enzyme maturation also affects the 
bioavailability of drugs and failure to account for it has in part accounted for low 
exposures in children when mg/kg doses are used as in adults.  In children gastric 
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emptying time appears to approach adult values within the first 6 to 8 months of life. 
Intestinal motor activity matures throughout early infancy with increases in the 
frequency, amplitude, and duration of propagating contractions and is also influenced by 
food (al Tawil & Berseth 1996).  
A study of Zhu et al found that absorption of pyrazinamide in children was 32% slower 
compared to that of the adults studied and the volume of distribution of the children 32% 
greater than that of the adults (Zhu et al. 2002). However, when volume is normalized to 
weight per kilogram, the absolute value may be lower. Children also prescribed the 
standard 10 mg/kg body weight had lower concentrations compared to adults who 
received a similar dose (Schaaf et al. 2009b). The relatively low plasma concentration of 
rifampicin in children has been found in other studies where rifampicin prescribed at 10–
12 mg/kg produced peak concentrations ranging from 3–9 mg/L (McCracken et al. 
1980). In another study, ethambutol was thought to lower the exposures of rifampicin 
(Thee et al. 2009). Like isoniazid, the authors suggest that rifampicin doses may be 
calculated on the basis of body surface area rather than body weight, especially in 
younger children. Encouragingly, children receiving a dosage of 300 mg/m
2
 body 
surface and at the age of 3 months to 2.5 years had mean serum concentrations of 
9.1 mg/L, which is above the target of 8 mg/L and was close to the desired serum level 
of 10 mg/L (Thee et al. 2009).  
Younger children receiving 10 mg/kg of isoniazid (dose similar to adults) had 
significantly lower AUC than adults, leading to the suggestion that younger children 
eliminate isoniazid faster than adults (Schaaf et al. 2005). The faster clearance (adjusted 
according to body) of isoniazid could be attributed to the higher proportion of liver size 
to total body weight; hence it was proposed that children should be dosed according to 
body surface area (BSA). In support, when serum levels of isoniazid were compared 
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when children were dosed according to body weight (mg/kg) and BSA, weight-based 
isoniazid concentrations were lower than those dosed according to BSA especially in 
children less than 8 years, and BSA-based doses gave similar exposures as in adults 
(Thee et al. 2010). Also, a study conducted in South African children with tuberculosis 
had showed that children who received 4-6 mg/kg dose of isoniazid had 58% lower peak 
versus those who received 8-10 mg/kg dose, and in about 70% of children who received 
4-6 mg/kg, the peak concentrations were below the recommended range of 3 mg/L 
(McIlleron et al. 2009).   
Similar trends of lower concentrations, exposures and  shorter half-lives were reported in 
children on pyrazinamide  (McIlleron et al. 2011, Ramachandran et al. 2013)
 
and 
increase in doses has been suggested. However a study by Thee et al (Thee et al. 2008) 
which described the pharmacokinetics of children who received higher doses of 30 
mg/kg of pyrazinamide has shown that Cmax was reached in all three groups receiving 
pyrazinamide 3 h after dosing and was 37.9 mg/ml, 31.3 mg/ml and 33.3 mg/ml in the 
age groups < 6, 6-10 and 10-14 years. There was no significant difference between the 
concentrations in the three age groups. Unlike isoniazid, the similar pyrazinamide 
concentrations found in their study across a range of ages indicated that dosing should 
probably be based on body weight rather than body surface area. The findings of Ellard 
(Ellard 1969) support the opinions of the study by Thee et al.  Conversely, the results of 
Zhu et al in children with a mean age of four years receiving a mean pyrazinamide 
dosage of 25 mg/kg and those of Graham et al from children age less than four years 
receiving a PZA dosage of 30.5 mg/kg do suggest that any lowering of the dosage to less 
than 30 mg/kg will result in a significant proportion of younger children being exposed 
to serum Cmax concentrations of <20 mg/L (Graham et al. 2006b, Zhu et al. 2002). 
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Recently, a study conducted in adults with HIV co-infection showed that for 10 kg 
increase in body weight was associated with 14.1 % (CI, 7.5, 20.8), 14.1% (95% CI, 
−0.7, 31.1), and 6.1% (95% CI, 2.7, 9.6) decrease in respective AUC0-12 of rifampicin, 
isoniazid and pyrazinamide (McIlleron et al. 2012).  
 
Nutritional Status 
The association between pharmacokinetics of drugs for treatment of tuberculosis and 
nutritional status has long been debated. In malnourished children, it has been suggested 
that drugs used in current standard doses, calculated on the basis of age or body weight 
(mg/kg), may not produce the desired therapeutic effect (Mehta 1990). The 
pathophysiological changes associated with malnutrition can alter pharmacokinetic 
processes, drug responses and toxicity (Krishnaswamy 1989). It is common that patients 
with tuberculosis are often malnourished, and a significant association between 
malnutrition and severe forms of childhood tuberculosis has been reported (Vijayakumar 
et al. 1990). But, studies which evaluated the effect of malnutrition on the 
pharmacokinetics of anti-tuberculosis drugs have had conflicting results. A study in 
South Africa showed that changing conditions of disease or nutrition did not 
significantly influence isoniazid elimination in children (Schaaf et al. 2005).  
 
Genetic factors 
There pharmacokinetics of drugs such as rifamycins and isoniazid are influenced by 
genetic factors. Recent data indicate that a single nucleotide polymorphism in solute 
carrier organic anion transporter family, member 1B1 (SLCO1B1) gene that encodes the 
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OATP1B1 transmembrane receptor affects rifampin drug concentrations (Weiner et al. 
2004). OATP1B1 is an influx transporter that regulates hepatic uptake of xenobiotics 
and is important for numerous drugs  (Chigutsa et al. 2011, Kalliokoski et al. 2010, 
Pasanen et al. 2006). Persons with the SLCO1B1 rs11045819 gene mutation at exon 4 
(variant name c463C>A) had 42% lower AUC and 34% lower Cmax values than those 
without it in one study (Weiner et al. 2004), and an rs4149032 C>T polymorphism was 
associated with 20% and 28% reductions in rifampin bioavailability in heterozygotes and 
homozygotes, respectively in another (Chigutsa et al. 2011).  Importantly, SLCO 
variants appear to be more common in Black patients than White patients. The 
contribution of genetic factors to differences in rifapentine pharmacokinetics is 
unknown.   
 
The effect of arylamine N-acetyltransferase 2 (NAT2) on pharmacokinetics of isoniazid 
is well known. A study conducted by Mcllleron et al. in South African children showed 
dose in mg/kg body weight and NAT2 genotypes to be dominant determinants of 
isoniazid concentrations. Hence dose reduction below 6 mg/kg body weight would 
disadvantage fast acetylators, while slow acetylators would require only a 3 mg/kg dose 
to achieve a satisfactory exposure of isoniazid (McIlleron et al. 2009). It has, therefore 
been suggested that the optimal dosage of isoniazid should consider age and possibly 
NAT2 genotype.  Polymorphism in the NAT2 and its ability to metabolise isoniazid has 
led to three distinct trends in clearance: slow, intermediate and fast acetylators 
(McIlleron et al. 2009, Schaaf et al. 2005). and the effect of maturation of NAT2 on 
pharmacokinetics of isoniazid has been shown to be become apparent from as early as 
the first 3 months of life (Kiser et al. 2012). There is wide geographical variation in the 
distribution of NAT-2 polymorphisms (Sabbagh et al. 2008). The NAT2 alleles NAT2*5, 
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*6 and *14,  have been found predominantly in Africa (Matimba et al. 2009), and these 
polymorphism results in slow to intermediate acetylation of isoniazid. The NAT2*4 is 
the ancestral and is associated with a fast phenotype, while the other alleles NAT2*5, *6 
and *14 are associated with slow phenotype. 
 
Effect of food 
Food has been reported to decrease the rate of absorption of rifampicin as evidenced by 
an increase in Tmax (Zent & Smith 1995) which may result in reduced Cmax (Jeanes et 
al. 1972). Food has also been shown to lower bioavailability of rifampicin (Zent & 
Smith 1995), and effect which was not found in Peloquin’s study(Peloquin et al. 1999). 
The effect of food had been reported to lower the bioavailability of isoniazid (Zent & 
Smith 1995)  and higher exposure may be achieved by administration of isoniazid on an 
empty stomach.  For rifapentine, unlike rifampicin, concomitant food has a marked 
increase on rifampicin absorption giving high bioavailability (Chan et al. 1994). The 
effect of food on systemic rifapentine exposure may therefore impact treatment activity 
and safety. However the effects on other meal types which are often used in tuberculosis 
control programs remains unknown. However, delay in absorption of ofloxacin was 
observed which may be attributed to food effect (Stambaugh et al. 2002).  
 
1.3.4 Pharmacokinetics and pharmacodynamics (PKPD) relationships 
One descriptor of sterilizing and bactericidal activity of anti-tuberculosis drugs have 
been the link between pharmacokinetic exposures and MIC. Drugs such as rifampicin 
have reported to have concentration dependent killing where the rate of bacterial killing 
increases as the concentration of antibiotic increases over a wide range of concentrations. 
The magnitude of the pharmacokinetic/pharmacodynamic parameters required for 
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efficacy for such drugs may be relatively similar in animal infection models and in 
human infections (Craig 1998).  
Dose fractionation studies for rifampicin showed that doses expected to achieve an 
AUC/MIC ratio of 271 in the mouse were associated with a 1 log10 reduction in lung 
CFU counts after 6 daily doses. But, these doses were on the low end of the dose-
response curve. In humans, the AUC/MIC ratio associated with activity was expected to 
be close to 120 after a 600 mg oral dose of rifampicin (Kenny & Strates 1981). While 
this value meets the target values for AUC/MIC associated with efficacy for other 
concentration-dependent antibiotics against gram-negative bacilli, it is clear that higher 
doses of rifampicin or more potent rifamycins might exert substantially greater activity. 
Lower doses of rifampicin appear to be less effective in clinical studies. One randomized 
clinical trial demonstrated a decline in the activity of rifampicin with a dose reduction 
from 600 to 450 mg daily (Long et al. 1979). Furthermore, it has been established that 
rifampicin unbound AUC/MIC correlated better with killing of M.tuberculosis than 
Cmax/MIC using the hollow-fiber bioreactor system (HFS) (Gumbo et al. 2007a). The 
unbound Cmax (fCmax)/MIC≥175 of rifampicin in plasma result in prevention of 
resistance to rifampicin (Gumbo et al. 2007a), while plasma AUC0-24/MIC≥271 and 
epithelial lining fluid (ELF) AUC0-24/MIC ≥665 were associated with a 1-log10-CFU 
reduction in the total lung bacterial load in mice(Jayaram et al. 2003).  In the early 
phases of infection bacteria multiply in alveolar macrophages, hence concentrations of 
rifampicin in macrophages and ELF may be important. In alveolar cell, rifampicin 
concentration after 600 mg dose were more than 10 fold higher than in plasma, but in 
ELF it was slightly lower (Goutelle et al. 2009). As a result, the rates of target attainment 
estimated by the model suggested that Cmax/MIC≥175 was 95% in alveolar cell, 48.8% 
in plasma, and 35.9% in ELF. Furthermore, rifampicin killing effect was determined to 
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be 100% in plasma, while in macrophages it was 54.5%, while doubling the dose of 
rifampicin to 1200 mg gave improved target ratios (Goutelle et al. 2009), hence recent 
studies propose increasing the dose of rifampicin from 600 mg(de Steenwinkel et al. 
2013, van Ingen et al. 2011).  
On the other hand, rifapentine is a more promising candidate than rifampicin owing to 
better pharmacokinetics.. It has a long half-life (Burman et al. 2001, Keung et al. 1999) 
and superior in vitro potency against M.tuberculosis in comparison with rifampin 
(Heifets et al. 1990), making it an attractive candidate for shortening and simplifying 
antitubercular therapy. Like rifampicin, higher doses have been suggested to overcome 
development of ARR, and relapse may be associated with intermittent dosing (Burman 
et al. 2006, Menzies et al. 2009). The sterilising effect of rifapentine has been shown to 
be dose dependent in murine studies which suggest that daily doses of rifapentine may 
reduce treatment duration to less than 3 months (Rosenthal et al. 2006, 2007; Zhang et 
al. 2009). Furthermore, higher doses of rifapentine are associated with improved early 
bactericidal activity in humans (Sirgel et al. 2005). But in the TBTC study 29A, increase 
in exposure due to daily rifapentine failed to accelerate bacterial elimination in humans 
which was not expected following mouse studies (Dorman et al. 2012). Following this 
failure, Mitchison suggested that this could be due to presence of low-tolerance 
persisters in humans which are absent in mouse studies, hence Cmax could be important 
determinant of kill rather than AUC/MIC as found in mouse studies (Mitchison 2012). 
Rifapentine has been shown to have significantly higher intracellular concentrations 
since the MIC and minimal bactericidal concentrations were against M.tuberculosis 
H37Rv within macrophages were 4 times lower compared with corresponding values for 
extracellular bacilli (Mor et al. 1995). Consequently, rifapentine could be 8 times more 
potent against intracellular M.tuberculosis when compared with rifampicin because 
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rifampicin had 2 times higher intracellular MIC and minimal bactericidal concentrations  
(Mor et al. 1995). But, a study in guinea pigs established that rifapentine is not more 
active than rifampicin against chronic dosing (Dutta et al. 2012). However, little is 
known about the effect AUC and Cmax on the probability of failure or relapse.  
Studies on PKPD of pyrazinamide are few. In a HFS study, resistance suppression has 
been linked to duration of time the concentration is above MIC while maximal bacterial 
killing in epithelial lining fluid has been associated with AUC0-24/MIC ratio ≥ 209 
(Gumbo et al. 2009).  Also, a study conducted in Botswana has shown that pyrazinamide 
concentrations lower than 35 mg/L were associated with increased risk of treatment 
failure (Chideya et al. 2009). Furthermore a recent study based on HFS has established 
that peak pyrazinamide concentration (cut-off 53.8 mg/L) was the most important 
predictor of both 2-month sputum conversion (Pasipanodya et al. 2013), hence 
pyrazinamide remains an important drug in treatment of tuberculosis.   
 
For isoniazid, activity has been proposed to be concentration dependent following a 
single clinical trial using divided dosing. Of interest from this study was that 400 mg 
daily doses of isoniazid were more effective than 200 mg given twice daily, but the 400 
mg daily study only provided concentrations above the MIC for only 50–75% of the 
dosing interval from rapid acetylators, while the 200 mg twice daily had concentrations 
above the MIC for the entire dosing interval (Gangadharam et al. 1961). The efficacy of 
isoniazid had a demonstrated plateau interval (Gangadharam et al. 1961) but there were 
no significant differences in outcomes between slow and rapid acetylators or between 
patients receiving 400 or 700 mg isoniazid. Recent studies showed that the activity of 
mycobacterial kill of isoniazid is related to the AUC/MIC ratio compared to Cmax/MIC 
ratios or the time above MIC (Gumbo et al. 2007b). Importantly, Chigutsa et al., had 
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shown that isoniazid may antagonize sterilizing activity in PTB patients on standard first 
line regimen (Chigutsa et al. 2013), which supports mouse models suggesting 
antagonism (Grosset et al. 1992).  
 
The efficacy of fluoroquinolones including moxifloxacin and ofloxacin has been related 
to the fAUC0-24/MIC (Shandil et al. 2007). Based on in vitro, murine, and clinical 
studies, a fAUC0-24/MIC ratio of at least 100–125 has been proposed as a minimum 
target for bactericidal activity against gram-positive and gram-negative bacteria 
(Schentag et al. 2003a,b). The HFS study  has suggested a minimum target fAUC0-
24/MIC ratio of 53 for M.tuberculosis as the identified target for suppressing the 
outgrowth of moxifloxacin-resistant mutants and not necessarily optimal bactericidal 
activity (Gumbo et al. 2004). However, there is no agreed value on the target ratio to be 
used when fluoroquinolones are used. Fluoroquinolones generally achieve higher 
concentrations in ELF than in plasma (Kiem & Schentag 2008), which could be 
advantageous where patients had cavities. Compared with other fluoroquinolones, 
moxifloxacin has been found to have greater efficacy than levofloxacin in mice despite a 
lower plasma AUC/MIC ratio (Ahmad et al. 2013), which is due to higher intracellular 
concentrations of moxifloxacin. Levofloxacin penetrates into cerebrospinal fluid of 
patients with tuberculosis meningitis better than ciprofloxacin and gatifloxacin 
(Thwaites et al. 2011).  
In general, the PKPD indices of either AUC/MIC or Cmax/MIC and their potential to 





Tolerability of higher doses 
Even though higher doses of anti-tuberculosis drugs are associated with more favorable 
outcomes, of concern is lack of concrete knowledge about dose-toxicity relationships. In 
all these drugs higher doses are proposed in children to match adult exposures (Steingart 
et al. 2011). It is debatable to say that rifamycin higher doses are likely to cause toxic 
effects. For rifampicin doses, doses above 600 mg (10 mg/kg) are not used because of 
concern about toxicity, but there is little evidence that higher doses of rifampicin are 
associated with toxicity (Acocella et al. 1971, Curci et al. 1972, Favez et al. 1972). In 
small-scale studies, higher doses of rifampicin have been used and were shown to have 
bactericidal activity which is twice that of 10 mg/kg (Diacon et al. 2007). The toxic 
effects of rifampicin, “flu-like” syndrome were suggested to be linked to intermittency 
rather than the magnitude of dose (Peloquin 2003). However, the situation might be 
different in children who experience various physiological changes such as maturation of 
enzymes and drug transporters. For rifapentine, limited studies which have been 
conducted using doses up to 1200 mg once weekly being used and were tolerated in 
humans (Weiner et al. 2004). However, convincing evidence still needs to be presented 
in ongoing clinical trials.  
For pyrazinamide, the major limitation to increased doses is high rate of adverse 
reactions, frequently reported are arthralgia and hepatic toxicity (Blumberg et al. 2003, 
Corbella et al. 1995). Interestingly and contrary to many reports, a recent meta-analysis 
has shown that doses ranging from 43 to ≥60 mg/kg were  associated with sporadic 
hepatotoxicity and there was no significant difference with those who were on lower 
doses (Pasipanodya & Gumbo 2010). However, the use of higher doses of isoniazid is 
associated with acute and chronic toxicities. Use of doses ≥20 mg/kg increase the 
likelihood of seizures (Lheureux et al. 2005). Elevated body temperatures, tachycardia 
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and tachypnea may occur due to seizure activity. Consequently, long-term sequelae 
include anoxic encephalopathy and dementia (McLay et al. 2005). Chronic toxic effects 
include hepatotoxicity and peripheral neuropathy. Peripheral neuropathy, uncommon 
with lower doses, has been reported after 7.8-9.6 mg/kg daily doses of isoniazid in 
poorly nourished patients (Devadatta et al. 1960), hence the use of pyridoxine to 
minimize  peripheral neuropathy.  The other most commonly encountered side-effects of 
isoniazid which are dose-related are elevated serum transaminase, bilirirubinemia, 
jaundice, hepatitis and vomiting.  
Higher doses of fluoroquinolones may increase side effects including QT interval 
prolongation observed even at recommended doses (Falagas et al. 2007). Given the long 
duration of treatment of MDR-TB, QT interval prolongation is of particular concern. 
However, limited studies seem to suggest safety of higher doses. A recent study by 
Ruslami et al. (Ruslami et al. 2013) which evaluated higher doses of moxifloxacin, 800 
mg daily, did not show increased toxicity. In support, a study by Alffenar et al. showed 
tolerability at 600 mg and 800 mg moxifloxacin (Alffenaar et al. 2009). An ongoing 
clinical trial by Alffenar et al. is evaluating the safety of moxifloxacin at escalated doses 
of 600 and 800 mg (NCT01329250: http://clinicaltrials.gov/show/NCT01329250).  
 
Nonlinear mixed effect modeling (pharmacometrics)  
Pharmacometrics is a science that involves quantitative interpretation of pharmacological 
observations which help in optimization of dosing regimens, clinical trial design, 
efficacy of drugs, drug labeling, disease progression and responsiveness to therapy. The 
United States Food and Drug Administration based (FDA) extensively defined 
pharmacometrics as a branch of science that quantifies drug, disease and trial 
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information to aid efficient drug development and/or regulatory decisions where disease, 
trial and drug disease models are important. Disease models describe the association 
between biomarkers and clinical outcomes, placebo effects and time course of disease. 
Then trial models for the inclusion/exclusion criteria, patient discontinuation and 
adherence. Lastly, drug models describe the relationship between exposure (or 
pharmacokinetics), response (or pharmacodynamics) and individual patient 
characteristics (FDA 2010).  
 
The term population pharmacokinetics is often used in pharmacometrics, which is the 
study of pharmacokinetics where drug concentration data from all individuals in a 
population are pooled together and evaluated simultaneously using a single 
pharmacometric model, and an association with pharmacodynamic responses may be 
evaluated (Sheiner & Beal 1980). The main components of describing the observed data 
within a population include: structural model; statistical model; covariate model; and 
software used. Structural models describe the median concentration time course within 
the population while statistical models cater for variabilities in in observed data within 
the population such as interindividual variability (IOV), interoccassional variability 
(IOV) and random unexplained variability. Covariate models explain variability 
predicted by individual’s clinical and demographic characteristics.  
 
The most important strength of the population approach is simulation of different 
scenarios which are beyond the scope of just analyzing or describing the data. Through 
the use of Monte-Carlo simulation, therapeutic effectiveness, toxicity, adequacy of doses 
or other factors which may affect clinical outcomes can be predicted and optimised for 
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future population. Another importance advantage of a population approach to analysis is 
the ability to interpret be sparsely sampled data (mostly phase 3 clinical data) such 
compared with  a traditional  standard two stage approach or the naive pooled method 
(Sheiner & Beal 1980, 1983).  
 
Modeling and simulation has been shown to be an important development towards 
improvement of decision making in the pharmaceutical industry (Gieschke & Steimer 
2000, Miller et al. 2005). The increased use of modeling and simulation as part of drug 
development is expected to lead to fewer drug failures and smaller numbers of studies 
before a drug succeeds in a new drug application (Rajman 2008). Also, The FDA 
recommended the use of pharmacometric approach for successful application of 
investigational new drug entities 
 
Therefore, in light of the above introduction and literature highlighting the past, present 
and future efforts in treatment of tuberculosis, further work is still required in using 
pharmacometric approaches to optimise dosing regimens, understanding what drives 
efficacy, and how to improve treatment of drug-resistant tuberculosis.    
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2 PROBLEM STATEMENT AND JUSTIFICATION 
 
South Africa has the second highest per capita annual risk of tuberculosis disease after 
Swaziland, and its communities have extremely high tuberculosis transmission rates. The 
classical therapy for pulmonary tuberculosis consists of rifampicin, isoniazid, 
pyrazinamide and ethambutol for 2 months followed by a continuation phase of 
rifampicin and isoniazid, and has been used for the past four decades. When these 
standard regimen is optimally administered, cure rates of 85% or more can be achieved 
in patients with drug sensitive organisms (Fox et al. 1999, Jindani et al. 2004). But, the 
cure rates in public health care programs remain worryingly lower (WHO 2012b) 
especially in children, making it important to optimize treatment regimens especially in 
children, and investigate other treatment strategies. 
 
In high disease burden settings, children contribute 15-20% of tuberculosis cases (Marais 
et al. 2006). Young children (<5 years of age) and children infected with HIV are prone 
to rapid progression to tuberculosis disease following infection, and children are prone to 
severe forms of tuberculosis including disseminated disease and meningitis (Marais et al. 
2006). Lack of novel and better pharmacokinetic approaches in analyzing data in 
children limited optimization of doses in children assuming that adults from similar 
ethnic populations receive therapeutic doses.  Furthermore, the majority of studies which 
had evaluated the pharmacokinetics of drugs used for the treatment have used non 
compartmental analysis (NCA) methods..  The NCA method is informative only after 
rigorous and intensive pharmacokinetic sampling in patients, and is often limited by 
financial resources, ethical constraints related to burden of the research on the patient, 
cost and convenience due to intensive sampling schedule required. In addition NCA has 
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limited application outside the scope of descriptive statistics such as simulations of 
different scenarios or study design.  
 
Novel regimens aiming at shortening the duration of tuberculosis treatment or offering 
more intermittent therapy (i.e., once weekly or even less frequently) without lowering 
efficacy are required in reducing the burden of supervised drug therapy. New treatment 
strategies are evaluating the combination of moxifloxacin and intermittent high dose 
rifapentine as a first-line agent. Like rifapentine, moxifloxacin has a long half-life (9 - 12 
h) (Dooley et al. 2008, Siefert et al. 1999), making it an attractive companion drug to 
prevent selection of rifapentine-resistant strains when the drugs are administered 
intermittently. Hence describing the population pharmacokinetics of moxifloxacin and 
rifapentine help in identifying potential sources of variability (covariate effects), and also 
evaluating the possibility of drug-drug interactions when they are used together. 
Furthermore, there is limited information about the effects of pharmacokinetics 
parameters such as time above MIC, Cmax and AUC in relation to proportion of patients 
with relapse or treatment failure per regimen, adjusted for duration of treatment/study 
regimen. 
Fluoroquinolones play an important role in the treatment of multi-drug resistant 
tuberculosis (MDR-TB) (Falzon et al. 2011) which is defined by resistance to both 
rifampicin and isoniazid (WHO 2008a). Fluoroquinolones differ from each other in their 
efficacy against M.tuberculosis as measured by fAUC0-24/MIC, and also display 
differences in their clinical pharmacokinetics. New fluoroquinolones are usually 
preferred to the earlier-generation ones (WHO 2011), but ofloxacin is still widely used to 
treat MDR-TB, because of its affordability and availability. Even though the in vitro 
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bactericidal activity of moxifloxacin against M.tuberculosis is superior to that of 
ofloxacin (Hu et al. 2003), little is known as to whether this will be the case in humans 
where distribution of AUCs of drugs used for treatment of MDR-TB and their respective 
MIC distributions in relevant patient population is taken into account.  
 
Population pharmacokinetics of rifapentine  
Population pharmacokinetic studies of rifapentine are very few. The only studies 
conducted in Southern African populations have limited scope when evaluating steady 
state population pharmacokinetics (Langdon et al. 2004, 2005).  Concomitant food has a 
marked effect on rifapentine absorption (Chan et al. 1994). The effect of food on 
systemic rifapentine exposure may therefore impact treatment activity and safety. The 
study by Chan et al was studied on English breakfast (fat meal) which may not be 
applicable to resource limited countries like South Africa; hence there is need for further 
evaluation when other meal types are considered. Additionally, rifapentine has a 
microbiologically active metabolite, 25-desacetyl rifapentine  (Heifets et al. 1990), 
evaluating pharmacokinetics of this metabolite have to be considered.  
The population pharmacokinetics of rifapentine is not only affected by food, but other 
factors like pharmacogenetics have to be considered. Recent advances in evaluating the 
pharmacogenetic correlates of rifamycin pharmacokinetics had determined that 
rifampicin drug concentrations and AUC are altered after a  single nucleotide 
polymorphism of SLCO1B1 gene which encodes the OATP1B1 transmembrane receptor 
(Weiner et al. 2010). A recent study in South African population where pharmacometric 
approaches were used to quantify the effect of SLCO1B1 mutation showed significantly 
reduced bioavailability of rifampicin (Chigutsa et al. 2011).   Given that rifapentine is a 
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rifamycin, the relative contribution of genetic differences in drug handling to these 
differences is unknown; hence similar pharmacometric evaluations are important.   
Population pharmacokinetics of moxifloxacin and its efficacy in MDR-tuberculosis 
Moxifloxacin and ofloxacin are rapidly absorbed following oral administration with peak 
concentrations reached within 2 h after dose, but moxifloxacin has a longer half-life of 
approximately 12 h (Dooley et al. 2008) versus 6 h of ofloxacin  (Belousov et al. 1996).  
A further pharmacokinetic difference between these two drugs is that moxifloxacin has 
moderate renal excretion which comprise 6-20% of total elimination after intravenous 
administration (Siefert et al. 1999), while  ofloxacin is primarily renally eliminated 
(Lode et al. 1987). In light of this highlighted differences in pharmacokinetics, whether it 
contributes to differences in efficacy between these two drugs is unclear. Hence non-
linear mixed effects modelling approaches could then be used to quantify the efficacy of 
moxifloxacin and ofloxacin against each other when fAUC/MIC ratios are taken into 
account. 
Rifapentine and moxifloxacin drug interactions 
Little is known about the interaction between moxifloxacin and rifapentine.  
Moxifloxacin is a substrate of inducible P-gp (Brillault et al. 2009), sulfotransferases 
(Senggunprai et al. 2009), and glucuronosyltransferases (Tachibana et al. 2005). Co-
administration of moxifloxacin with rifapentine (enzyme and transporter inducer) 
resulted in a 17.2% (Dooley et al. 2008) decrease in moxifloxacin exposure in healthy 
volunteers (dosed three times a week). Hence there is need to evaluate the extent of 




Investigation of population pharmacokinetic summary variables of rifapentine and 
moxifloxacin as of predictors of treatment outcome 
Novel clinical trials are evaluating the combination of rifapentine and moxifloxacin as 
first-line therapy. Information gathered in these novel regimens is important in 
optimizing the doses of respective drugs used. Most importantly, risk factors that 
resulted in unfavorable outcome should be investigated and this information is still to be 
known. Hence there is need to estimate the PKPD indices of both moxifloxacin and 
rifapentine, among them time above MIC, Cmax, AUC either for once weekly or twice 
weekly regimens all at steady state, and time above MIC (TAMIC), and evaluate them as 
predictors of treatment outcome.  
 
Optimization of rifampicin, isoniazid and pyrazinamide dosages in children using a 
population pharmacokinetic approach 
The widely used daily dosages of first-line antituberculosis drugs recommended in 
children were derived from adult dosage based on the assumption that the same dose per 
kg is appropriate across all ages of patients. Even though rifampicin, isoniazid and 
pyrazinamide have been available for many years, the limited pharmacokinetic 
information in children suggests that young children receiving adult-derived dosages 
have drug exposures lower than adults (McIlleron et al. 2009, Schaaf et al. 2005, 2009b). 
The majority of the studies used NCA for analysis. In children, factors such as 
maturation of metabolizing enzymes and transporters, body composition, organ function, 
nutritional status, and the pathophysiology of severe forms of tuberculosis may 
contribute to changes in pharmacokinetics, drug response and toxicity (Kearns et al. 
2003). WHO has recently recommended increased dosage of the first-line 
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antituberculosis drugs for children (WHO 2010), which are to be implemented using 
dispersible FDC tablets for paediatric use, manufactured according to newly 
recommended specifications, with each tablet containing 50 mg isoniazid, 75 mg 
rifampicin and 150 mg pyrazinamide (WHO 2012c).  Hence there is a need to describe 
the population pharmacokinetics of rifampicin, pyrazinamide, and isoniazid through a 
pharmacometric approach non-linear mixed-effects models, and use final models to 
predict AUC and Cmax in a paediatric population and compare them with the 
corresponding pharmacokinetic measures in ethnically similar adults with tuberculosis, 






The principal purpose of this work was to:  
1. Describe the population pharmacokinetics of rifampicin, pyrazinamide and 
isoniazid in children with tuberculosis, and to evaluate the adequacy of currently 
recommended doses using a pharmacometric approach 
2. Describe the population pharmacokinetics of rifapentine in order to quantify the 
effects of four different meal types on the population pharmacokinetics of single-
dose rifapentine in healthy male volunteers  
3. Quantify the drug interaction between moxifloxacin and intermittent high dose 
rifapentine  
4. Describe the population pharmacokinetics of moxifloxacin, and compare 
moxifloxacin pharmacodynamic efficacy against widely used comparator 
ofloxacin 
5. Investigation of population pharmacokinetic summary variables of rifapentine and 









4.1 Declaration of work 
 
This thesis is based on the pharmacometric analysis of different studies, namely: Two 
studies of the pharmacokinetics of first-line antituberculosis drugs in children; a healthy 
male volunteer study; the RIFAQUIN clinical trial; a population pharmacokinetic study 
of ofloxacin in patients with multidrug-resistant TB, and an investigation of the MICs for 
moxifloxacin and ofloxacin in Mycobacterium tuberculosis isolates resistant to 
rifampicin and isoniazid. More details about the above-mentioned studies are given in 
section 4.2.  Patient enrollment, drug administration and monitoring, pharmacokinetic 
sampling, follow up and all data collection for the work described in this Chapter was 
carried out by a study team and not by the candidate. All the drug plasma concentration 
determination was carried out by the University of Cape Town Division Of Clinical 
Pharmacology, except in 20 Children where it was carried out at Desmond Tutu 
Tuberculosis Centre, Department of  Paediatrics and Child Health, Faculty of Health 
Sciences, Stellenbosch University, Tygerberg, South Africa. All the data analysis, 
modeling and simulation were performed by the candidate. The candidate used 
previously published models in adults for rifampicin (Wilkins et al. 2008), pyrazinamide 
(Wilkins et al. 2006) and isoniazid (Wilkins et al. 2011) to derive reference exposures in 
adults, and a previously published population pharmacokinetic and pharmacodynamic 
model for ofloxacin (Chigutsa et al. 2012) used in this thesis to compare efficacy 
between moxifloxacin and ofloxacin was not developed by the candidate. The 
determination of moxifloxacin and ofloxacin MICs in patient sputum isolates was done 
at DST/NRF Centre of Excellence for Biomedical Tuberculosis Research/MRC Centre 
for Molecular and Cellular Biology, Division of Molecular Biology and Human 
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Genetics, Faculty of Health Science, Stellenbosch University, Stellenbosch, South 
Africa.  
In the RIFAQUIN study the candidate was responsible for aspects of coordination of 
data collection, data collation, giving updates on progress and sites needing assistance in 
enrolling patients, and visiting the sites to identify potential sources of confounders and 
variability. The candidate did all the pharmacometric analysis. 
 
4.2 Patient population and studies used in this thesis 
 
This thesis is based on the population pharmacokinetic and pharmacodynamic evaluation 
of data from the following studies:  
4.2.1 Studies of pharmacokinetics of first-line antituberculosis drugs 
The previously published studies used in this thesis described the plasma concentrations of 
rifampicin (Schaaf et al. 2009b), pyrazinamide (McIlleron et al. 2011) and isoniazid (Wilkins 
et al. 2011) in one cohort of 56 South African children with tuberculosis. These studies were 
further combined with another cohort describing the plasma concentrations of rifampicin, 
isoniazid and pyrazinamide in a cohort of 20 South African children (Thee et al. 2011).  In 
addition, previously published models describing the population pharmacokinetics of 
rifampicin (Wilkins et al. 2008), pyrazinamide (Wilkins et al. 2006) and isoniazid (Wilkins et 
al. 2011) were used to derive reference exposures in adults. 
4.2.2 Healthy male volunteer study 
Thirty-five adult male healthy volunteers were enrolled in an open-label, randomized, 
sequential, five-way, crossover design study at Groote Schuur Hospital, Cape Town, South 
Africa. The aim of the study was to investigate the effect of four different meal types on the 
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population pharmacokinetics of rifapentine and its primary metabolite 25-desacetyl 
rifapentine. 
4.2.3 RIFAQUIN clinical trial 
The standard therapy of tuberculosis consists of 2 months of daily ethambutol, isoniazid, 
rifampicin, and pyrazinamide followed by 4 months of daily isoniazid and rifampicin (WHO 
2013). The RIFAQUIN trial was a Phase 3 study (Jindani et al. 2013, RIFAQUIN 2008) 
which evaluated substitution (in the current standard therapy) of isoniazid with moxifloxacin 
in all phases in the tuberculosis treatment together with replacement of rifampicin with high 
dose intermittent rifapentine only in the continuation phase in standard tuberculosis 
treatment. The dosing schedules of two experimental arms of the RIFAQUIN study were: 1) 
4-month regimen where isoniazid was replaced by 400 mg moxifloxacin daily for 2 months 
followed by 2 months of twice-weekly 400 mg moxifloxacin and 900mg rifapentine; 2) 6-
month regimen where isoniazid was replaced by 400 mg moxifloxacin daily for 2 months 
followed by 4 months of once-weekly moxifloxacin and 1200mg rifapentine. The participants 
were followed up to 18 months with scheduled visits at  1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 
18 months after starting therapy. 
4.2.4 MIC of moxifloxacin and ofloxacin   
The MICs for moxifloxacin and ofloxacin were obtained from a separate study comparing 
mutations in the quinolone resistance-determining region of the gyrA gene and flanking 
sequences with the MICs of ofloxacin and moxifloxacin for M.tuberculosis (Sirgel et al. 
2012). The total number of isolates and the methodology on which how the MIC were 





4.2.5 Population pharmacokinetics and pharmacodynamics of ofloxacin. 
 
A population pharmacokinetic and pharmacodynamic model used in this thesis was 
previously published (Chigutsa et al. 2012). The study described ofloxacin 
pharmacokinetics in 56 South African patients being treated for multidrug-resistant 
tuberculosis and assessed the adequacy of ofloxacin drug exposure with respect to the 
probability of pharmacodynamic target attainment (PTA). The MIC distributions used 
were obtained from the study described in Section 4.2.4.  
4.3 Plasma sample handling and drug concentration determination 
 
In the studies of pharmacokinetics of first-line antituberculosis drugs, 56 children 
(Cohort 1), plasma concentrations of rifampicin, pyrazinamide, and isoniazid were 
determined by liquid chromatography tandem mass spectrometry, using an Applied 
Biosystems API 2000 (LC/MS/MS) as detailed previously (McIlleron et al. 2007, 2009, 
2011). At each time after dose, the blood samples were immediately placed on ice, and 
centrifuged at 750 g for 10 min within 1 h of collection.  Then 1 ml plasma from each 
sample was stored in polypropylene tubes at -80
o
C and away from light until analysis 
was done. The analysis was done at the Division of Clinical Pharmacology, University 
of Cape Town, South Africa. The samples were processed with a protein precipitation 
method using 3 vol precipitation solution (acetonitrile) containing the appropriate 
internal standards. The internal standards used were rifapentine for rifampicin and 
sulfamethoxazole for isoniazid and pyrazinamide. The injection volume of plasma 
samples was 5 µL. For rifampicin, a gradient chromatographic separation was achieved 
with a mobile phase containing 10-90% acetonitrile in 0.1% formic acid, with 5 min run 
time delivered at 0.3 ml/min. For pyrazinamide and isoniazid, an isocratic elution  was 
used; the mobile phase consisted of 80% acetonitrile in 0.1% formic acid. The selected 
52 
 
reaction monitoring of transitions of protonated molecular ions to product ions were: 
rifampicin m/z 823.5-791.4. For rifampicin, pyrazinamide and isoniazid, the linear 
ranges for standard curves were 0.1–30 mg/L, 0.2–70 mg/L and 0.1–15 mg/L. The lower 
limit of quantification (LLOQ) for both rifampicin and isoniazid was 0.1 mg/L and for 
pyrazinamide was 0.2 mg/L, and intra-and inter day assay variability was less than 10%. 
Data below LLOQ was handled using M3 method (Bergstrand & Karlsson 2009) where 
the likelihood of being below LLOQ was estimated.  
In 20 children (Cohort 2), the drug determination was done at Stellenbosch University, 
South Africa. Rifampicin was determined by LC/MS/MS (Thee et al. 2011). However 
the difference with cohort 1 was that reaction monitoring of transitions of protonated 
molecular ions to product ions for rifampicin was at m/z 823.5-89.2. For isoniazid and 
pyrazinamide plasma concentrations were determined by high-performance liquid 
chromatography (HPLC) and ultra-violet (UV) detection (Thee et al. 2011). Isoniazid 
was derivatized with cinnamaldehyde, an approach shown to improve detection of 
isoniazid at 340 nm (Seifart et al. 1995). Pyrazinamide was measured directly at 269 nm. 
The lower limit of detection (LLOD) in Cohort 2, under which no concentration was 
reported, was 0.25, 0.5, and 0.15 mg/L for rifampicin, pyrazinamide and isoniazid, 
respectively.  
In the healthy male volunteer study, plasma concentrations of rifapentine and 25-
desacetyl rifapentine in health volunteer study were determined simultaneously using a 
validated high-performance tandem liquid chromatography (HPLC) method developed at 
the Division of Clinical Pharmacology, Cape Town, South Africa (Langdon et al. 2004). 
The drugs were extracted using 3 ml BondElut C18 solid phase extraction columns 
(Anatech, Sittard, The Netherlands). Detection of the drugs was at 270 nm with an 
isocratic flow rate of 2 ml/min using a mobile phase comprising of 50% acetonitrile and 
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0.1% trifluoroacetic acid in distilled water. The intra-day coefficients of variation ranges 
were 2.8% - 4.4% and 4.4% -5.6% for rifapentine and 25-desacetyl rifapentine, 
respectively. The coefficients of variation between the 3 days were 2.5% -4.7% and 
4.0% -6.3% for rifapentine and 25-desacetyl rifapentine, respectively. The assay was 
validated over the concentration range of 0.6 to 30 mg/L for both parent and metabolite. 
Linearity values of the calibration curve (r
2
) were 0.9975 and 0.9946 for rifapentine and 
25-desacetyl rifapentine, respectively. 
Plasma moxifloxacin concentrations from the RIFAQUIN study were determined using a 
validated liquid chromatography-tandem mass spectrometry assay method developed in 
the Division of Clinical Pharmacology, University of Cape Town. The samples were 
processed with a protein precipitation extraction method using 20 μl plasma with 200 μl 
precipitation solution (acetonitrile) containing the internal standard gatifloxacin at a 
concentration of 0.5 mg/L. Gradient chromatographic separation was achieved on a 
Phenomenex, Gemini-NX 5-μm C18 (110-A, 50-mm by 2-mm) analytical column using 
acetonitrile and 0.1% formic acid as the mobile phase and was delivered at a flow rate of 
400 μl/min. An AB Sciex API 3200 Q-trap mass spectrometer was operated at unit 
resolution in the multiple-reaction-monitoring mode, monitoring the transition of the 
protonated molecular ions at m/z 402.1 to the product ions at m/z 358.3 for moxifloxacin 
and the protonated molecular ions at m/z 376.1 to the product ions at m/z 332.4 for the 
internal standard. The assay was validated over the concentration range of 0.063 mg/L to 
16 mg/L. The accuracies for the moxifloxacin assay were 106.3%, 100.7%, and 102% at 
the low, medium, and high quality control (QC) levels, respectively, during interbatch 
validation. The precision (expressed as the percent coefficient of variation) was less than 
5.5% at the low, medium, and high QC levels. The lower limit of quantification (LLOD) 
was 0.063 mg/L.  
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Plasma rifapentine concentrations from the RIFAQUIN study were determined with a 
validated liquid chromatography-tandem mass spectrometry assay developed in the 
Division of Clinical Pharmacology, University of Cape Town. Samples were processed 
with a protein precipitation extraction method using rifaximin as internal standard, 
followed by high performance liquid chromatography with MS/MS detection using an 
AB SCIEX API 3200 instrument. The analyte and internal standard were monitored at 
mass transitions of the protonated precursor ions m/z 877.3 and m/z 786.3 to the product 
ions m/z 845.4 and m/z 754.1 for rifapentine and rifaximin, respectively. The calibration 
curves fit quadratic (weighted by 1/concentration) regressions over the ranges 0.0390 – 
40.0 mg/L for rifapentine. The accuracies for the moxifloxacin assay were 103.9%, 
102.8%, and 97.5% at the low, medium, and high QC levels, respectively, during 
interbatch validation. The LLOQ was 0.156 mg/L. 
4.4 Determination of moxifloxacin and ofloxacin MICs in patient sputum isolates 
 
The M.tuberculosis isolates were obtained from a separate study, in patients with drug-
resistant tuberculosis in the Western Cape, South Africa during the period 2007–2009  
(Sirgel et al. 2012). The isolates had previously been subjected to routine drug 
susceptibility testing on Middlebrook 7H11 agar and had known IS6110 restriction 
fragment length polymorphism and spoligotype patterns. As previously described 
(Donald et al. 2001), the MICs were determined by quantitative drug susceptibility 
testing using an automated BACTEC mycobacterial growth indicator tube (MGIT) 960 
instrument (BD Bioscience, Sparks, MD, USA) equipped with TBeXiST and 
EpiCentreTM V5.75A software (BD Bioscience, Erembodegem, Belgium). The 
concentrations tested were 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10, 50.0 mg/L for ofloxacin and 
0.125, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0 mg/L for moxifloxacin (24). The 0.25 mg/L 
55 
 
and 2.0 mg/L concentrations of moxifloxacin and ofloxacin were used as susceptibility 
breakpoints to differentiate between susceptible and resistant strains as suggested by 
WHO (WHO 2008b). 
 
4.5 General pharmacometric methodology 
 
The general methods used in data analysis which forms the basis of this PhD thesis are 
described in this section. 
4.5.1 Classification NAT2 polymorphism 
 
On the basis of analysis of genetic polymorphisms of the NAT2 gene, the children were 
categorized as slow, intermediate, or fast acetylator genotypes for acetylation of 
isoniazid. The methods used in classification of NAT2 genotypes have been previously 
described for cohort 1 comprised of 56 South African children with tuberculosis (Schaaf 
et al. 2005) and cohort 2 comprised of 20 children (Thee et al. 2011). In both cohorts, 
NAT2 genotyping  and categorization of alleles was done at Stellenbosch University, 
South Africa (Schaaf et al. 2005). The NAT2 genotypes were analyzed using polymerase 
chain reaction (PCR) and restricted fragment length polymorphism. Separate PCR 
aliquots were restricted with the MspI, FokI, KpnI, TaqI, DdeI, and BamHI restriction 
enzymes (according to the manufacturer’s recommendations) to delineate the 
polymorphisms at nucleotide positions 191, 282, 481, 590, 803, and 857, 









-3′], which initiates amplification in the case 











-3′], which only amplifies in the case of the 341T allelic sequence (a 










amplify a gene specific PCR product (475bp) in the reaction mixture which serves as an 
internal amplification control. After analysing the genomic DNA for 
the NAT2*5, 2*6, 2*7, 2*12, 2*13, and 2*14 alleles, the alleles were assigned into 
acetylator status of isoniazid according to the Vatsis nomenclature (Vatsis et al. 1995).  
The wild type fast allele (F) is assigned as NAT2*4, 2*12, or 2*13. These alleles confer 
normal enzyme activity on the NAT2 protein. The mutant slow alleles (S), classified 
as NAT2*5, 2*6, 2*7, and 2*14 in humans, confer a decreased enzyme activity on the 
NAT2 protein (Vatsis et al. 1995). In cohort 2, NAT2 genotyping was done at 
Stellenbosch University.The genomic DNA was analysed for NAT2*5, NAT2*6, 
NAT2*7, NAT2*12, NAT2*13, and NAT2*14 alleles. The assignment of these alleles 
into acetylator category was done according to the NAT2 nomenclature. The NAT2*4 
allele was designated the wild-type, which together with the NAT2*12 and NAT2*13 
alleles, were defined as the rapid-acetylator (F) status. The slow acetylator is defined by 
decreased or impaired NAT2 enzyme activity which is encoded by the mutant alleles 
NAT2*5, NAT2*6, NAT2*7, and NAT2*14. Hence, individuals were classified as 
homozygous fast (FF), heterozygous intermediate (FS), or homozygous slow (SS) 
acetylators, based on the combination of alleles detected. 
4.5.2 Calculation of arm muscle area and arm fat area in children (Lee 2001) 
 






     4 x π 
 
where MUAC is mid upper arm circumference (mm) and π = 3.14.  
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Arm Muscle Area (AMA) was calculated as:  
AMA (mm
2
) = [MUAC – (π x TSF)]
2 
  
         4 x π 
where TSF is skinfold thickness. 
 
Then Arm Fat Area (AFA) was calculated as:   
AFA (mm
2
) = AA (mm
2




The AMA values were derived from percentiles from the United States Health and 
Nutrition Examination Survey I from 1971 to 1974 (Heymsfield et al. 1979), and the z-
scores were derived from National Center for Health Statistics/Centers for Disease 
Control and Prevention/World Health Organization (NCHS/CDC/WHO) international 
reference standards (Gibson 2005). 
4.5.3 Population pharmacokinetic analysis  
 
The overall methodology used for the pharmacokinetic analysis is described in this 
section applied to all the plasma drug concentration-time data.  
The concentration-time data for each drug were analyzed separately using a non-linear 
mixed-effects approach. Non-linear mixed effects modeling implemented in the 
NONMEM® software program (Icon Development Solutions, Ellicott City, MD, USA) 
(Beal et al. 2009) was used for analysis. NONMEM version 7.2 was used.The program 
was operated on a cluster of LINUX machines using an Intel Fortran Compiler. The 
execution of runs was through Perl-speaks-NONMEM (PsN) (Lindbom et al. 2005) and 
graphical diagnostics were created using Xpose 4 (Jonsson & Karlsson 1999) and 
Census® (Wilkins 2005). 
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4.5.3.1 Model building and validation 
 
Estimation of typical population pharmacokinetic parameters, along with their random 
inter-individual (IIV) and inter-occasional (IOV) variability was performed using the 
first-order conditional estimation method with ε-η interaction (FOCE INTER) (Karlsson 
& Sheiner 1993). The general approach included building the base model with all the 
variabilities included and testing for significant relationships between parameters and 
covariate. Various pharmacokinetic models, including one or two compartments with 
first-order absorption and first- order elimination (Holford et al. 1992), incorporating 
either lag times (to describe the delay in the appearance of drug in plasma) or transit 
absorption compartments (Rousseau et al. 2004, Savic et al. 2007), time-varying 
clearance (Langdon et al. 2005), and enterohepatic recirculation (Roberts et al. 2002), 
were fitted to the data during model development. Use of additive and proportional error 
terms was also investigated.  
Time-varying clearance was introduced into the model as: 
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where     is the oral clearance for the ith individual,    
   
 
   is the typical oral 
clearance which later changes to    
   
 
   at model event time (MTIME),          
remains zero until MTIME when it changes to 1,  
 
   
  represents the IIV and  
 
   
  
represents the IOV.  
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In general, if there was data below lower limit of quantification (LLOQ) with the values 
reported, where appropriate was handled by fixing the error structure to additive with 
size LLOQ/2, to include these samples in the fit while accounting for the lower 
precision. In some cases where some LLOQ values were missing in one cohort, LLOQ 
values were imputed to lower limit of detection (LLOD)/2 reported from the laboratory, 
discarding consecutive undetectable concentrations in a series. However, if the LLOQ 
values were not reported at all, the M3 method (Beal 2001) was preferred, where the 
likelihood of being below LLOQ was estimated.  
Model discrimination was based on graphical assessment of conditional weighted 
residuals (CWRES) versus time, basic goodness of fit (GOF) plots, and changes in the 
NONMEM OFV during model development. OFV is equal to approximately −2 × log 
likelihood, and ΔOFV is assumed to be chi squared distributed. Statistical significance 
was set at 5% (ΔOFV > 3.84) for a single degree of freedom (i.e., addition of one model 
parameter) and at 1% significance level (ΔOFV > 6.63) for deletion of one parameter 
(Wahlby et al. 2001). Assessment of IIV estimates and their corresponding standard 
errors (SE) was done to check for η shrinkage since η and ε shrinkage values above 30% 
result in a model with a low power to detect model and residual error misspecification, 
which may hide true relationships (Karlsson & Savic 2007). Precision of parameter 
estimates as provided by the covariance step (if successfully completed), and visual 
predictive checks (VPC) (Holford 2005) were also considered during model selection. In 
cases where the covariance step failed to run, measures of parameter uncertainty were 
obtained through a nonparametric bootstrap of the final model and the number of 











Potential covariate relationships were identified by clinical and statistical significance. 
The covariate relationships were tested in the model by stepwise addition (forward step) 
using a ∆OFV of ≥ 3.84 (p ≤ 0.05) as the cut-off for inclusion, followed by stepwise 
deletion (backward step) using ∆OFV of ≥ 6.83 (p ≤ 0.01) as a requisite for covariate 
retention.  Missing continuous covariate data were replaced with the individual 
information from the other dosing and sampling occasion, if available. The covariate 
analysis using the basic models was performed via forward addition and backward 
elimination using stepwise covariate model (SCM) building as implemented in PsN. 
Using SCM, one model for each relevant parameter-covariate relationship is prepared 
and tested in a univariate manner. In the first step the model that gives the best fit of the 
data according to some criteria is retained and taken forward to the next step. In the 
subsequent steps all remaining parameter-covariate combinations are tested until no 
more covariates meet the criteria for being included into the model. The forward 
selection can be followed by backward elimination, which proceeds as the forward 
selection  and backwards using ∆OFV cut-offs mentioned above. 
The effect of continuous covariates was parameterized as shown in equation below: 
                             
where    is the parameter (   ) estimate in a typical individual (a median covariate 
value of       ), while      is the fractional change in     with each unit change in 
the covariate (   ) from       .  
For categorical covariates, such as acetylator genotype, a separate typical value for the 
parameter under test was estimated in each group. For the categorical covariates (sex and 
HIV status), the covariate model was expressed as a fractional change         from the 
estimate for a typical value     ) due to covariate (COV) using the following equation: 
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                    ) 
COV takes the values between 0 and 1. Total body weight (WT) where relevant was 
included through allometric scaling was applied on oral clearance (CL) and apparent 
volume of distribution in plasma (Vc) according to Anderson and Holford (Anderson & 
Holford 2008) was used and scaled as shown below:  
CLi = CLstd ·(WTi/WTstd)
0.75
 
Vci = Vstd·(WTi/ WTstd)
1
 
where CLi is the scaled typical value of CL/F for individual i, CLstd is its typical CL for 
an individual of median weight (WTstd) in the patient population. A similar notation 
applies to Vci. In the case of a two-compartment model, allometric scaling was also 
applied on inter-compartmental clearance (Q) similar to CL/F and on apparent peripheral 
volume of distribution (Vp) similar to Vc. Normal fat mass (NFM), fat-free mass (FFM) 
and fat mass (FAT) were tested through allometric scaling instead of total body weight. 
The FFM was calculated as follows according to Janmahasatien et al (Janmahasatian et 
al. 2005): 
    
            
    
            
 
where for females           = 37.99 and      =35.98 and for males 
          = 42.92 and      =30.93, and HT is height (m) and WT is total body 
weight (kg). Then                    .      is parameter-specific fat 
fraction associated with size. If      is 1 then WT is used for allometric scaling, if      




After allometric scaling was included, the need for including maturation models 
following the approach previously described by Anderson and Holford  (Anderson & 
Holford 2009) was evaluated. The maturation factor (MF) was calculated as: 




where PMA is age derived by adding 36 weeks to post-natal age, assuming no premature 
birth. TM50 is the age at which maturation reaches 50% of the final value, and Hill is the 
coefficient that regulates the rate of onset of the maturation. Models with and without the 
Hill factor fixed to 1 were tested. 
In cases where the drug has a metabolite, the above procedure was also applied to build 
the metabolite model. The exposures of each drug were obtained from NONMEM using 
the $ABBREVIATED COMRES when required.  
4.5.3.2 Parametric survival analysis 
 
The hazard of a treatment failure at time t was modeled as: h(t)=Pr(t≤T<(t+dt|T>t); 
where Pr is the probability of having an event within a time interval dt, give the scenario 
that that the event did not occur before time t. The probability of having favorable 
outcome was modeled as a function of the cumulative hazard of an unfavorable event 
(integral of the hazard with respect to time) for each day from start of observation using 
the following function:        ∫       
 
 . The probability density function (pdf) of 
having an event at time t was modeled as: pdf = h(t) x S(t). The baseline survival models 
tested where parameterized as follows (Weibull function) as follows:           
 
 
where   is the baseline hazard and α is the shape parameter. If α =1, then the hazard in 
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constant over time, if α <1, then hazard decreases with time and if α >1 the hazard 







5 Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in 
children with tuberculosis, in silico evaluation of currently recommended doses 
 
5.1 Introduction 
Tuberculosis is the most frequent infectious cause of death worldwide with high impact 
in developing countries (WHO 2013). In settings with high disease burden such as South 
Africa, children comprise 15-20% of tuberculosis cases (Marais et al. 2006). Young 
children (<5 years of age) and children infected with HIV are prone to rapid progression 
to tuberculosis disease following infection, and frequently experience severe forms of 
tuberculosis including disseminated disease and meningitis (Marais et al. 2006). 
Isoniazid and rifampicin are important for their bactericidal activity against 
metabolically active M.tuberculosis. The sterilizing activities of pyrazinamide and 
rifampicin prevent relapse of disease after treatment (Hu et al. 2006, Steele & Des Prez 
1988). Isoniazid plays an important role in preventing the development of resistance to 
companion drugs such as rifampicin (Mitchison 2000). Dosages of rifampicin higher 
than those currently employed have been suggested to improve efficacy (Gumbo et al. 
2007a). 
Until recently, the daily dosages of first-line antituberculosis drugs recommended in 
children were derived from adult dosage based on the assumption that the same dose per 
kg is appropriate across all ages of patients. Even though rifampicin, isoniazid and 
pyrazinamide have been available for many years, the limited pharmacokinetic 
information in children suggests that young children receiving adult-derived dosages 
have drug exposures lower than adults (McIlleron et al. 2009, Schaaf et al. 2005, 2009b). 
In children, factors such as maturation of metabolizing enzymes and transporters, body 
composition, organ function, nutritional status, and the pathophysiology of severe forms 
65 
 
of tuberculosis may contribute to changes in pharmacokinetics, drug response and 
toxicity (Kearns et al. 2003). Previous studies have reported reduced tuberculosis drug 
concentrations in adults with HIV infection (Gurumurthy et al. 2004a) but the effect of 
HIV infection on the pharmacokinetics of tuberculosis drugs has not been adequately 
evaluated in children. The WHO has recently recommended increased dosage some of 
the first-line antituberculosis drugs for children (WHO 2010), which are to be 
implemented using dispersible FDC tablets for paediatric use, manufactured according to 
newly recommended specifications, with each tablet containing 50 mg isoniazid, 75 mg 
rifampicin and 150 mg pyrazinamide (WHO 2012c). 
The aim of this study was to describe the population pharmacokinetics of rifampicin, 
pyrazinamide, and isoniazid in non-linear mixed-effects models, using previously 
published data from children with tuberculosis aged 2 months to 11.3 years who were 
given a wide range of dosages (McIlleron et al. 2009, 2011; Schaaf et al. 2009b, Thee et 
al. 2011). In addition, use final models to predict steady state area AUC and Cmax in a 
paediatric population and compared them with the corresponding pharmacokinetic 
measures in ethnically similar adults with tuberculosis.  
5.2 Setting and Study Design 
Pharmacokinetic data from studies of pharmacokinetics of first-line antituberculosis 
drugs were used (Section 4.2.1). The studies described the pharmacokinetics of 
rifampicin, pyrazinamide and isoniazid in children with tuberculosis. A total of 76 
children were used in this analysis. On the basis of analysis of genetic polymorphisms 
determined on NAT2 gene, the children were categorized as slow, intermediate, or fast 
acetylator genotypes for acetylation of isoniazid. The methods used in classification of 
NAT2 genotypes have been previously described under Methodology section 4.5.1 for 
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cohort 1 (Schaaf et al. 2005) and cohort 2 (Thee et al. 2011). The demographic, clinical 
characteristics and doses given of 76 children are summarized in Table 5.1.  






Number of patients 56 20 76 
Sex (M/F) 29/27 11/9 40/36 
Genotype (S/I/F/Ms) 20/24/8/4 8/4/8/0 28/28/16/4 
HIV positive (M/F) 22 (12/10) 5 (2/3) 27 (14/13) 






Weight (kg) 12.5 (4.87, 26.9) 7.80 (4.12, 12.8) 10.5 (4.90, 21.8) 
RIF dose 1
st
 PK (mg/kg) 9.54 (6.70, 13.3) 10.1 (9.0, 10.5) 9.71 (7.07, 13.2) 
RIF dose 2
nd
 PK (mg/kg) 9.57 (5.46, 16.0) 15.4 (10.4, 15.8) 10.3 (6.37, 15.9) 
PZA dose 1
st
 PK (mg/kg) 22.7 (15.9, 26.7) 25.2 (22.5, 26.5) 24.6 (17.6, 26.5) 
PZA dose 2
nd 
PK (mg/kg) 22.2 (12.2, 26.3) 36.2 (33.4, 39.5) 33.7 (15.6, 39.1) 
INH dose 1
st
 PK (mg/kg) 4.92 (3.35, 12.8) 5.04 (4.50, 5.36) 5.03 (3.56, 12.1) 
INH dose 2
nd 
PK (mg/kg) 4.95 (2.36, 16.0) 10.2 (8.74, 10.8) 9.77 (2.73, 13.3) 
M/F, males/females; Ms, missing covariate data; S/I/F, slow/intermediate/fast arylamine 
N-acetyltransferase acetylators; RIF stands for rifampicin; PZA for pyrazinamide; INH 
for isoniazid; 1
st
 PK and 2
nd
 PK stand for first and second PK sampling occasion, 
respectively; 
a 





percentile), while the size of each group is reported for categorical covariates (McIlleron 
et al. 2009, 2011; Schaaf et al. 2009b, Thee et al. 2011).  
 
 
Daily doses of rifampicin and isoniazid were given for 6 months with pyrazinamide 
added for the first two months. Dispersible FDC tablets formulated for children were 
used (McIlleron et al. 2009, 2011; Schaaf et al. 2009b, Thee et al. 2011). At each 
sampling occasion venous blood was drawn at 0.75, 1.5, 3, 4, and 6 h post-dose. Cohort 
2 underwent pharmacokinetic sampling 2 weeks or more after initiation of 
antituberculosis therapy and sampling was repeated one week later, with samples drawn 
pre-dose and at 0.5, 1.5, 3, and 5 h after the dose. Plasma rifampicin, pyrazinamide and 
isoniazid concentrations for each cohort were determined as detailed under section 4.3.  
67 
 
5.2.1 Pharmacokinetic data analysis 
The methodology applied for model building has been described in section 4.5.3. In all 
models, allometric scaling was applied to CL/F and apparent volume of distribution in 
Vc according to Anderson and Holford (Anderson & Holford 2008). As a reference, the 
median body weight of 12.5 kg from cohort 1 (Table 5.1) was used and scaled as shown 
below: 
CLi = CLstd ·(WTi/12.5)
0.75
 
Vci = Vstd·(WTi/ 12.5)
1
 
where CLi is the scaled typical value of CL/F for individual i, CLstd is its typical CL for 
an individual of median weight of 12.5 kg in the patient population. A similar notation 
applies to Vci. In the case of a two-compartment model, allometric scaling was also 
applied on Q (similar to CLi) and on Vp (similar to Vci). After allometric scaling was 
included, the need for including maturation models following the approach previously 
described by Anderson and Holford  (Anderson & Holford 2009) was evaluated. The MF 
was calculated as: 
MF = 1/ [1+ (PMA/TM50)
-Hill
] 
where PMA is age derived by adding 36 weeks to post-natal age, assuming no premature 
birth. TM50 is the age at which maturation reaches 50% of the final value, and Hill is the 
coefficient that regulates the rate of onset of the maturation. Models with and without the 
Hill factor fixed to 1 were tested.  
The structural models tested included one- and two-compartment with first-order 
elimination. Different absorption models were explored such as first-order absorption or 
a sequence of zero- and first-order absorption incorporating either lag times or transit 
compartment absorption (Savic et al. 2007, Wilkins et al. 2008). The effect of a dose on 
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the pharmacokinetic parameters was also tested. For relative bioavailability (F), first-
order absorption rate constant (ka), mean transit time (MTT) and CL of rifampicin (a 
substrate of polymorphic OATP1B1 transporter  (Chigutsa et al. 2011) and isoniazid (a 
substrate of polymorphic metabolizing enzyme NAT2),  the possibility of 
subpopulations having different parameter estimates was tested using mixture models. A 
log-normal model for IIV and IOV was used and shrinkage in the post-hoc estimates was 
derived. Additive and/or proportional models for the residual unexplained variability 
(RUV) were evaluated. In Cohort 1, the drug concentrations reported as below the 
LLOQ were 0.6%, 0%, and 3.4% for rifampicin, pyrazinamide, and isoniazid, 
respectively. In Cohort 2, the values below the LLOD were 19%, 5.5%, and 17.1% for 
rifampicin, pyrazinamide, and isoniazid, respectively. Additionally, 4.5%, 3%, and 
24.1% of the concentrations of rifampicin, pyrazinamide, and isoniazid, respectively, 
were in the “low precision” range of the assay, but above LLOD. The larger proportion 
of low concentrations in Cohort 2 is partly due to the collection of a pre-dose sample. All 
the data below LLOQ in Cohort 1 was handled by fixing the error structure to additive 
with size LLOQ/2, to include these samples in the fit while accounting for the lower 
precision. The lower limit of detection (LLOD) in Cohort 2, under which no 
concentration was reported, was 0.25, 0.5 and 0.15 mg/L for rifampicin, pyrazinamide 
and isoniazid, respectively. Moreover, the assay could not guarantee 5% precision 
between the LLOD (0.75, 1.5 and 1 mg/L for rifampicin, pyrazinamide and isoniazid, 
respectively) and LLOQ values. The effect of age, sex and HIV infection was tested on 
F, CL, Vc, Vp, ka and MTT. Arm muscle area (AMA) was tested as a predictor for CL, 
Vc and Vp while albumin and other nutritional status measures (weight-for-age, weight-




The AMA was calculated for each child using formula detailed in Section 4.5.2. The 
reference AMA values were derived from percentiles from the United States Health and 
Nutrition Examination Survey I from 1971 to 1974 (Heymsfield et al. 1979), and the z-
scores were derived from National Center for Health Statistics/Centers for Disease 
Control and Prevention/World Health Organization (NCHS/CDC/WHO) international 
reference standards (Gibson 2005). Missing continuous covariate data were replaced 
with the individual information from the other dosing and sampling occasion, if 
available. Otherwise, median values from the cohort were used. Missing categorical 
covariates were replaced with the most common category, except for acetylator 
genotype. For the missing genotype data (4 individuals), a mixture model was used. The 
likelihood of belonging to each acetylator status was fixed to the frequency observed in 
the subjects for whom the information was available. 
The effect of continuous and categorical covariates, and model validation were evaluated 
as described under section 4.5.3.1. Model selection was based on VPC (Holford 2005), 
CWRES versus time, GOF plots, and ∆OFV. The covariate relationships were tested in 
the model by stepwise addition (forward step) using a ∆OFV of ≥ 3.84 (p ≤ 0.05) as the 
cut-off for inclusion, followed by stepwise deletion (backward step) using ∆OFV of ≥ 
6.83 (p ≤ 0.01) as a requisite for covariate retention.   
5.2.2 Simulations 
Monte Carlo simulations were used to predict the model-based AUC and Cmax in a 
paediatric population should they be dosed in pragmatic weight bands (adhering as 
closely as possible to the revised guidelines in dose per unit weight) using 1 to 4 
undivided tablets of a FDC with the newly recommended specifications. Reference AUC 
and Cmax values in adults with tuberculosis given the doses currently recommended for 
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adults by the WHO (WHO 2003), were derived using previously published models 
(Wilkins et al. 2006, 2008, 2011). 
Using Monte Carlo simulations, the final models were used to simulate steady state AUC 
and Cmax for children using pragmatic weight bands (adhering as closely as possible to 
the revised guidelines in dose per unit weight) (WHO 2010)   using 1 to 4 undivided 
tablets of a FDC with the newly recommended specifications (i.e. 75/50/150 mg 
rifampicin/isoniazid/pyrazinamide in each FDC tablet) (WHO 2012c). AUC and Cmax 
were predicted for children weighing 4.0-7.9, 8.0-11.9, 12.0-15.9 and 16.0-24.0 kg 
receiving respective daily doses of 1, 2, 3 and 4 FDCs. Individual weight and age values 
were available from historical data of 246 South African children with tuberculosis, 72% 
infected with HIV (2% with HIV status unknown), and 54% males. Pooling these with 
the present data from the two cohorts (Table 5.1), we obtained a dataset of baseline 
values for 312 children. The pharmacokinetic models were applied (1000 repetitions) to 
this in-silico population, using the WHO-recommended dosing guidelines, and AUC and 
Cmax values were collected for each weight band. To obtain reference values for 
comparison, previously published pharmacokinetic models (Wilkins et al. 2006, 2008, 
2011) from an ethnically similar population of adult patients were used to simulate AUC 
and Cmax ranges using the current WHO-recommended dosing guidelines for adults 
(WHO 2008c). The respective daily doses used for simulations in adults weighing 30.0-
37.9, 38.0-54.9, 55.0-69.9, and ≥ 70 kg were: 300, 450, 600 and 750 mg for rifampicin; 
800, 1200, 1600 and 2000 mg for pyrazinamide; and 150, 225, 300 and 375 mg for 
isoniazid.   
5.3 Results 
Rifampicin. A total of 629 concentration-time data points were available for 67 children 
(Schaaf et al. 2009b, Thee et al. 2011). 9 Children were resistant to rifampicin. The final 
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pharmacokinetic model for rifampicin was a one-compartment model with transit 
compartments absorption (Savic et al. 2007), and first-order elimination. The parameter 
estimates of the final model are shown in Table 5.2.   
The absorption transit model was simplified by fixing ka to the same value as the first-
order transit rate constant (ktr), since the two were not found significantly different. HIV 
status and albumin levels had no influence on the pharmacokinetics of rifampicin. Age 
maturation was supported on CL and MTT and resulted in a 23 point improvement in 
OFV, explaining 16 % IIV in CL and 17 % IOV in MTT (no IIV on MTT was present in 
the model). TM50 was estimated to be 58.2 weeks which is 22.2 weeks (0.43 years) after 
birth for both CL and MTT. The estimate of typical ktr was 7.8 h
-1
. The proportional 
change of each parameter with post-natal age is shown in Figure 5.1.  
Table 5.2: Parameter estimates of the final rifampicin pharmacokinetic model 














CLstd (L/h) 8.15 (9.00) 32.6 (27.7) 25.1 (20.0) 
Vcstd (L) 16.2 (10.2) 43.4 (19.8)  
MTT (h) 1.04 (6.10)  40.6 (8.60) 
NN  8.04 (11.9)   
F (%) 1 (fixed)  48.1 (12.7) 
TM50 (weeks) 58.2 (9.00)   
Hill 2.21 (11.7)   
Additive error, Cohort 1 
(mg/L) 
0.122 (24.6)   
Additive error, Cohort 2 
(mg/L) 
0.630 (30.3)   
Proportional error, (%)  23.4 (4.50)   
CLstd and Vcstd are oral clearance and apparent volume of distribution, respectively. The 
values reported refer to a 12.5 kg child and for CL at full maturation. MTT, absorption 
mean transit time, value at full maturation; NN, number of transit compartments; F, 
relative bioavailability. TM50, post-menstrual age at which 50% of clearance and mean 
transit time maturation is achieved; Hill, steepness of the maturation function; 
a
RSE, 
relative standard error reported on the approximate standard deviation scale; 
b
IIV, inter-
individual variability expressed as percent coefficient of variation (% CV); 
c
IOV, inter-




The final model included IIV, expressed as percent coefficient of variation (% CV), on 
CL (33%) and Vc (43%), while IOV was significant on CL (25%), F (48%) and MTT 
(40%). The residual error model had both additive (0.122 mg/L for Cohort 1 and 0.63 
mg/L for Cohort 2) and proportional terms (23% for both cohorts). The final 
pharmacokinetic model described the data well, as shown in the VPC (Figure 5.2). When 
scaled to a 70 kg individual, the typical values for CL and Vc were 29.7 L/h and 90.7 L, 
respectively. The run record and control stream of final rifampicin pharmacokinetic 
model are shown in Appendix 1. 
 
 
Figure 5.1: Maturation of oral clearance (CL) and mean transit time (MTT) of rifampicin 
and CL/F of isoniazid in a typical patient with post-natal age. The plot is not adjusted for 
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Figure 5.2: Visual predictive checks for the final model of rifampicin. The lower, middle 
and upper lines (dotted/solid) are the 5
th
, median, and 95
th
 percentiles of the observed 
data, respectively. The shaded areas are the 95% confidence intervals for the 5
th
 
percentile, median and the 95
th
 percentile of the simulated data.  
 
Pyrazinamide. A total of 518 concentration-time data points were available in 55 
children (McIlleron et al. 2011, Thee et al. 2011). The final pharmacokinetic model for 
pyrazinamide was a one-compartment distribution model with absorption transit 
compartments, first-order absorption and elimination. Final parameter estimates are 
shown in Table 5.3. No significant covariate relationships were supported by the data. 
IIV, expressed as percent coefficient of variation (% CV), was supported on CL (27%), 
while IOV was significant for CL (26%), ka (86%), F (25%) and MTT (112%). The 
residual error model was proportional (10% for Cohort 1 and 6% for Cohort 2). The 
VPC for the final pyrazinamide model is displayed on Figure 5.3, showing that the final 
model described the data well. The typical values of CL and Vc were 3.9 L/h and 54 L, 
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respectively, when scaled to a 70 kg individual. The run record and control stream of 
final pyrazinamide pharmacokinetic model are shown in Appendix 2. 
 
Table 5.3: Parameter estimates of the final pyrazinamide pharmacokinetic model 














CLstd (L/h) 1.08 (5.60) 27.1 (16.3) 25.5 (11.3) 
Vcstd (L) 9.64 (2.60)   
ka (h
-1
) 4.48 (6.10)  86.4 (14.6) 
MTT (h) 0.10 (17.7)  112 (22.5) 
NN 3.94 (8.00)   
F (%) 1 (fixed)  24.7 (8.40) 
Proportional error, Cohort 
1 (%) 
10.0 (4.90)   
Proportional error, Cohort 
2 (%) 
5.53 (7.20)   
CLstd and Vcstd are oral clearance and apparent volume of distribution, respectively. The 
values reported refer to a 12.5 kg child. ka, first-order absorption rate constant; MTT, 
absorption mean transit time, value at full maturation; NN, number of transit 
compartments; F, relative bioavailability; 
a
RSE, relative standard error reported on the 
approximate standard deviation scale; 
b
IIV, inter-individual variability expressed as 
percent coefficient of variation (% CV); 
c






Figure 5.3: Visual predictive checks for the final model of pyrazinamide. The lower, 
middle and upper lines (dotted/solid) are the 5
th
, median, and 95
th
 percentiles of the 
observed data, respectively. The shaded areas are the 95% confidence intervals for the 
5
th
 percentile, median and the 95
th
 percentile of the simulated data.  
 
Isoniazid. A total of 715 concentration-time data points were available in all 76 children 
(McIlleron et al. 2009, Thee et al. 2011). A two-compartment distribution model with 
absorption transit compartments and first-order elimination best described the 









Table 5.4: Final parameter estimates for isoniazid pharmacokinetics 
















 4.44 (11.6) 25.1 (12.3)  
CLstd.ia(L/h)
d
 8.94 (13.1)  25.1 (12.3)  
CLstd.fa(L/h)
d
 11.3 (14.8)  25.1 (12.3)  
Vcstd (L)
d
 11.0 (10.2)   
ka (h
-1
) 2.47 (12.8)  61.6 (12.4) 
MTT (h) 0.179 (10.9)  93.9 (17.9) 
NN 4 (fixed)   
Qstd (L/h)
d
 2.00 (26.3)   
Vpstd (L)
d
 5.03 (33.4)   
Fsa 1 (fixed)  39.7 (5.80) 
Fim/fa 0.772 (30.3)   39.7 (5.80) 
TM50 (weeks) 49.0 (13.5)   
Hill 2.19 (46.1)   
Proportional error, 
Cohort 1 (%)  
20.6 (2.80)   
Proportional error, 
Cohort 2 (%)  
7.00 (18.7)   
CLstd.sa, CLstd.ia and CLstd.fa are oral clearance for slow, intermediate and fast acetylators, 
respectively. They refer to a child weighing 12.5 kg and at full maturation; Vcstd, 
apparent volume of distribution in the central compartment for 12.5 kg child; ka, first 
order absorption rate constant; MTT, absorption mean transit time; NN, number of 
hypothetical transit compartments. Qstd, inter-compartmental clearance for 12.5 kg child; 
Vpstd, volume of distribution in the peripheral compartment for 12.5 kg child; Fsa, 
relative bioavailability of slow acetylators; Fim/fa, relative bioavailability of intermediate 
and fast acetylators relative to slow acetylators; TM50, post-menstrual age at 50% of 
adult clearance; Hill, steepness of the maturation function; 
a
RSE, relative standard error 
reported on the approximate standard deviation scale; 
b
IIV, inter-individual variability 
expressed percent coefficient of variation (% CV); 
c
IOV, inter-occasional variability 
expressed as % CV; 
d
In order to obtain the values of CL/F, Vc/F, Q/F and Vp/F, the 
values in the Table 5.4 should be divided by the respective value of bioavailability, 
which changes according to acetylator status. The IIV in CL was set to the same value 
for irrespective of metaboliser status. 
 
 
NAT2 genotype was a significant covariate on CL and F. The OFV improved by 55.7 
points when including acetylator status, which explained 45% of the IIV in CL. 
Estimation of F for intermediate and fast acetylators (relative to slow acetylators) and 
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accounting for age maturation of CL further improved the OFV by 11 and 16 points, 
respectively. The age maturation explained 6% IIV in CL. With respect to intermediate 
acetylators (CL=8.94 L/h), slow acetylators had 50% lower CL (4.44 L/h), while fast 
acetylators had 26% higher CL (11.3 L/h). Also, F in intermediate and fast acetylators 
was estimated to 77.2% which is 23% lower than in slow acetylators. Thus, combining 
the genotype effect on CL and bioavailability, the value of CL/F is 4.44, 11.6, and 14.6 
L/h for slow, intermediate and fast acetylators, respectively. The final model included 
IIV, expressed as percent coefficient of variation (% CV), in CL (25%) and IOV in ka 
(61%), MTT (94%) and F (40%). Maturation of CL is represented in Figure 5.1 and the 
VPC for the final model is shown in Figure 5.4. When scaled to a 70 kg individual, the 
typical values of CL (not CL/F, so before adjusting for the effect of NAT2 genotype on 
F) were 16.2, 32.5, and 41.1 L/h for slow, intermediate and fast acetylators, respectively, 
and Vc and Vp were 61.6 L and 28.2 L. Appendix 3 shows the run record and control 






Figure 5.4: Visual predictive checks for the final model of isoniazid. The lower, middle 
and upper lines (dotted/solid) are the 5
th
, median, and 95
th
 percentiles of the observed 
data, respectively. The shaded areas are the 95% confidence intervals for the 5
th
 
percentile, median and the 95
th
 percentile of the simulated data.  
 
5.3.1 Simulations 
Using the final models and WHO’s newly recommended higher dosages utilizing revised 
FDC recommendations, the predicted steady state AUC for all weight bands are shown 
in Figures 5.5, 5.6 and 5.7 for rifampicin, pyrazinamide, and isoniazid, respectively. 
Median rifampicin exposures were similar to those in adults, although wider variability 
was present in the simulated paediatric AUCs as shown in Figure 5.1. The simulation 
results suggest that a 50 mg/kg dose for children in the lowest weight band of 5.0-7.9 kg 
would achieve the same median AUC as that in the adults.  Exposure after pyrazinamide 
and isoniazid were adequate, but younger children, particularly those in the lowest 
weight band, had lower exposures than those in the reference adult population, and 
79 
 
intermediate and rapid acetylators had reduced isoniazid exposures compared to the 
majority of adults.  
 
Figure 5.5: Box plot of simulated steady-state area under the concentration-time curve 
(AUC) of rifampicin across different age and weight bands, obtained adhering as closely 
as possible to the revised guidelines in dose per unit weight according to World Health 
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). The lower, middle, and upper dashed lines are the derived 5
th 
(9.0 
mg∙h/L), median (30.7 mg∙h/L) and 95
th
 (52.4 mg∙h/L) percentiles of the adult AUC, 










Figure 5.6: Box plot of simulated steady-state area under the concentration-time curve of 
pyrazinamide across different age and weight bands, obtained adhering as closely as 
possible to the revised guidelines in dose per unit weight according to World Health 
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). The lower, middle, and upper dashed lines are the derived 5
th 
(244.0 
mg∙h/L), median (427.0 mg∙h/L), and 95
th
 (675.0 mg∙h/L) percentiles of the adult AUC, 








Figure 5.7: Box plot of simulated steady-state area under the concentration-time curve 
(AUC) of isoniazid in slow (S), intermediate (I) and fast (F) acetylators across different 
age and weight bands, obtained adhering as closely as possible to the revised guidelines 
in dose per unit weight according to World Health Organisation 2010 dosing guidelines. 




 percentile of simulated AUC and the symbol “x” shows 




). The lower, middle, and 
upper dashed lines are the derived 5
th 
(9.8 mg∙h/L), median (23.4 mg∙h/L), and 95
th
 (55.6 








The results of this current study also predicted that from 3 months to 2 years of age, the 
AUC decreased by 56% and 50% for rifampicin and isoniazid, respectively, but only 
18% for pyrazinamide (refer to respective Figure 5.8-5.10 below).  
 
 
Figure 5.8: Scatter plot of simulated rifampicin steady state area under the concentration-
time curve (AUC) versus post-natal age, based on the final model. AUCpop (black 
triangles) are the population predicted values for each individual, obtained under the 
assumption that each subject is characterised by the typical parameter values of the 
population, i.e. no random effects are included. AUCi (grey open circles) are the 
individual simulated predictions, obtained by including the random effects, generated 
according to the level of variability identified in the population. Data from the 5.0-7.9 kg 






Figure 5.9: Scatter plot of simulated pyrazinamide steady state area under the 
concentration-time curve (AUC) versus post-natal age, based on the final model. 
AUCpop (black triangles) are the population predicted values for each individual, 
obtained under the assumption that each subject is characterised by the typical parameter 
values of the population, i.e. no random effects are included. AUCi (grey open circles) 
are the individual simulated predictions, obtained by including the random effects, 
generated according to the level of variability identified in the population. Data from the 






Figure 5.10: Scatter plot of simulated isoniazid steady state area under the concentration-
time curve (AUC) versus post-natal age, based on the final model. AUCpop (black 
triangles) are the population predicted values for each individual, obtained under the 
assumption that each subject is characterised by the typical parameter values of the 
population, i.e. no random effects are included. AUCi (grey open circles) are the 
individual simulated predictions, obtained by including the random effects, generated 
according to the level of variability identified in the population. Data from the 5.0-7.9 kg 
weight band is shown. Please note that for isoniazid the simulations were repeated three 
times, assuming fast, intermediate, or slow metaboliser status, thus the separate trends 
visible in the charts for AUCpop. Age was included as a covariate in the final model. 
 
5.4 Discussion 
We described the population pharmacokinetics of rifampicin, pyrazinamide and 
isoniazid in South African children treated for tuberculosis. In addition, drug exposures 
resulting from the dosages recently recommended by the WHO were investigated. In this 
current study, simulations predicted that, even with the increased dosages, smaller 
children would achieve relatively low exposures to pyrazinamide and isoniazid. 
Moreover, intermediate and fast acetylators (together comprising 61% of South African 
population) may be under-dosed with respect to isoniazid, if exposures in an ethnically 
similar population of adults are considered therapeutic (Figure 5.7). It should be noted 
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that the doses of pyrazinamide and isoniazid used for these predictions tended to be 
somewhat lower than the recommended dose per kg, especially in the youngest children. 
The choice of weight bands was based on ongoing discussions about the optimal dose of 
the FDC by weight band, pragmatic considerations, such as the stability and equal 
distribution of active ingredients in each portion after breaking the FDC tablets, and 
concern that pharmacokinetic maturation could still be incomplete in young children 
(Fletcher et al. 2012, Pariente-Khayat et al. 1997, Schaaf et al. 2005). In this current 
study, the proposed doses were optimized assuming that dividing the FDC tablets should 
be avoided if possible.  
 
The typical paediatric parameter estimates for rifampicin CL/F and Vc/F are in line with 
adult values reported in an ethnically similar population (Wilkins et al. 2008). After 
adjusting for the difference in body size (the median weight of the adult population used 
for comparison was 50 kg), CL/F was 23.1 L/h in children versus 19.2 L/h in adults and 
Vc/F was 64.8 L versus 53.2 L, respectively. This suggests that pharmacokinetic 
differences between children and adults could mainly be explained by differences in 
body size (which was accounted for by allometric scaling) and enzyme maturation. To 
date, this is the only paper that that evaluated non-linearity within the current dose range 
in children. However, the data did not support non-linearity in the pharmacokinetics of 
rifampicin, even though the doses given ranged from approximately 5 to almost 18 
mg/kg daily. These results therefore suggest that at the doses used in the children 
studied, rifampicin may not display the dose-dependent non-linear pharmacokinetics in 
children that has been described in adults (Pargal & Rani 2001). However, further 
studies, including sufficient numbers of children being given the increased dosages, 
would be needed to confirm this. A Cmax of at least 8 mg/L has been suggested as 
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therapeutic for rifampicin (Peloquin 2002) although even higher concentrations are 
likely necessary for maximal bactericidal activity (Gumbo et al. 2007a). However, such 
concentrations are rarely achieved in children prescribed 8-12 mg/kg/day doses of 
rifampicin (Schaaf et al. 2009b). If the pharmacokinetics in an ethnically similar adult 
population (Wilkins et al. 2008) given the currently-recommended doses is used for 




 percentile range of 
exposures in the adult patients (Figure 5.6). The simulated adult exposures were similar 
to those found in a large pharmacokinetic study conducted in adults with pulmonary 
tuberculosis in Botswana (Chideya et al. 2009).Simulations for children using newly 
recommended WHO paediatric guidelines predicted more variable rifampicin exposures 
than those for the reference adult population (Figure 5.6). Moreover, both the predicted 
mean Cmax using the revised paediatric guidelines (6.6 mg/L) and the current doses 
recommended by WHO in the adult reference population (4.8 mg/L) were lower than the 
proposed minimum Cmax of 8 mg/L (Peloquin 2002), implying that even higher doses 
of rifampicin should be considered for both children and adults.  
 
Using the final pyrazinamide model and parameter estimates for CL/F and Vc/F scaled 
to the median weight of the adults population used for comparison (51.5 kg) (Wilkins et 
al. 2006), the children had similar CL/F (about 3.1 versus 3.42 L/h) and higher Vc/F 
(39.7 versus 29.2 L) compared to the adults. The higher Vc/F in children could partly be 
due to malnutrition and severe forms of tuberculosis disease. When previously-reported 
exposures in an ethnically similar adult population who received doses recommended by 
WHO are used as targets, simulation results predicted that children weighing 5.0-7.9 kg 
may be under-dosed (Figure 5.6). As noted above, children in the lowest weight band 
tended to receive doses somewhat lower than the 30-40 mg/kg target proposed in the 
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revised guidelines. The pyrazinamide exposures simulated for the reference adult 
population were similar to those in the large cohort in Botswana (Chideya et al. 2009). In 
addition, the majority of adults had simulated Cmax within the suggested range of 20-50 
mg/L (Peloquin 2002). Importantly, patients in the Botswana cohort with pyrazinamide 
Cmax lower than 35 mg/L had an increased risk of poor treatment outcome. 
 
Isoniazid pharmacokinetics is highly dependent on the polymorphic NAT2 locus, which 
is a major determinant of isoniazid plasma concentrations (Parkin et al. 1997). Targeting 
average exposures simulated for ethnically similar adults following doses currently 
recommended by WHO, the new doses recommended by the WHO for children are 
adequate for slow acetylators, but insufficient for intermediate and fast acetylators 
(Figure 5.7. In this current analysis, there was wide IIVs in the systemic concentrations 
and AUC mostly because children were not dosed according to NAT2 acetylator 
genotype. Hence further studies are needed to adequately define the implications of IIVs 
for safety and efficacy in children. Interestingly, children who were younger than 1 year 
had higher AUC irrespective of their weight band. In addition, isoniazid CL showed 
maturation with age and this support the notion that finer weight bands in conjunction 
with age should be considered to avoid overdosing very young children. The reduced 
bioavailability for intermediate and fast acetylators is most likely a result of increased 
pre-systemic metabolism which also correlates with systemic clearance. The lower 
exposure in intermediate and fast acetylators may predispose to the development of 
ARR. In the Center for Disease Control (CDC) Study 22 (Weiner et al. 2005) an 
association was found between low isoniazid plasma concentrations and the occurrence 
of relapse in patients on a regimen of once weekly rifapentine and isoniazid, suggesting 
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that isoniazid might have been ineffective in preventing development of rifamycin 
resistance.  
 
In all the models, clearance and volume were scaled using allometric approach, and this 
choice over using weight as a linear covariate was also supported by the data following 
general criteria such as the OFV. The use of allometric to account for differences in 
pharmacokinetics due to body size is supported by both empirical observation and 
biological theory, as discussed in depth by Anderson and Holford (Anderson & Holford 
2008, 2009). 
 
Although children in this current study received similar formulations across the 2 
cohorts, formulation is known to be an important determinant of bioavailability 
(Agrawal et al. 2004, McIlleron et al. 2006). Other factors encountered when preparing 
suspensions and administering the drug are likely to play a role in young children who 
cannot swallow tablets. There is a need for studies to evaluate such sources of variability 
in paediatric drug exposure and to develop solutions to reduce it. Genetic diversity is 
also an important consideration when extrapolating the results of pharmacokinetic 
studies. There is considerable geographic variation in the distribution of NAT2 
polymorphisms (Fuselli et al. 2007, Sabbagh et al. 2011). Moreover, recent studies have 
identified polymorphisms of SLCO1B1 (which encodes the OATP1B1 transporter) 
occurring in relatively high frequencies in African populations, associated with 
substantially reduced rifampicin exposure (Chigutsa et al. 2011, Weiner et al. 2010). 





Limitations of the pharmacokinetic models include the fact that the AMA values and z-
scores used to test anthropometric associations with the pharmacokinetic parameters 
were not derived specifically from an African population, and thus they may not have 
correctly described the children used in this analysis. Furthermore, a limitation of 
simulation approach of this current analysis is that it did not into account for any 
nonlinearity in the pharmacokinetics that may occur at the higher doses; hence 
predictions in this analysis should be confirmed in pharmacokinetic studies in children 
dosed according to the revised guidelines. Also, non-linearity at higher doses could be a 
toxicity rather than efficacy concern.  Finally, the simulations used were against 
pharmacokinetic and not pharmacodynamics target though it is still debatable.  
5.5 Conclusion  
In summary, the models in this study described the population pharmacokinetics of 
rifampicin, pyrazinamide and isoniazid in children with tuberculosis. Simulations based 
on these models predict that the newly-recommended weight band-based doses in WHO 
guidelines for children result in rifampicin exposures in paediatric population which are 
similar to those in adults from the same study population. But, when children are dosed 
in pragmatic weight bands, there is wide variability in drug exposure, and pyrazinamide 
and isoniazid exposures in many children will be lower than those in an ethnically 
similar adult population. Hence, adjustment of the recommended doses may be 
warranted should the findings be confirmed in other populations.  
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6 Effects of Four Different Meal Types on the Population Pharmacokinetics 
of Single-Dose Rifapentine in Healthy Male Volunteers 
 
6.1 Introduction 
Rifapentine, a cyclopentyl rifamycin, is an orally administered drug registered by the 
Food and Drug Administration (FDA) for the treatment of pulmonary tuberculosis. It 
exerts its antibacterial activity through inhibition of DNA-dependent RNA 
polymerase in susceptible strains of Mycobacterium tuberculosis (Wehrli 1983). 
Rifapentine has a microbiologically active metabolite, 25-desacetyl rifapentine  
(Heifets et al. 1990). Rifapentine has a long half-life (Burman et al. 2001, Keung et al. 
1999) and superior in vitro potency against M. tuberculosis in comparison with 
rifampin (Heifets et al. 1990), making it an attractive candidate for shortening and 
simplifying antitubercular therapy. 
Currently, rifapentine is dosed at 600 mg either once weekly or twice weekly in HIV-
negative patients with noncavitary tuberculosis (Blumberg et al. 2003). There is 
concern that the development of ARR, treatment failure, and relapse may be 
associated with intermittent dosing (Burman et al. 2006, Menzies et al. 2009), 
insufficient companion drug exposure (Weiner et al. 2005), or low rifamycin 
concentrations (Gumbo et al. 2007a, Mitchison 1998). Previously, rifapentine's 
sterilizing effect has been shown to be dose dependent in murine studies which 
suggest that daily doses of rifapentine may reduce treatment duration to just 3 months 
(Rosenthal et al. 2006, 2007; Zhang et al. 2009), and higher doses of rifapentine are 
associated with improved early bactericidal activity in humans (Sirgel et al. 2005). 
Clinical trials are currently evaluating new antituberculosis regimens containing 
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higher doses of rifapentine used intermittently or daily doses of rifapentine. 
Concomitant food has a marked effect on rifapentine absorption (Chan et al. 1994). 
The effect of food on systemic rifapentine exposure may therefore impact treatment 
activity and safety. The aim of this study was to investigate the effect of meals 
differing in fat and bulk content on the rate and extent of rifapentine absorption and 
25-desacetyl rifapentine disposition. The study was designed to include meals 
comprising largely maize, a staple cereal in many parts of Africa and South America, 
and a light meal (i.e., a reconstituted powdered chicken soup). The study was 
conducted in 1999 shortly after the release of results from studies evaluating 
intermittent 600-mg doses of rifapentine, which displayed unacceptably high relapse 
rates in patients with lung cavities or immune suppression. It was therefore 
anticipated that future studies would evaluate higher doses of rifapentine. 
6.2 Setting and Study Design 
The data used were from the health volunteer study described in Section 4.2.2.  Each 
participant provided written informed consent before being enrolled into the study. 
The study protocol (M000473/1LO1) was reviewed and approved by the Research 
Ethics Committee of the University of Cape Town and the Medicines Control Council 





















Two rashers of bacon (20 g), 1 fried egg 
(50 g), one slice white toast (30 g) with 
butter (7 g) and marmalade (10 g), two 
cups decaffeinated coffee (400 ml) with 
full cream milk (100 ml) and two 
teaspoons of sugar (10 g) (English 
breakfast) 
18.9 27 38 1966 627 
B (low fat 
and bulky 
breakfast) 
One-and-half cups soft maize meal 
porridge (375 g cooked) with three 
teaspoons of sugar (15 g), one cup of 
decaffeinated coffee (200 ml) with full 
cream milk (50 ml) and one teaspoon of 
sugar (5 g) (Maize meal porridge) 
6 3 66 1285 645 
C (high fat 
and bulky 
breakfast) 
One-and-half cups soft maize meal 
porridge (375 g cooked) with three 
teaspoons of sugar (15 g) and five 
teaspoons of lard (25 g), one cup of 
decaffeinated coffee (200 ml) with full 
cream milk (50 ml) and one teaspoon of 
sugar (5 g) (Maize meal porridge with 
lard) 
6 28 66 2229 670 




Two cups of reconstituted (powder) 
chicken noodle soup (400 ml), one cup of 
decaffeinated coffee (200 ml) with 
skimmed milk (50 ml) and one teaspoon of 
sugar (5 g) 
9 4 28 774 660 
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Volunteers were eligible if they weighed at least 50 kg, had normal physical 
examination and baseline laboratory evaluation, and were nonsmokers. Exclusion 
criteria included a history of TB, active allergies, excessive coffee or alcohol 
consumption, recent blood donation of more than 500 ml, and clinically relevant 
cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease. In 
order to limit the risks of unintended fetal exposure to the unregistered drug, women 
were excluded. Likewise HIV- or hepatitis B virus (HBV)-infected volunteers were 
excluded due to the risks of undiagnosed tuberculosis and adverse effects, 
respectively. Table 6.2 shows clinical and demographic characteristics of healthy 
male volunteers.   
Table 6.2: Demographic and clinical characteristics of healthy male volunteers 
    Variable
a
 Value 
Number of patients 35 
Median age, range (years) 23 (18, 46) 
Median weight, range (kg) 71.5 (56, 110) 
Median height, range (cm) 177(159, 192)) 
BMI, range (kg/m
2
) 22.9 (18.9, 29.8) 
a
BMI, body mass index 
 
After an overnight fast, participants received a single 900-mg dose of rifapentine 
(200 ml of water with six 150-mg Priftin tablets; Hoechst Marion Roussel, Italy) 30 
min after the meal (Table 4.1). Individuals were randomized to receive the 
rifapentine dose in the fasted state (meal E) on one occasion. Other scheduled meals 
included a standardized lunch and dinner at 6 or 12 h postdose. At each visit a 20-ml 
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blood sample was collected prior to drug administration, and 10-ml samples were 
collected 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 24, 36, 48, and 72 h after the dose to obtain 
plasma for quantification of rifapentine and 25-desacety rifapentine. Each dose was 
separated by a 14-day washout period. Seven participants were randomized to each 
of five different meal sequences. Due to the large number of potential meal 
sequences, the design was not fully balanced. The blood samples were collected by 
venipuncture into lithium-heparin-coated glass tubes and centrifuged at 2,500 rpm 
within 1 h of collection. The supernatants were transferred into two dry 
polypropylene tubes and stored at −80°C away from light until analysis.  
6.2.1 Population pharmacokinetic analysis 
The methodology applied for model building has been described in section 4.5.3 
(Population pharmacokinetic analysis). For the rifapentine concentration-time data, 
various pharmacokinetic models, including one or two compartments with first-order 
absorption and first- or zero-order elimination (Holford et al. 1992), incorporating 
either lag times (to describe the delay in the appearance of drug in plasma) or transit 
absorption compartments (Rousseau et al. 2004, Savic et al. 2007), time-varying 
clearance (Langdon et al. 2005), and enterohepatic recirculation (Roberts et al. 2002), 
were fitted to the data during model development.  
Time-varying clearance was introduced into the model as: 
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where     is the oral clearance for the ith individual,    
   
 
   is the typical oral 
clearance which later changes to    
   
 
   at MTIME,          remains zero until 
MTIME when it changes to 1,  
 
   
  represents the IIV and  
 
   
  represents the IOV.  
Covariates (age and body weight) were evaluated with respect to their impact on IIV 
in F and CL/F parameters. The effect of continuous and categorical covariates, and 
model validation were evaluated as described under section 4.5.3.1 (Model building 
and validation).  
The following equation was used in quantifying meal effects:  
                                                      
TVF is the typical bioavailability, RXF is the fractional change (all five visits) in F 
due to a given meal relative to the fasted state,    is the value of F under fasting 
conditions (fixed to 1). A similar approach was used to evaluate meal effects on the 
fixed effects for MTT and ka. The delay in absorption was modeled using a transit 
absorption model where drug absorption is described as drug movement through a 
series of hypothetical presystemic compartments, as previously suggested (Savic et al. 
2007). Carryover effects on clearance and MTIME values at each treatment period 
were evaluated relative to the first treatment period using the equation below: 
TVMT = θMTIME·(1 − θmtocc) 
where θMTIME is the typical value of MTIME (TVMT), and θmtocc is the fractional 
change in MTIME at a given occasion relative to the first occasion. After developing 
the model for rifapentine, all the parameter estimates were fixed and a model for the 
metabolite was developed. The above-mentioned pharmacokinetic models were also 
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evaluated for the 25-desacetyl rifapentine data. In addition, models accounting for 
presystemic formation of the metabolite (Kerbusch et al. 2003), loss of the parent 
drug to other metabolites (Taft et al. 1997), and saturable clearance of the metabolite 
(Relling et al. 1993) and a two-compartment model with time-varying CL/F were 
tested when developing the 25-desacetyl rifapentine  model. 
 
6.3 Results 
Rifapentine and 25-desacetyl rifapentine plasma concentrations in 2,272 samples from 
34 participants were available. Data for 1 participant, who withdrew after a single 
visit, were not available. Less than 1% of the concentration-time data were below the 
limit of quantification and therefore excluded in the pharmacokinetic analysis. A one-
compartment model with first-order absorption and time-varying clearance best 
described the rifapentine data (Figure 6.1).   
The delay in absorption was described using a transit absorption model. The residual 
error model, selected by GOF plots, IWRES versus time, and decrease in OFV, had 
both additive and proportional error terms. The model described the data well, as 
shown in Figure 6.2.  The population pharmacokinetic parameter estimates for 









Figure 6.1: Illustration of the parent metabolite model. All rifapentine is assumed to 
be converted to the major metabolite (25-desacetylrifapentine). N1represents the first 
hypothetical transit compartment up to Nn compartment. ktr is the transit rate 
constant. ka is the absorption rate constant from the hypothetical drug depot 
compartment to plasma. k (calculated as CL/Vc) is the elimination rate constant of 
rifapentine. CLm is the time-varying metabolite clearance. Vm represents volume of 
distribution of the metabolite. k34 is the first-order rate constant of the metabolite 
from plasma to the peripheral compartment, and k43 is the first-order rate constant of 









Figure 6.2: Visual predictive check for the final (left) and metabolite (right) models. 
The lower, middle, and upper solid lines are the 5th, 50th, and 95th percentiles of the 
observed data, respectively. The dotted and dashed-dotted (50th percentile) lines 
around each percentile show the 95% confidence interval from the model prediction. 
The circles are the observed concentration-time data points. 
 
Table 6.3: Final parameter estimates for rifapentine 
























 3.22 (11.9) 19.2 
(24.3) 
12.2 (9.1) 
MTT (h) 1.45 (10.8) 9.5 (87) 24.4 (13.4) 





 43 (2.6)   
V/F (L) 60.6 (9.2)   
NN 10.9 (9.6)   
ka (h
-1
) 1.66 (13.1)   
Residual variability 
Additive error  (mg/L) 0.206 (12.3)   
Proportional error (%) 10.6 (1.81)   
a
RSE, relative standard error expressed as percentage of estimate; 
b
IIV, 
interindividual variability expressed as coefficient of variation (CV); 
c
IOV, 
interoccasional variability expressed as CV; 
d
Oral clearance of rifapentine before 
MTIME; 
e
Oral clearance of rifapentine after MTIME; 
f
MTIME is the estimated time 
when oral clearance of rifapentine increases.  
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Meal A 85.7 20.1 
Meal B 32.7 40.4 
Meal C 45.7 29.3 
Meal D 48.9 30.7 
a 
Meals are described in Table 4.1 under Materials and methods. The model was 
parameterized for meal effects on oral bioavailability (F), first-order absorption rate 
constant (ka) and mean transit time (MTT). Meal effects on ka and MTT were dropped 
in the final model since they became insignificant. 
b
RSE, relative standard error 
expressed as percentage of estimate 
 
All the meals investigated in this current study increased the bioavailability of 
rifapentine relative to fasting conditions. No clinically significant demographic 
covariates were supported by the data. Accounting for the correlation between F and 
MTT (correlation coefficient = 0.65) and between CL/F and MTT (correlation 
coefficient = −0.56) in the RFP model significantly improved the model. The η 
shrinkage values for RFP CL/F, MTT, and F were 6%, 40%, and 13%, respectively. 
For model diagnostic, a VPC was preferred. 25-desacetyl rifapentine pharmacokinetic 
data were best described by a two-compartment model with time-varying clearance 
(Figure 6.1). Final PK parameter estimates for 25-desacetyl rifapentine are 
summarized in Table 6.3 and the VPC is shown in Figure 6.2. The run record and 
control stream final pharmacokinetic model for rifapentine and 25-desacetyl 





Table 6.5:  Final parameter estimates for 25-desacetyl rifapentine   





























 46.8 (0.3)   
VMC/F (L)
g
 6.36 (5.8)   
VMP/F (L)
h
 22.1 (4.8)   
QM(/h)
i
 4.4 (6.9)   
Residual variability    
Additive error  (mg/L) 0.211 (9.7)   
Proportional error (%) 19.1 (0.7)   
a
 RSE, relative standard error expressed as percentage of estimate; 
b
IIV, 
interindividual variability expressed as coefficient of variation (CV); 
c
IOV, 
interoccasional variability expressed as CV; 
d
Oral clearance of 25-desacetyl 
rifapentine before MTIME; 
e
Oral clearance of 25-desacetyl rifapentine  after MTIME; 
f
MTIME is the estimated time when oral clearance of rifapentine increases. 
g
Apparent 
volume of distribution of 25-DRFP in the central compartment; 
h
Apparent volume of 
25-desacetyl rifapentine distribution of in the peripheral compartment; 
i
intercompartmental clearance of 25-desacetyl rifapentine   
 
Clinical adverse events were mild. Three volunteers were withdrawn due to elevated 
alanine transaminase (ALT) levels. One volunteer withdrew after the first rifapentine 
dose and had an ALT level 2 times the upper normal limit (UNL). Two volunteers 
were withdrawn after the second dose; they had ALT levels 2.2 and 6.9 times the 
ULN. ALT levels in these 3 participants returned to the normal range after 
withdrawal, and they remained clinically well and asymptomatic throughout. There 
was no evidence of a relationship between toxicity and drug concentrations or meal 
type. 
6.4 Discussion 
The bioavailability of rifapentine and consequently 25-desacetyl rifapentine exposure 
were increased when single 900-mg rifapentine oral doses were administrated 
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immediately after food. The high-fat meal (an English breakfast which included one 
fried egg) had the greatest effect (Table 6.2), increasing the oral bioavailability by 
85.7%. This finding is consistent with previous studies (Chan et al. 1994, Langdon et 
al. 2005). A study conducted in Hong Kong found that 2 eggs with toast increased the 
bioavailability of rifapentine to almost the same extent as a high-fat English breakfast 
(Chan et al. 1994). This meal effect finding forms the basis for the concomitant meal 
used in the ongoing RIFAQUIN study described in section 4.2.3, in which patients 
have 2 boiled eggs and bread immediately before each weekly 1,200-mg dose or 
twice-weekly 900-mg dose of rifapentine. The finding of high-fat breakfast without 
eggs (meal C) increased bioavailability of rifapentine by only 45.7% supports the 
notion proposed by Chan et al. (Chan et al. 1994) that eggs may be effective in 
promoting rifapentine absorption, although the mechanism is unclear. Meal effects on 
tablet dissolution, gastric emptying time (hence duration of absorption), and pH 
(which may affect solubility or absorption) may, in part, account for the 
pharmacokinetic differences observed with the different meals. Surprisingly, the low-
fat chicken noodle soup (meal D) increased RFP bioavailability to an extent 
comparable to that of the maize meal porridge with lard (meal C). Monosodium 
glutamate (MSG) was one of the ingredients in the chicken noodle soup. MSG 
accelerates gastric emptying time in a high-energy, high-protein liquid diet (Zai et al. 
2009), and we suspect that it could have played a role in meal D's effect. Even though 
in the final model there was no statistically significant effects of all meals on ka and 
MTT, meal D gave the highest increase in ka (100% against the fasting state), showing 
its influence on RFP pharmacokinetics. 
The pharmacokinetics of rifapentine was best described by a one-compartment model 
with transit absorption compartments, first-order absorption, and first-order 
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elimination with time-varying clearance. Time-varying clearance is suggestive of 
autoinduction (Gordi et al. 2005, Zhu et al. 2009), and this finding is consistent with a 
recent study by Dooley et al. (Dooley et al. 2008) in which thrice-weekly doses of 
rifapentine were administered. In this current study, the autoinduction effect was 
detected with a 2-week washout between single 900-mg doses of rifapentine. The 
baseline CL/F tended to increase slightly in a cumulative manner with subsequent 
dosing occasions, and there was a tendency for the time of change (i.e., MTIME) to 
decrease slightly after each subsequent dose. Given that rifapentine and 25-desacetyl 
rifapentine  were still identifiable in plasma up to 72 h postdose and that rifapentine is 
a potent enzyme inducer, it is not surprising that the duration of its effect on clearance 
should be similar to that of rifampin (Niemi et al. 2003). 
As rifapentine concentrations had a double peak, an enterohepatic recirculation model 
was investigated. However, based on ΔOFV and other diagnostic procedures the data 
did not support an enterohepatic recirculation model. Other possible explanations 
include analytical interference due to food ingested 6 h after the dose, absorption 
windows, or progressive solubilization along the gastrointestinal tract and variable 
gastric emptying. The final pharmacokinetics models for both rifapentine and 25-
desacetyl rifapentine  differ from a previously published model (Langdon et al. 2005). 
The previous model was developed to describe patient data where the participants 
were preinduced by rifampin and were on other antituberculosis drugs. Furthermore, 
wider variability is expected among the patients described in the previous model than 
in healthy volunteers. We identified a positive correlation between IIV of oral 
bioavailability and MTT (r = 0.65), which was expected since increased MTT allows 
more time for drug absorption, while negative correlations between η values for 
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CL/F and MTT (r = −0.56) were probably due to association between IIVs for 
CL and F. 
The prominent food effect has important implications for the interpretation of studies 
evaluating antituberculosis regimens. Assuming linear pharmacokinetics of 
rifapentine over different dose ranges (Weiner et al. 2004), the results of this current 
analysis indicate that drug exposure following a 600-mg dose of rifapentine after a 
high fat meal is 24% higher than exposure after a 900-mg dose under fasting 
conditions. While higher rifapentine exposure may be beneficial in enhancing the 
efficacy of regimens, there is concern that the risk of adverse events is increased 
(Bock et al. 2002). Thus, rigorous trials of a new dosing regimen would include proof 
of efficacy and safety when rifapentine is taken with and without food, as is likely to 
occur under operational conditions. 
6.5 Conclusion 
In conclusion, as rifapentine has dose-related activity, concomitant food should be 
considered when evaluating optimal rifapentine doses in rifapentine -based regimens. 
The effects of rifapentine should be evaluated under the meal conditions that can 
feasibly be provided by tuberculosis control programs in high-burden countries; in 




7 Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary 
Tuberculosis and the Effect of Intermittent High-Dose Rifapentine 
 
7.1 Introduction 
The duration of standard therapy for pulmonary tuberculosis is at least 6 months, and 
direct observation of treatment doses is promoted to support treatment adherence. 
Strategies aiming to shorten the duration of treatment or reduce the frequency of 
treatment doses are desirable. Rifapentine has a long half-life (Burman et al. 2001) 
and has superior in vitro activity against Mycobacterium tuberculosis compared to 
rifampin (Heifets et al. 1990). Moxifloxacin has demonstrated potent bactericidal and 
sterilizing activity against M. tuberculosis in vitro and in mouse models (Hu et al. 
2003, Ji et al. 1998). Like rifapentine, moxifloxacin has a long half-life (9 to 12 h) 
(Dooley et al. 2008, Siefert et al. 1999), making it an attractive companion drug to 
prevent selection of rifapentine-resistant strains when the drugs are administered 
intermittently. However, moxifloxacin is a substrate of p glycoprotein (Brillault et al. 
2009), sulfotransferases (Senggunprai et al. 2009), and glucuronosyltransferases 
(Tachibana et al. 2005), which may be induced by rifapentine, thus potentially 
reducing systemic concentrations of moxifloxacin. 
The aim of this study was to investigate the effects of rifapentine on moxifloxacin 
pharmacokinetics, 28 adults diagnosed with pulmonary tuberculosis who were 




7.2 Setting and Study Design 
This analysis was a sub-study of RIFAQUIN study detailed in Section 4.2.3. Separate 
written informed consent for the pharmacokinetic study was obtained from 
RIFAQUIN study participants who were randomized to the two investigational arms 
with continuation-phase regimens of 1,200 mg rifapentine and 400 mg moxifloxacin 
once weekly or 900 mg rifapentine and 400 mg moxifloxacin twice weekly. The study 
protocol was reviewed and approved by the Research Ethics Committee of the 
University of Cape Town and the Medicines Control Council of South Africa. Plasma 
concentration data were collected during coadministration of moxifloxacin and 
rifapentine in the fourth month of tuberculosis treatment and again after a single 400-
mg moxifloxacin dose 4 to 8 weeks after completion of tuberculosis treatment. At 
each occasion, blood samples were collected immediately before and at 1, 3, 5, 7, 10, 
12, 26, and 50 h after the dose. 
After blood collection, plasma was separated and immediately stored at -80°C. 
Moxifloxacin concentrations were determined using LC-MS/MS as previously 
described section 4.3. The lower limit of quantification was 0.063 mg/L 
7.3 Population Pharmacokinetic analysis 
 
Moxifloxacin plasma concentration-time data were determined using LC-MS/MS as 
previously described in Section 4.3. The lower limit of quantification was 0.063 
mg/L. The methodology applied for model building has been described in section 
4.5.3. Allometric scaling was explored using either WT, FFM or NFM (calculated 
separately for each sampling period) on CL/F, Q/F, Vc/F, and Vp/F according to 
Anderson and Holford (Anderson & Holford 2008, 2009). The use of allometric 
scaling was evaluated as described under section 4.5.3 as shown below: 
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CLi = CLstd ·(WTi/52)
0.75
 
Vi = Vstd·(WTi/ 52)
1
 
where CLi is the scaled typical value of CL/F for individual i, CLstd is its typical CL 
for an individual of median weight of 52 kg in the patient population. A similar 
notation applies to Vi.. For a two-compartment model, allometric scaling was also 
applied on Q and Vp. NFM, FFM and FAT were tested through allometric scaling 
instead of total body weight. 
The FFM was calculated as follows according to Janmahasatien et al (Janmahasatian 
et al. 2005): 
    
            
    
            
 
where for females          = 37.99 and     =35.98 and for males 
          = 42.92 and     =30.93, and HT is height (m) and WT is total body 
weight (kg). Then                    .      is parameter-specific fat 
fraction associated with size. If      is 1 then WT is used for allometric scaling, if 
     is zero (0) then FFM is used. 
The effect of presence of rifapentine was parameterised as presence or absence of 
rifapentine. The following equation was used:  
                    ) 
where      fractional change in typical value       of PAR due to presence of 
covariate (COV) . The covariate relationships were tested in the model by stepwise 
addition using a change in objective function value (ΔOFV) of ≥3.84 (P ≤ 0.05) as the 
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cutoff for inclusion, followed by stepwise deletion using an ΔOFV of ≥6.83 (P ≤ 







 percentiles) age, weight, and height of the study patients 
were 40 (21, 51) years, 52 (42, 71) kg, and 163 (154, 176) cm, respectively.  
The pharmacokinetics of moxifloxacin was best described by a model with transit 
absorption compartments (Savic et al. 2007). The introduction of a second 
compartment to which distribution appears relatively late (Figure 7.1) resulted in 
ΔOFV of 99.8 points. The final structural model is represented in Figure 7.1. 
 Allometric scaling using FFM gave the best fit and was applied on CL/F, Q/F,Vc/F, 
and Vp/F. Inclusion of the effect of rifapentine on moxifloxacin CL/F further 
improved the fit (ΔOFV = −29 points) and reduced the IOV in bioavailability from 
22.9% to17.5%. Parameter estimates of the final moxifloxacin model are shown in 
Table 7.1. The co-administration of intermittent high-dose rifapentine increased the 
CL/F of moxifloxacin by 8%, corresponding to a reduction in the AUC from 0 h to 
infinity hours (AUC0-∞) of approximately the same magnitude (Table 7.2).  A one-
compartment model was previously used to describe moxifloxacin pharmacokinetics 
(Peloquin et al. 2008) and reported a somewhat lower half-life (6.53 h), CL/F (6.66 
liters/h), and apparent volume of distribution (62.79 liters); these differences are 
probably largely due to a different study design and model structure. Appendix 5 
summarises the run record and also shows the control stream of final moxifloxacin 
pharmacokinetic model. Table 7.2 shows pharmacokinetic values for different 




Figure 7.1: Illustration of the final moxifloxacin pharmacokinetic model (bottom). 
N1 to Nnrepresents a series of hypothetical transit compartments used to model the 
delay in onset of absorption, and ktr is the transit rate constant. ka is the absorption rate 
constant from the hypothetical drug absorption site (depot) compartment to 
plasma. Vc, Vp, CL, and Q are the central and peripheral volumes of distribution and 
the oral and intercompartmental clearance, respectively. (Top) Visual predictive 
check of the final moxifloxacin pharmacokinetic model. The lower, middle, and upper 
solid lines are the 5th percentiles, medians, and 95th percentiles of the observed data, 
respectively. The shaded areas are the 95% confidence intervals for the 5th percentile, 














RSE, relative standard error reported on standard deviation scale (it is approximate 
for IIV and IOV); CL/F, oral clearance; Vc/F, apparent volume of distribution of the 
central compartment; ka, first-order absorption rate constant; MTT, absorption mean 
transit time; NN, number of hypothetical transit compartments; Q/F, inter-
compartmental clearance; V/Fp, apparent volume of distribution of the peripheral 
compartment; F, oral bioavailability fixed to 1. 
b
IIV, inter-individual variability 
expressed as approximate percent coefficient of variation (% CV). 
c
IOV, inter-
occasional variability expressed as approximate % CV; 
d
CL/F, TV[CL/F]·(1+EFFRFP) 
where TV[CL/F] is the typical value of moxifloxacin CL/F when not coadministered 
with rifapentine, while EFFRFP is the fractional change in CL/F due to the 
coadministration of rifapentine; 
e
t1/2= calculated population elimination half-life when 
















TV[CL/F] (L/h) 8.50 (4.9) 12.6 (28.1)  
Vc/F (L) 114 (4.0)   
ka (h
-1
) 1.85 (22.3)  74.7 (31.0) 
MTT (h) 0.483 (22.4)  70.4 (27.0) 
NN 22.5 (44.9)   
Q/F (L/h) 2.90 (12.1)   
Vp/F(L) 41.6 (9.1)   
F 1.00  17.5 (16.3) 
EFFRFP (%)
d 
8.03 (21.5)   
t1/2
e
 (h) 9.23   
Additive residual 
error (mg/L) 
0.0189 (19.5)   
Proportional residual 
error (%) 
8.94 (4.7)   
110 
 

































Cmax, maximum plasma concentration; 
b
AUC, area under concentration-time curve; 
c
moxifloxacin coadministered with rifapentine 
 
7.5 Discussion  
 
This study found that high-dose intermittent rifapentine increased the CL/F of 
moxifloxacin by only 8% (Table 7.2). A direct effect on bioavailability was tested but 
did not reach statistical significance. The extent of interaction in our study was lower 
than the 17.2% decrease in moxifloxacin exposure previously reported in healthy 
volunteers dosed three times a week (Dooley et al. 2008). The discrepancy between 
these results may be due to differences in physiology between tuberculosis patients 
and healthy volunteers with respect to the activity of drug-metabolizing enzymes, 
genetic differences in the study population, or the different dosing strategies. Carry-
over effects due to multiple dosing of moxifloxacin during rifapentine administration 
are unlikely to have affected the results, as predose moxifloxacin concentrations were 
below the validated range in all patients but two (both received twice-weekly doses, 
and they had predose concentrations of 0.088 and 0.066 mg/L, respectively). The 
induction effect of rifapentine on moxifloxacin in this current study was less than that 
of 450 mg of rifampin dosed three times weekly (Nijland et al. 2007), possibly due to 
different dosing frequencies. Interestingly, Bliven-Sizemore et al. recently showed 
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that rifapentine in doses of 10 to 20 mg/kg is as potent an inducer of CYP3A as 
rifampin (Bliven-Sizemore et al. 2011), all dosed daily. The difference in 
moxifloxacin exposure or clearance between the regimens used in this current study 
was not detectable. Importantly, the results in this study showed that rifapentine and 
moxifloxacin can be used together but the results may not be applicable to other 
scenario where these drugs are administered more frequently. For these results to be 
generally applicable to all regimens being currently being contemplated, more studies 
are needed evaluate the autoinductive effect of rifapentine when administrated more 
frequently and at different doses, and the extent to which it affect the exposures of 
moxifloxacin.  
7.6 Conclusion 
In summary, moxifloxacin exposures were not affected by high doses of rifapentine 
given to tuberculosis patients in once- or twice-weekly doses, and the potential 




8 Moxifloxacin population pharmacokinetics and model-based comparison 
of efficacy between moxifloxacin and ofloxacin in African patients 
8.1 Introduction 
Fluoroquinolones play an important role in the treatment of MDR-TB (Falzon et al. 
2011) which is defined by resistance to both rifampicin and isoniazid (WHO 2008a). 
Fluoroquinolones differ from each other in their efficacy against M.tuberculosis as 
measured by the ratio of fAUC0-24/MIC, and also display differences in their clinical 
pharmacokinetics. The in vitro bactericidal activity of moxifloxacin against 
M.tuberculosis is superior to that of ofloxacin (Hu et al. 2003); its improved potency 
has also been confirmed in mice (Yoshimatsu et al. 2002). The substitution of 
ethambutol by moxifloxacin, but not ofloxacin, in combination with isoniazid, 
rifampicin and pyrazinamide in the treatment of susceptible tuberculosis, resulted in 
faster culture conversion (Conde et al. 2009, Rustomjee et al. 2008). New 
fluoroquinolones are usually preferred to the earlier-generation ones (WHO 2011), 
but ofloxacin is still widely used to treat MDR-TB, because of its affordability and 
availability.  
 
Moxifloxacin is rapidly absorbed and the major fraction of the dose reaches the 
systemic circulation within 2 h (Dooley et al. 2008, Siefert et al. 1999). It has a long 
half-life in humans (Dooley et al. 2008, Siefert et al. 1999) with moderate renal 
excretion of 6-20% of total elimination after intravenous administration (Siefert et al. 
1999). Moxifloxacin is a substrate of inducible P-gp (Brillault et al. 2009), 
sulfotransferases (Senggunprai et al. 2009), and glucuronosyltransferases (Tachibana 
et al. 2005). Co-administration of moxifloxacin with rifapentine (enzyme and 
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transporter inducer) gave 17.2% (Dooley et al. 2008) and 8% (Next section of results 
(Zvada et al. 2012)) decrease in moxifloxacin exposure in healthy volunteers (dosed 
three times a week) and tuberculosis patients (dosed once/twice weekly), respectively. 
Ofloxacin is rapidly absorbed with peak concentrations reached within 2 h and with a 
half-life of 6 h, which is comparable between healthy volunteers (Yuk et al. 1991) and 
patients (Belousov et al. 1996). Ofloxacin is primarily renally eliminated (Lode et al. 
1987); its concentrations were reported to increase linearly with dose, but elimination 
of ofloxacin decreases with declining renal function and increasing age (Stambaugh et 
al. 2002).  
 
The critical concentration for drug susceptibility is defined as the lowest 
concentration of a drug that inhibits ≥95% of wild-type strains lacking acquired or 
mutational resistance mechanisms to the specific drug (Canetti et al. 1969). 
Accordingly, the WHO recommends susceptibility testing breakpoint concentrations 
for moxifloxacin and ofloxacin of 0.25 and 2.0 mg/L, respectively (WHO 2008b). The 
efficacy of fluoroquinolones has been related to the fAUC0-24/MIC (Shandil et al. 
2007). Based on in vitro, murine, and clinical studies, a fAUC0-24/MIC ratio of at least 
100–125 has been proposed as reliable predictor of bactericidal activity against gram-
positive and gram-negative bacteria (Schentag et al. 2003a,b). The HFS has suggested 
a minimum target fAUC0-24/MIC ratio of 53 for M.tuberculosis as the identified target 
for suppressing the outgrowth of moxifloxacin-resistant mutants and not necessarily 
optimal bactericidal activity (Gumbo et al. 2004).  
This study aimed to describe the population pharmacokinetics of moxifloxacin using 
data from 241 South African and Zimbabwean patients with pulmonary tuberculosis 
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who participated in the RIFAQUIN study (Section 4.2.3). Monte Carlo simulations 
were then employed to assess the probability of reaching the fAUC0-24/MIC target 
using moxifloxacin and ofloxacin at the recommended doses for MDR-TB (WHO 
2008a). For ofloxacin pharmacokinetics we used a population model that we reported 
previously (Chigutsa et al. 2012), while the MIC distribution of moxifloxacin and 
ofloxacin for drug-resistant M.tuberculosis isolates were previously determined 
(Sirgel et al. 2012).  
 
8.2 Setting and Study Design 
This analysis was a sub-study of RIFAQUIN study described in Section 4.2.3. 
Patients (n=241) with pulmonary TB received an initial intensive phase of therapy 
including daily rifampicin and moxifloxacin for 2 months. For the continuation phase 
they were treated with either 400 mg moxifloxacin once weekly together with 1200 
mg rifapentine or 400 mg moxifloxacin twice weekly with 900 mg of rifapentine. 
Pharmacokinetic sampling was carried out during the 4th month of therapy. The doses 
of rifapentine and moxifloxacin were taken with 240 mL of water 15 minutes after the 
patients received 2 hard-boiled eggs with bread. Four hours after dosing, a light meal, 
snacks and fluids were provided. Pharmacokinetic samples were obtained 
immediately before dosing and at 1, 2, 3, 5, 7, 10, 12, 26 and 50 h after the dose in 28 
patients. In the remaining 213 patients samples were obtained at 2 (± 0.5) h, 5 (± 0.5) 
h, and 24 (± 3) h or 48 (± 3) h after dosing. HIV positive patients who required 
antiretroviral treatment at randomisation were excluded. Separate written informed 
consent for the pharmacokinetic study was obtained from the RIFAQUIN study 
participants in Harare (Zimbabwe), and Johannesburg (Gauteng) and Worcester 
(Western Cape, South Africa). The study protocol was reviewed and approved by the 
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London-Surrey Borders Research Ethics Committee (ref: 07/Q0806/58), the Research 
Ethics Committee of the University of Cape Town, the Medicines Control Council of 
South Africa, the Medicines Research Council of Zimbabwe, and the Medicines 
Control Authority of Zimbabwe. After blood collection, plasma was separated and 
immediately stored at -80°C, and moxifloxacin concentrations were determined using 
LC-MS/MS as previously described in Section 4.3. The lower limit of quantification 
was 0.063 mg/L. The MICs of Clinical isolates are shown in Table 8.1. MICs of 
moxifloxacin and ofloxacin were determined for 197 drug-resistant M.tuberculosis 
isolates from patients in the Western Cape, South Africa by BACTEC MIGIT 960 as 
previously described in Section 4.2.4. The 0.25 mg/L and 2.0 mg/L concentrations of 
moxifloxacin and ofloxacin were used as susceptibility breakpoints to differentiate 
between susceptible and resistant strains as suggested by WHO (WHO 2008b). 
8.2.1 Population pharmacokinetic analysis.  
The methodology applied for model building has been described in  Section 4.5.3 
(Population pharmacokinetic analysis). In addition, a lognormal distribution for IIV 
was assumed and additive and/or proportional models for the RUV were evaluated. 
LLOQ data were modelled using the M3 method (Bergstrand & Karlsson 2009). The 
tested covariates included age, HIV status, sex, site, and regimen/arm (once weekly 
vs. twice weekly). The detected covariate effects were included in the final model if 




Table 8.1: The MIC distribution of moxifloxacin and ofloxacin in 197 Mycobacterium tuberculosis isolates 

















Moxifloxacin           
INH
 
68         68 
RIF 5         5 
MDR 55 2 1       58 
MDR+INJ 12 2 3       17 
MDR+FLQ    3 2     5 
XDR  2 1 17 22 2    44 
Ofloxacin           
INH
 
  59 9      68 
RIF   5       5 
MDR   47 9 1 1    58 
MDR+INJ   9 2 6     17 
MDR+FLQ      3  1 1 5 
XDR     1 10 6 10 17 44 
*Resistance Profiles: Resistance to either isoniazid (INH) or rifampicin (RIF) is mono-resistance; MDR is resistance to both INH and RIF; 
MDR+INJ, MDR plus resistant to an injectable; MDR+FLQ, MDR plus resistant to either fluoroquinolone; XDR is MDR plus resistance to both 
a FLQ and an injectable 
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Precision of parameter estimates were obtained from a non-parametric bootstrap 
(N=200). The use of allometric scaling was evaluated as described under section 4.5.3. 
The following equation was used for allometric scaling:  
CLi = CLstd ·(WTi/55.8)
0.75
 
Vi = Vstd·(WTi/ 55.8)
1
 
where CLi is the scaled typical value of CL/F for individual i, CLstd is its typical CL for 
an individual of median weight of 55.8 kg in the patient population. A similar notation 
applies to Vi. For a two-compartment model, allometric scaling was also applied on Q 
and Vp. NFM, FFM and FAT were tested through allometric scaling instead of total 
body weight. The FFM was calculated as follows according to Janmahasatien et al 
(Janmahasatian et al. 2005): 
    
            
    
            
 
where for females          = 37.99 and     =35.98 and for males 
          = 42.92 and     =30.93, and HT is height (m) and WT is total body 
weight (kg). Then                    .      is parameter-specific fat 
fraction associated with size. If      is 1 then WT is used for allometric scaling, if      
is zero (0) then FFM is used.  
8.2.2 Pharmacokinetic simulations and probability of target attainment  
The final pharmacokinetic model was used to perform Monte Carlo simulations in 
10,000 individuals after multiple daily doses of 400 mg moxifloxacin to obtain steady-
state fAUC0-24. Daily doses of 800 mg of moxifloxacin were also explored. The 
simulated fAUC0-24 were obtained by using covariate distributions similar to the 
population on which the model was developed, and assuming 50% plasma protein 
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binding for moxifloxacin (Andersson & MacGowan 2003, Siefert et al. 1999, Zhanel et 
al. 2002). Similar simulations were performed to obtain the fAUC0-24 for ofloxacin using 
a previously published model, developed from South African patients with MDR-TB 
(Chigutsa et al. 2012), using unbound fraction of 0.75 in humans (Lode et al. 1987).The 
estimated fAUC0-24/MIC ratios were obtained dividing fAUC0-24 by MICs ranging from 
0.125 to 8 mg/L. MIC distributions of moxifloxacin and ofloxacin of drug-resistant 
M.tuberculosis isolates were from a separate study in patients from the Western Cape, 
South Africa (Sirgel et al. 2012). For the comparison we used targets fAUC0-24/MIC 
≥100 and fAUC0-24/MIC ≥53. The probability of target attainment (PTA) was calculated 
as the proportion of individuals achieving fAUC0-24/MIC ≥100 (or ≥53) for a specific 
MIC. The cumulative fraction of response (CFR) (Mouton et al. 2005) was calculated as 
the weighted average of the PTA across the MIC strata, as shown below: 
      ∑                 
 
   
 (1) 
The PTA at each MICi level was multiplied by the relative frequency of that MIC in the 
study population, p(MICi). The used in this current analysis was target was CFR ≥90%. 
 
8.3 Results 
Although the RIFAQUIN study patients had drug-susceptible pulmonary tuberculosis, 
while the patients in the ofloxacin pharmacokinetic study had MDR-TB, their 
demographic and patient characteristics were similar, and only differed by HIV status 
and sex (Table 8.2). The 241 patients on moxifloxacin provided 856 concentration-time 
points and only 4% were below LLOQ. Similar to  other analysis (Zvada et al. 2012), the 
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population pharmacokinetics of moxifloxacin was well described by a two-compartment 
model with first-order elimination and transit absorption compartments.  
Table 8.2: Characteristics of patients who received moxifloxacin in the RIFAQUIN 
trial, and those who were on ofloxacin in a previous study 
a
Variable Patients on 
Moxifloxacin (Jindani 
et al. 2013, 
RIFAQUIN 2008, 
Zvada et al. 2012) 
Patients on Ofloxacin 





Males (%) 153 (63) 52 (80) 






























114 (47) N/A 
a
HIV+, patients infected with Human immunodeficiency virus (HIV); BMI, body mass index 
FFM was used for allometric scaling of CL, Q and Vc, while Vp was better scaled with 
FAT. The final parameter estimates are shown in Table 8.3 and a VPC of the final model 
is shown in Figure 8.1. No significant difference in the pharmacokinetic parameters was 
found between the once and twice weekly dosing approaches, and no additional 
covariates were included except for body size, which was incorporated via allometric 
scaling. The Monte Carlo simulations predicted a median AUC0-24 of 38.7 after 400 mg 




percentiles were 21.9 and 69.6 mg∙h/L, 
respectively. Appendix 5 summarises the run record and also shows the control stream of 
final moxifloxacin pharmacokinetic model.  
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Table 8.3: Final parameter estimates for moxifloxacin population pharmacokinetic 
model 












 10.6 (2.68) 18.7 (4.05) 
Vc (L)
e





 1.50 (2.15) 69.9 (3.62) 
MTT (h)
g
 0.723 (7.02) 73.4 (2.58) 
Number of transit 
compartments 
11.6 (2.39)  
Q (L/h)
h
 2.14 (2.92) 32.9 (3.17) 
Vp (L)
i
 89.8 (3.66)  
F
j
 1 FIX 17.7 (3.28) 
Proportional error (%) 7.85 (1.44)  
a
RSE, relative standard error reported on the approximate standard deviation scale 
obtained from a bootstrap sample size of 200; 
b
IIV, inter-individual variability expressed 
as percent coefficient of variation (% CV); 
c
CL, oral clearance; 
d
Vc, volume of 
distribution in the central compartment; ka, first-order absorption rate constant; 
f
MTT, 
absorption mean transit time; 
g
Q, inter-compartmental clearance; 
h
Vp, volume of 
distribution in the peripheral compartment; 
i
F, oral bioavailability fixed to 1 since we do 
not have intravenous injection data; In this table the values of parameters directly 
estimated by the model; To obtain CL/F, the values of CL must be combined with those 
of F. Since the typical value of F was fixed to 1, the typical value of CL/F has the same 
value as CL, while the BSV of CL/F needs to keep into account both the BSV in CL and 






Figure 8.1: Visual predictive check (VPC) for the final moxifloxacin population 
pharmacokinetic model. In the upper panel, the lower, middle and upper solid lines are 
the 2.5th, median, and 97.5th percentiles of the observed plasma concentration, 
respectively, while the shaded areas are the 95% confidence intervals for the same 
percentiles of the simulated data. The lower panel shows the fraction of observed data 
below lower limit of quantification (LOQ) which is represented by the solid line. The 
shaded area shows simulation based 95% confidence interval around the median of LOQ 
data. 
 
The MIC distributions of moxifloxacin and ofloxacin are listed in Table 8.1. The PTA 
values for fAUC0-24/MIC ratio of >53 and >100 for both moxifloxacin and ofloxacin are 
shown in Table 8.4 and corresponding plots are shown in Figure 8.2. The PTA with a 
target fAUC0-24/MIC ratio of >53 across the range of MIC values for daily 400 mg and 
800 mg moxifloxacin doses is shown in Figure 8.3, while PTA for daily 800 mg 






Table 8.4: PTA values of ofloxacin and moxifloxacin for different target ratios 
 Target 53 Target 100 
MIC Ofloxacin Moxifloxacin Ofloxacin Moxifloxacin 
0.125 1 1 1 0.970954 
0.25 1 0.946058 0.96 0.286307 
0.5 1 0.215768 0.51 0 
1 0.94 0 0.1 0 
2 0.48 0 0 0 
4 0.07 0 0 0 













Figure 8.3: Probability of target attainment (target fAUC0-24/MIC≥ ratio 53) versus 
Mycobacterium tuberculosis isolates minimum inhibitory concentrations (MIC) for 400 
mg and 800 mg moxifloxacin dose. MDR and XDR are MIC distributions from 
multidrug resistant and extensive drug resistant isolates, respectively. MDR+INJ and 
MDR+FLQ are MIC distributions from isolates resistant to injectables and 
fluroroquinolones, respectively. The distributions of these MICs are represented by right 






Figure 8.4: Probability of target attainment (target fAUC0-24/MIC≥ ratio 53 or 100) 
versus Mycobacterium tuberculosis isolates minimum inhibitory concentrations (MIC) 
for 800 mg ofloxacin dose. MDR and XDR are MIC distributions from multidrug 
resistant and extensive drug resistant isolates, respectively. MDR+INJ and MDR+FLQ 
are MIC distributions from isolates resistant to injectables and fluroroquinolones, 
respectively. The distributions of these MICs are represented by right side y-axis. 
 
Table 8.5 shows the CFR for daily 400 mg and 800 mg moxifloxacin, and daily 800 mg 
ofloxacin with a target fAUC0-24/MIC of either >53 or >100. Moxifloxacin 400 mg had 








Table 8.5: The cumulative fraction of response (CFR) for daily doses of 400 mg and 
800mg moxifloxacin, and 800 mg ofloxacin for target fAUC0-24/MIC ratio of 53 (Gumbo 
















MDR  0.98 1.00 0.84 
MDR+INJ 0.84 0.98 0.58 
MDR+FLQ 0.00 0.09 0.00 
XDR 0.04 0.12 0.00 
fAUC0-24/MIC≥100 
MDR  0.88 0.98 0.43 
MDR+INJ 0.68 0.85 0.28 
MDR+FLQ 0.00 0.00 0.00 
XDR 0.01 0.04 0.00 
MDR is resistance to both isoniazid (INH) and rifampicin (RIF); MDR+INJ, MDR plus 
resistant to an injectable; MDR+FLQ, MDR plus resistant to either fluoroquinolone; 
XDR is MDR plus resistance to both a FLQ and an injectable. 
 
8.4 Discussion  
The results of this analysis revealed that the CFR for 400 mg moxifloxacin was 98% 
versus 84% for 800 mg ofloxacin by using a target fAUC0-24/MIC ratio of >53. With the 
more stringent target ratio of >100, the difference in the performance of the drugs was 
even more marked, and both regimens fell short of the 90% CFR threshold (the CFR for 
moxifloxacin was 88%, versus 43% for ofloxacin). On the other hand, with 800 mg 
doses of moxifloxacin in the same patients with MDR-TB and the target ratio of >100, a 
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CFR of 98% would be achieved (Table 8.5). The higher moxifloxacin dose (800 mg) 
also achieved the pharmacodynamic target ratio of >53 in 98% of MDR-TB patients 
with resistance to an injectable agent whereas the standard 400 mg dose had a marginal 
CFR of 84% (Table 8.5). 
Moxifloxacin has structural differences to ofloxacin at the C-7 position that reduces the 
ability of the bacterium to efflux moxifloxacin across the cell wall, thus lowering the 
MIC. Moxifloxacin also has superior intracellular killing kinetics to ofloxacin. 
Experimental data show that moxifloxacin MICs in macrophages increased by only 2-
fold when compared to MIC in extracellular broth, while 4-fold increases were 
demonstrated for ofloxacin (Shandil et al. 2007). 
Using a target fAUC0-24/MIC ≥53, the currently recommended 400 mg daily dose of 
moxifloxacin, obtained a PTA greater than 90% when the isolates had MICs ≤0.25 
mg/L. On the other hand, ofloxacin failed to achieve a PTA of more than 90% when the 
MIC was >0.5 mg/L, as found in about 20% of the isolates, classified by standard 
procedures as resistant to rifampicin and isoniazid but not to injectable second line drugs 
(such as capreomycin, kanamycin or amikacin), or fluoroquinolones. Hence, findings in 
this study suggest that a 4-fold reduction in the susceptibility breakpoint for ofloxacin, 
which is currently set at 2.0 mg/L, may be warranted. However, clinical correlates for 
the fAUC0-24/MIC targets are lacking for patients with tuberculosis, and using the target 
of 100 would suggest revision of the ofloxacin susceptibility breakpoint down to 0.25 
mg/L. It should be noted that the target ratio of 53 which we used for comparison of 
fluoroquinolones was derived only for moxifloxacin and this value is not necessarily 
applicable to ofloxacin. The current doses for moxifloxacin (400 mg) and ofloxacin (800 
mg) may thus be suboptimal for the treatment of drug-resistant tuberculosis if a 
pharmacodynamic target of fAUC0-24/MIC ≥100 correlates better with successful clinical 
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outcomes. Simulations results in this study suggest susceptibility breakpoints of 0.125 
mg/L for 400 mg doses of moxifloxacin and 0.25 mg/L for 800 mg ofloxacin. Doubling 
the dose of ofloxacin is unlikely to achieve acceptable PTA in many patients when a 
target of 100 and critical concentration of 2.0 mg/L are considered (Table 8.4, Figure 
8.2) supporting previous findings (Chigutsa et al. 2012). On the other hand, simulations 
in this study show that doubling the moxifloxacin dose to 800 mg daily could lead to 
acceptable PTA (Table 8.4 and Figure 8.2-3), and this is consistent with previous reports 
(Gumbo et al. 2004). Higher doses of moxifloxacin may increase moxifloxacin side 
effects including QT interval prolongation (Falagas et al. 2007) and this concern is 
particularly serious, given the long duration of MDR-TB treatment. However, limited 
studies seem to suggest safety of higher doses. A recent study by Ruslami et al. (Ruslami 
et al. 2013) which evaluated daily 800 mg doses of moxifloxacin did not show increased 
toxicity, while a study by Alffenar et al. showed tolerability at 600 mg and 800 mg 
moxifloxacin (Alffenaar et al. 2009). An ongoing clinical trial by Alffenar et al. is 
evaluating the safety of moxifloxacin at escalated doses of 600 and 800 mg 
(NCT01329250: http://clinicaltrials.gov/show/NCT01329250).  
 
The continued use of fluoroquinolones in suboptimal doses may hinder their use in the 
future due to the development of fluoroquinolone resistance (Ginsburg et al. 2003).  The 
target fAUC0-24/MIC ratio of >53 is based on studies showing suppression of resistance 
emergence with moxifloxacin monotherapy in a HFS (Gumbo et al. 2004). In this 
current study study, 400 mg moxifloxacin was shown to attain a CFR >90% for 
M.tuberculosis. strains resistant to isoniazid and rifampicin but not injectable agents, 
while ofloxacin at 800 mg daily did not. However, for MDR-TB strains resistant to 
injectable agents only the 800 mg daily doses of moxifloxacin achieved a CFR >90%. 
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The target ratio >100 is based on review on studies in gram-positive and gram-negative 
bacteria conducted in animals (Schentag et al. 2003a) and humans (Schentag et al. 
2003b). In patients, values of 125–250 were associated with clinical cure and speed of 
bacterial eradication for gram-negative infections of the respiratory tract (Forrest et al. 
1993), and the target value of >100 was linked to decreased emergence of bacterial 
resistance (Thomas et al. 1998). For gram-negative organisms, a target of 100–125 
achieved acceptable activity, although more rapid eradication was achieved with a target 
fAUC0-24/MIC ratio of ≥250 (Forrest et al. 1993), when ciprofloxacin, grepafloxacin, 
levofloxacin, and gatifloxacin were evaluated. Considering sterilizing activity including 
killing of the M.tuberculosis within macrophages, the target of 100 may be more 
appropriate, as penetration to the site of action should be considered (Shandil et al. 
2007). Fluoroquinolones generally achieve higher concentrations in epithelial lining 
fluid (ELF) than in plasma (Kiem & Schentag 2008), which means that the PTA and 
CFR is this study would be higher at the site of action than when plasma concentrations 
are used. Compared with other fluoroquinolones, moxifloxacin has been found to have 
greater efficacy than levofloxacin in mice despite a lower plasma AUC/MIC ratio 
(Ahmad et al. 2013), presumably due to higher intracellular concentrations of 
moxifloxacin. Levofloxacin, however, penetrates into cerebrospinal fluid of patients with 
tuberculosis meningitis better than ciprofloxacin and gatifloxacin (Thwaites et al. 2011). 
In comparison to another moxifloxacin population pharmacokinetic model (Peloquin et 
al. 2008), we found a reduced IIV on V, but significant IIV on CL and F. In this current 
study, estimate of CL was 25% higher than that reported by Peloquin et al.; this may be 
due to the different the study population, but it may also be a consequence of the 
differences in dosing schedules, sampling times and the structural model used to 
interpret the data.  
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8.4.1 Limitations  
Due to limited sample size, the MIC data in this analysis may not represent the true 
distribution for some drug-resistance categories. The M.tuberculosis isolates used to 
determine the MICs originated from patients in the same region as those contributing 
data to the pharmacokinetic model (Table 8.1). Given the limited geographical 
distribution of the study population and M.tuberculosis isolates contributing to this 
current analysis, it cannot be assumed that the PTA and especially the CFR analyses will 
be applicable to other populations outside the region. In addition, this study compares 
the activities of moxifloxacin with ofloxacin using pharmacodynamic targets derived in 
experiments using the drugs alone, as monotherapy. Previous studies have shown that a 
combination of rifampicin (a rifamycin) and moxifloxacin suppresses resistance 
emergence, but at the price of slightly slowing bacterial kill (Balasubramanian et al. 
2012, Drusano et al. 2010). Comparisons in this study did not take into account within 
regimen synergy or antagonism (Balasubramanian et al. 2012), although these effects are 
unlikely to differ considerably within the fluoroquinolone class. The pharmacodynamic 
targets used are based on experimental models which differ from the organism-drug 
interface in patients. Importantly, the diversity of the M.tuberculosis growth states 
encountered in patients is not accounted for. Moreover, this study assumed unbound 
plasma concentrations as a marker of exposure, while tissue free drug concentration, 
would be more appropriate.  
8.5 Conclusion 
This analysis which is based on the pharmacokinetic and drug susceptibility distributions 
in African patients indicate that, in currently used doses, moxifloxacin is more 
efficacious than ofloxacin for the treatment of MDR-TB. Doubling the dose of 
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moxifloxacin to 800 mg daily improves the CFR. However, further clinical studies are 




9 Investigation of population pharmacokinetic summary variables of rifapentine and 
moxifloxacin as of predictors of treatment outcome 
9.1 Introduction  
 
The duration of standard therapy for tuberculosis of 6 month is lengthy. Novel regimens 
for the treatment of tuberculosis aiming at potentially reducing the duration of standard 
therapy from 6 months without compromising the efficacy of the drugs have been 
proposed based on mouse studies (Rosenthal et al. 2007). These novel combinations 
involve replacement of isoniazid with moxifloxacin in intensive and continuation phase, 
and replacement of rifampicin with high-dose daily or intermittent rifapentine in both 
intensive and continuation phase. The choice of replacing isoniazid with moxifloxacin 
was based on demonstrated potent bactericidal and sterilizing activity of moxifloxacin in 
vitro and in mouse models (Ji et al. 1998, Yoshimatsu et al. 2002).  
Like rifapentine, moxifloxacin has a long half-life (9 to 12 h) (Dooley et al. 2008, Siefert 
et al. 1999), making it an attractive companion drug to prevent selection of rifapentine-
resistant strains when the drugs are administered intermittently. The effect of high dose 
intermittent rifapentine on moxifloxacin pharmacokinetics has been shown to be 
clinically insignificant in patients, with only minor drug-drug interaction detected 
(Zvada et al. 2012).  Higher doses of rifamycin have been proposed to be more 
efficacious and beneficial preventing rifamycin resistance, and this is supported by 
studies of rifamycin activity in vitro (Gumbo et al. 2007a), murine (Jayaram et al. 2003) 
and in humans (Sirgel et al. 2005). A previous study evaluating higher doses of 
rifapentine suggested that they can be tolerated in humans (Weiner et al. 2004). 
Concomitant food has a marked effect on rifapentine absorption (Chan et al. 1994). 
Rifapentine has a long half-life (Burman et al. 2001, Keung et al. 1999), superior in vitro 
potency against M. tuberculosis in comparison with rifampin (Heifets et al. 1990), and 
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rifapentine is approximately 4 times more potent (on  equivalent 10 mg/kg body weight 
basis) than rifampicin when used alone and/or in combination with other first-line drugs 
(Rosenthal et al. 2012). Despite the encouraging results from mouse studies which 
supported the reduction of duration of therapy to less than 6 months,  a Phase 2 study in 
patients with tuberculosis (TBTC study 29) showed that rifapentine did not improve 2 
month culture conversion results (Dorman et al. 2012) as suggested by mouse studies; 
presumably due to high protein binding (98%) of rifapentine in humans (Mitchison 
1998). However, a follow up Phase 2b TBTC study 29X which evaluated daily 
rifapentine escalating doses up to 20 mg/kg showed superior 2-month culture results 
compared to standard dose of rifampicin (Savic et al. 2013).  
The Phase 3 RIFAQUIN clinical trial (Section 4.2.3) evaluated substitution of isoniazid 
with moxifloxacin in the intensive phase of tuberculosis treatment coupled with use of 
high dose intermittent rifapentine with moxifloxacin in the continuation phase of 
tuberculosis treatment using two different dosing schedules: twice weekly 900 mg 
rifapentine with moxifloxacin for 2 months in continuation phase or once weekly 1200 
mg rifapentine with 400 mg moxifloxacin for 4 months in continuation phase. Each 
rifapentine dose was administered under observation with a meal of two boiled eggs and 
bread in order to facilitate rifapentine absorption. Hence, the aim of this study was to 
investigate the relationship between probability of relapse in the RIFAQUIN study with 
pharmacokinetics and PKPD parameters (during continuation phase treatment) of 
rifapentine and moxifloxacin: AUC, Cmax, total AUC for continuation phase of 
treatment (AUCtotal), AUC/MIC, Cmax/MIC, TAMIC in modified “intention to treat” 
(mITT) group of patients in 4-month and 6-month.  In order to estimate rifapentine 
PKPD parameters, a population pharmacokinetic model for rifapentine was developed. 
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Estimation of moxifloxacin pharmacokinetics and PKPD parameters was done using the 
moxifloxacin model described in Chapter 7. 
 
9.2 Setting and Study design 
 
The RIFAQUIN study comprised of two experimental arms which were: 1) 4-month arm 
where isoniazid was substituted with moxifloxacin daily for 2 months during the intensive 
phase and the continuation phase comprised 2 months of twice-weekly moxifloxacin and 
900mg rifapentine; 2) 6-month arm: isoniazid replaced by moxifloxacin daily for the 2-month 
continuation phase which was followed by 4 months of once-weekly moxifloxacin and 
1200mg rifapentine. This analysis is a sub-study of RIFAQUIN trial (Section 4.2.3) which 
comprised of a subset of 241 patients from two experimental arms and these patients also 
underwent population pharmacokinetic analysis of rifapentine and moxifloxacin studies. The 
clinical and demographic characteristics of PKPD patient subset (N=241) included in this 
analysis are summarized in Table 9.1. Out of 241, a total of 18 patients (7.5%) relapsed (13 
and 5 from 4-month and 6-month arm, respectively). The study protocol was reviewed and 
approved by the Research Ethics Committee of the University of Cape Town, the Medicines 
Control Council of South Africa, the Medicines Research Council of Zimbabwe, and the 







Table 9.1: Baseline characteristics of pharmacokinetic-pharmacodynamic (PKPD) patient 
subset in 4-month and 6-month arms 
Variable
a
 Patients in 4-month and 6-
month (Jindani et al. 2013, 
RIFAQUIN 2008, Zvada et 
al. 2012) 
Number of patients 241 
Males (%) 153 (63) 
HIV+ (%) 46 (19) 
Median age, range (years) 31.8 
(18.5, 79.5) 
Median weight, range (kg) 55.8 
(37.7, 77.9) 










HIV+, patients infected with Human immunodeficiency virus (HIV); BMI, body mass index 
The doses of rifapentine and moxifloxacin were taken with 240 mL of water 15 minutes after 
the patients received 2 hard-boiled eggs with bread. Four hours after dosing, a light meal, 
snacks and fluids were provided. The population pharmacokinetic sampling for both 
rifapentine and moxifloxacin was done at the 4
th
 month after starting the treatment. A subset 
of 28 patients underwent intensive pharmacokinetic sampling where blood was drawn before 
dosing and at 1, 2, 3, 5, 7, 10, 12, 26 and 50 h after the dose. In the remaining 213 patients 
samples were obtained at 3 time points: 2 (± 0.5) h, 5 (± 0.5) h, and 24 (± 3) h or 48 (± 3) h 
after dosing. The intensively sampled 28 patients were also brought in 2 months after 
completion of treatment for additional pharmacokinetic evaluation of moxifloxacin 
pharmacokinetics without presence of rifapentine and this study is described in Chapter 8 of 
this thesis.  
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 HIV positive patients who required antiretroviral treatment at randomisation were excluded.  
After blood collection, plasma was separated and immediately stored at -80°C.  
Adequacy of treatment 
A patient was considered to have received adequate treatment if both of the following 
conditions were met: at least 40 doses of intensive phase treatment were taken with 70 days 
of starting treatment; at least 16 doses were taken within 13 weeks of starting the 
continuation phase for patients on 4-month arm or within 22 weeks for patients in 6-month 
arm. The doses were supervised at the clinic or by the domiciliary treatment monitor at home.  
Assessment of outcome 
Assessable patients were classified as having a favorable or unfavorable status at the end of 
scheduled follow-up. For the mITT population, unfavorable outcome was classified as: 
patients requiring an extension, a restart, or a change of treatment for any reason other than to 
make up missed doses during the intensive or continuation phase or pregnancy; women who 
become pregnant during treatment whose last culture result was positive; patients who had a 
positive culture when last seen; patients who died in the follow-up phase with evidence 
confirmed or suggestive of possible failure or relapse of their tuberculosis. Positive cultures 
identified as being non-tuberculous mycobacteria were considered as contaminated.  
9.3 Population pharmacokinetic analysis  
 
The plasma concentration determination of rifapentine followed procedures described section 
4.3. The methodology applied for model building has been described in section 4.5.3 of this 
thesis.  
For rifapentine, there were no samples below limit of quantification. The use of allometric 
scaling was evaluated as described under section 4.5.3. CL/F and Vc/F were allometrically 
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scaled using WT according to Anderson and Holford (Anderson & Holford 2008) shown 
below:  
CLi = CLstd ·(WTi/55.8)
0.75
 
Vi = Vstd·(WTi/ 55.8)
1
 
where CLi is the scaled typical value of CL/F for individual i, CLstd is its typical CL for an 
individual of median weight of 55.8 in the patient population. A similar notation applies to 
Vi. Allometric scaling with FFM was also assessed. The tested covariates included age, HIV 
status, sex, site, and arm (4-month versus 6-month) and evaluated as described in section 
4.5.3 of this thesis. The final pharmacokinetic model was used to generate AUC, Cmax, 
AUCtotal, AUC/MIC, Cmax/MIC, AUCtotal/MIC, and cumulative TAMIC; and these 
pharmacokinetic variables were compared between arms. The MIC value for rifapentine of 
0.12 mg/L was obtained from a study conducted in South African patients (Sirgel et al. 2005).  
 
The population pharmacokinetics model of moxifloxacin used in this analysis has been 
previously described in 241 patients who participated in the RIFAQUIN trial (Chapter 
8).  Briefly, moxifloxacin pharmacokinetics was best described by a two-compartment 
model with first-order elimination and transit absorption compartments. FFM was used 
for allometric scaling of CL, Q and Vc, while Vp was better scaled with FAT. This 
model was used to estimate pharmacokinetic variables such as AUC, Cmax, AUCtotal, 
AUC/MIC, Cmax/MIC, AUCtotal/MIC, and cumulative TAMIC. The MIC value of 0.25 
mg/L was used, which is the susceptibility testing breakpoint concentrations of 




For each drug, both parametric (t-test) and non-parametric (Mann–Whitney U test) 
methods were used to compare estimated pharmacokinetic variables between 4-month 
and 6-month arms. The two-tailed probability of rejecting null hypothesis was set at 5% 
significance level (p=0.05).  
9.4 Parametric hazard modeling (Pharmacokinetic-pharmacodynamic (PKPD) 
analysis) 
 
A parametric hazard model was fitted to the relapse data combined from the two 
experimental arms. The hazard of unfavorable outcome at time t was modeled as: 
h(t)=Pr(t≤T<(t+dt|T>t); where Pr is the probability of having an event within the very short 
time interval dt, provided that one did not have an event before time t. The probability of 
having favorable outcome was modeled as a function of the cumulative hazard of an 
unfavorable event (integral of the hazard with respect to time) for each day from date of 
randomization using the following function:        ∫       
 
 . The pdf of having an event at 
time t was modeled as: pdf = h(t) x S(t).  The baseline survival models tested were 
parameterized as follows (Weibull function):           
 
 where   is the baseline hazard 
and α is the shape parameter. If α =1, then the hazard in constant over time, if α <1, then 
hazard decreases with time and if α >1 the hazard increases with time. Model selection and 
choice was based on VPC and ∆OFV as in pharmacokinetic models.   
Continuous covariates tested on   and α were AUC, Cmax, AUCtotal, AUC/MIC, Cmax/MIC, 
AUCtotal/MIC, and cumulative TAMIC, CD4 count, age, and weight. Categorical covariates 
tested on   and α were: treatment duration, cavitation, history of smoking, HIV status and 






Population pharmacokinetics of rifapentine 
A total of 826 plasma concentration-time points were available from 241 patients who 
participated in the RIFAQUIN population pharmacokinetic study. The population 
pharmacokinetics of rifapentine was best described with a one compartment model with first-
order absorption and transit absorption compartments. Allometric scaling using total body 
weight on CL/F and Vc/F was best which improved the fit by 40 points ∆OFV, and it 
explained 4% of variability on either CL/F and 4% on Vc/F. HIV status was found to 
significantly reduce   bioavailability by 27.6% and it reduced correlation between CL/F and 
Vc/F from 66% to 60%.  Sex and arm were also found to exhibit significant effect on CL/F 
with females showing 15.2% lower CL/F and twice weekly arm exhibiting 10.4% increase in 
CL/F. Inclusion of sex and regimen effects explained 1% and 0.1% variability in CL/F 
respectively. The final estimate of correlation between CL/F and Vc/F was 0.6. The final 
parameter estimates are shown in Table 9.2, and Figure 9.1 shows the VPC stratified by arm. 
















CL (L/hr) 1.08 (3.0) 28.6 (4.5) 
Vc(L) 24.5 (2.4) 23.5 (6.5) 
ka (hr
-1
) 0.885 (8.7) 43.8 (17.6) 
MTT  (hr) 1.45 (4.2) 38.5 (8.1) 
NN 8.41 (15.1)  
F 1  
Proportional residual error (%) 10.8 (5.2)  
Additive residual error (mg/L) 0.463 (19.8)  
HIV+ on F  -27.6 (10.3)  
Twice weekly arm on CL +10.4 (36.7)  
Female on CL -15.2 (22)  
a
RSE, relative standard error reported on standard deviation scale (it is approximate for IIV 
and IOV); CL, oral clearance; Vc, apparent volume of distribution of the central 
compartment; ka, first-order absorption rate constant; MTT, absorption mean transit time; 
NN, number of hypothetical transit compartments; F, oral bioavailability fixed to 1. 
b
IIV, 






Figure 9.1: Visual predictive check (VPC) for the final rifapentine population 
pharmacokinetic model. The lower, middle and upper solid lines are the 2.5th, median, and 
97.5th percentiles of the observed plasma concentration, respectively, while the shaded areas 
are the 95% confidence intervals for the same percentiles of the simulated data.  
 
Pharmacokinetic-pharmacodynamic (PKPD) analysis 
Out of 241 patients who participated in the pharmacokinetic studies, 186 patients were 
eligible for mITT analysis. Out of these 186 patients, only 18 experienced relapse. The 
baseline hazard model for the mITT population (N=186) was best described with a constant 
hazard model. Time varying hazard model was somewhat better, however improvement in 
the fit was not significant (p=0.056). In the covariate analysis, the only significant covariate 
found was treatment duration (p=0.03) with 2 months of continuation phase significantly 
increasing relapse hazard compared to 4 months of continuation phase. The effect of AUC, 
Cmax, AUC/MIC, Cmax/MIC, cumulative TAMIC, in addition to patients clinical and 
demographics information, did not show relationship with treatment outcome in 186 patients 
subset studied in this current analysis. The final parameter estimates are shown in Table 9.3. 
An appendix 7 shows the control stream of the final parametric hazard model. 
4-month arm 6-month arm 
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Table 9.3: Parameter estimates for of the final parametric hazard model.  
 
a
RSE, relative standard error reported on standard deviation scale. The impact is for 4-month 
on baseline hazard relative to 6-month arm 
 
The only predictor of treatment response identified in this current analysis was treatment 
duration/arm effect. However given that there were quite few differences between two 
experimental arms (choice of dose, choice of dosing schedule and choice of treatment 
duration), the increased hazard in 4 month arm could not have been solely attributable to 
treatment duration and there is a possibility that this effect had been either co-founded by 
other pharmacokinetic and PKPD factors or the observable arm effect was as a result of a 
composite effect of several factors including treatment duration. Therefore, additional 
investigation to further understand how other pharmacokinetic and PKPD parameters 
compared between two experimental arms was performed.   
 




The AUC and Cmax after 1200 mg (6-month arm) were approximately 1.5 times higher than 
after 900 mg (4-month arm) for single dosing interval (Figure 9.2 and Table 9.3), and this 
difference was statistically significant (Table 9.3). The estimates of continuation phase 
AUCtotal, AUC/MIC, and TAMIC (even after adjusting for treatment duration and dosing 
schedule) for rifapentine were all higher in 6-month arm compared with 4-month arm (Figure 




Baseline 0.00001036 (44) 
Impact of treatment duration (%)
b
  +287% (80) 
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and cumulative TAMIC were significantly higher in the 6-month arm compared to the 4-
month arm, irrespective of less frequent administration of rifapentine. 
b) Moxifloxacin 
For a single dosing interval, the estimate of moxifloxacin AUC was slightly higher (10%) in 
the 6-month arm while there was no significant difference in Cmax and Cmax/MIC between 
two different regimens. Similarly, after adjusting for treatment duration and number of doses, 
moxifloxacin AUCtotal was slightly higher in the 6-month arm.  Figure 9.3 shows the boxplots 
of different pharmacokinetic variables of moxifloxacin, and Table 9.3 summarizes the 
estimates of these variables.  Overall, there were only slight differences in moxifloxacin 
pharmacokinetic and PKPD parameters between two different arms suggesting that twice 







AUC  for single dose interval 
 






Cmax for single dose interval Cmax/MIC 
  
 
Figure 9.2: Box plots of area under curve (AUC) from 0-infinity hours and peak 
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Cmax for single dose interval Cmax/MIC 
  
 
Figure 9.3: Box plots of area under curve (AUC) from 0-infinity hours and peak 















Table 9.4: Summary of pharmacokinetic variable for rifapentine and moxifloxacin, and significance 
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p = 0.129 
a
AUC - area under the curve from 0- infinity hours; Cmax - peak plasma concentration; TAMIC - 
time above MIC. 
b
Total - refers to whole duration continuation phase adjusted for dosing schedules.
 
c
min - minimum; max - maximum. 
d
SD - standard deviation. 
e
p-probability of rejecting the null 
hypothesis when it is true (false positive result). 
f
When the MIC of 
 
≤0.125 mg/L, value for majority 





Investigation of the role pharmacokinetic variables as predictors of treatment failure/relapse 
showed no conclusive effect within each experimental arm.  This is most likely due to a very 
small number of patients experiencing unfavorable outcome (5 patients in 6 months arm 
(2.7%) against 12 patients in 4 month arm (6.45%)). The only observable difference was 
treatment arm. Even though the treatment duration was the main difference between two 
experimental arms, given that the RIFAQUIN design altered several things between two 
investigational arms (dose, dosing frequency and treatment duration), it is hard to conclude if 
better outcomes seen in 6-month arm were solely due to longer treatment duration.  For 
example, most of the pharmacokinetic summary variables and pharmacokinetic and 
pharmacodynamics (PKPD) indices for rifapentine were significantly higher in the 6-month 
arm (Figure 9.2, Table 9.3): Cmax, Cmax/MIC, AUCtotal and cumulative TAMIC. Therefore 
significant difference in relapses can likely be attributable to either of these variables 
including treatment duration or most likely the observed effect is result of combined impact 
of all these factors (high Cmax, high cumulative AUC and longer treatment duration). These 
questions require further studies.  
Compared with other studies with high dose rifapentine (TBTC Study 29X), the AUC and 
Cmax in the RIFAQUIN study were significantly higher.  For example, in the study 29X, 
median reported values of AUC following 900 and 1200 mg dose were 472 and 578 mg∙h/L 
respectively (Savic et al. 2013). While in this study these values were 746 and 1132 mg∙h/L 
for 900 and 1200 mg dose respectively.  There are two likely reasons for that: auto-induction 
time course and type of food administered. Patients in the study 29X were given daily 
rifapentine which leads to full autoinduction with CL values being doubled by end of 2
nd
 
week of daily dosing  (Savic et al. 2011) . This will have an immediate impact on drug 
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exposure. Patients in study 29X were given rifapentine with high fat food which did not 
necessarily include egg, while patients in RIFAQUIN study had 2 boiled eggs and bread 
before rifapentine was administered. Egg has been shown to increase the bioavailability of 
rifapentine (Chan et al. 1994) and most likely can boost exposure even further compared to 
the high fat meal without egg. Importantly, strategies used in the  RIFAQUIN study 
(intermittent dosing and administration of drug with egg) resulted in the highest Cmax and 
AUC values ever achievable in studies to date.  
 
The population pharmacokinetics of rifapentine was best described with a one compartment 
model with first-order absorption and elimination. The VPC (Figure 9.1) shows that the 
model did not fit well higher concentrations in 4-month arm because there were few 
individuals with very high concentrations in 4-months arm. The estimates of  CL  and Vc 
(Table 9.3) were 2 and 1.5 times lower, respectively, than what has been reported previously 
in patients with tuberculosis from ethnically similar population (Langdon et al. 2005). The 
difference in these pharmacokinetic estimates is most likely due to differences in dosing 
frequency and food effect, but could also be partly explained by different severity of disease 
and inclusion of patients from different sites in RIFAQUIN study. The effect of HIV 
infection was significant on the bioavailability, where HIV infected patients had 28% lower 
bioavailability. For rifapentine, studies of differences in pharmacokinetic parameters in HIV-
positive and -negative individuals have produced mixed results, with some groups showing 
significant differences (Peloquin et al. 1996) and others finding no clinically significant effect 
(Choudhri et al. 1997). A study conducted in South Africa (Langdon et al. 2004) showed 
good absorption of rifapentine and no differences in pharmacokinetic parameters when 
compared to HIV-negative patients. Even though these results contradict the results of this 
current analysis, the detected effect of HIV status was highly significant and this is of clinical 
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relevance. Interestingly, females had 15% lower CL than males. These results also confirm 
the sex effect which was shown before (Langdon et al. 2005). Also patients in the twice 
weekly arm showed 10% higher clearance compared to the once weekly arm. This is most 
likely due to a partial autoinduction effect which was also reported in the study of thrice 
weekly rifapentine (Dooley et al. 2008).  
Limitations:  A major limitation of this study is design, which allowed for simultaneous 
change of three key factors responsible for treatment response: choice of dose, dosing 
schedule and treatment duration. Even though, there was a clearly significant difference 
between the two experimental arms, the design did not allow for identification of the most 
important out of three responsible factors and/or for quantification of the relative contribution 
of each of them. Even though, treatment duration is the most plausible one it is not possible 
to differentiate the effect of time against dose or against dosing schedule.  The next major 
limitation is a relatively small sample size enrolled in the PKPD study where only 18 patients 
who relapsed leading to lack of power to describe PKPD associations. The sample size could 
be extended by inclusion of all eligible patients enrolled in the RIFAQUIN study even-
though they did not undergo pharmacokinetic sampling. For those patients, pharmacokinetic 
summary variables can be derived based on the dose and covariate information (HIV status, 
weight, sex and dose schedule and they can be included into the extended PKPD analysis.  
Also, the individual data on the actual number of doses and adherence patterns were not used 
in this analysis. The number of doses taken was supposed to be used to more precisely 
quantify the cumulative AUCs while adherence patterns were supposed to be used to derive 
entire continuation phase pharmacokinetic profiles for each patient, which would provide 
much more granularity and insight into the actual pharmacokinetic plasma variations for both 
rifapentine and moxifloxacin.  Also, the patients were on rifampicin during the intensive 
phase of the treatment, rifampicin induces its own metabolism. It has been shown that it takes 
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40 days for the autoinduction of rifampicin to reach its steady-state and causing more than 
40% reduction in AUC (Smythe et al. 2013). Little is known about how long this 
autoinduction takes to clear. Hence, because there was no pharmacokinetic sampling of 
rifapentine or moxifloxacin on the beginning on continuation phase, it cannot be clearly 
deduced to what extent the exposures in the 4
th
 months of treatment have altered. 
Furthermore, this analysis could have been limited by the combined endpoint of 
failure/relapse/death. Factors like treatment modification could have also confounded the 
analysis of effect of pharmacokinetic indices of moxifloxacin and rifapentine. Moreso, a 
handful of HIV positive patients were started on therapy, and there could have been an 
interaction with investigational drugs. In terms of MIC value of 0.25 mg/L used for 
moxifloxacin following WHO recommendation; this value was rather at an extreme end of 
the distribution for patients without pre-XDR or XDR who had MIC ≤0.125 mg/L (Zvada et 
al. 2014); hence the calculated AUC/MIC, Cmax/MIC and TAMIC for moxifloxacin could be 
2 times higher than values shown in Table 9.4. 
9.7 Conclusion 
This analysis concludes that the composite effect of longer treatment duration, higher 
rifapentine Cmax and AUCtotal is associated with better treatment response; however it is not 
conclusive as to whether longer treatment duration is the major factor needed for successful 
treatment outcome. Intermittent rifapentine administration and the impact of a meal with egg 
resulted in the highest rifapentine AUC and Cmax values ever achieved in the patient 
population; therefore these two strategies can be utilized in future studies to optimize target 




10 Overall discussion and conclusions 
Cure rates of more than 95% can be achieved with 6 month long standard therapy using 
drugs discovered more than 4 decades ago. However, these cure rates may be rarely 
achieved due to long duration of therapy, drug adverse effects, and complications due to 
HIV coinfection. All these factors may lead to poor adherence. Hence studies which aim 
at optimizing these therapies and reducing the duration of therapy or more intermittent 
administration are very important. Several reports have now suggested that the doses of 
drugs, particularly the rifamycins, used in the standard therapy of tuberculosis are low, 
and suggestions for higher doses should be prioritized. Even though the majority of 
studies have been conducted in adults, a handful of studies conducted in children 
indicated that children have lower drug exposures rarely achieving concentrations 
similar to adults. This gives an extra dimension to tuberculosis research where better 
dose optimization methods should be employed firstly, to establish optimal doses in 
adults based on pharmacokinetic-pharmacodynamic relationships, and secondly to 
ensure that children have exposures at least matching those in adults in ethnically similar 
populations. The most striking factor is that children are not always considered during 
optimization of drug therapies, yet they frequently experience severe forms of 
tuberculosis including disseminated disease and meningitis (Marais et al. 2006).   
 
On top of aiming to achieve similar exposures in both adults and children, studies 
investigating new treatment strategies should be prioritized. The current novel regimens 
aimed at shortening the duration of tuberculosis treatment or offering intermittent 
therapy (i.e., once weekly or even less frequently) without compromising efficacy come 
with the advantages of reducing the burden of supervised drug therapy. Evidence now 
exists that such regimens could be achieved, but more thorough investigation into why 
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some these studies fail should be considered, including evaluation of the 
pharmacokinetic parameters of the drugs together with other risk factors for therapeutic 
failure or relapse after treatment. Combination of moxifloxacin and rifapentine is 
complicated by the unknown extent of interaction when these two drugs when they are 
administered together.  The main problem being the possibility of drug-drug interactions 
where rifapentine may result in decreased exposures of moxifloxacin. Most important 
approaches towards optimization of the doses rifapentine and moxifloxacin would be to 
consider their pharmacokinetic correlates with treatment outcome. 
 
Furthermore, there is need to improve 2
nd
 –line regimens used for MDR-TB, where 
optimal use of the available drugs is prioritized. Fluoroquinolones have wider 
therapeutic margin than many second line drugs used for the treatment of drug-resistant 
tuberculosis. The only limitation is that there is limited information regarding their 
safety at higher doses. It should be noted that fluoroquinolones differ from each other in 
their efficacy against M.tuberculosis as measured by fAUC0-24/MIC, and also display 
differences in their clinical pharmacokinetics. Even though the in vitro bactericidal 
activity of moxifloxacin against M.tuberculosis is superior to that of ofloxacin (Hu et al. 
2003), ofloxacin is used widely in  developing countries due to its affordability but has 
very low therapeutic effectiveness. Recommendations made to replace ofloxacin with 
moxifloxacin should be based on scientific and clinical evaluation of efficacy between 
these two drugs.  
The work in this thesis demonstrates the significant role of pharmacometrics in 
optimising dosing regimens, understanding what drives the efficacy, and how to improve 
the treatment of drug-resistant tuberculosis.  
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10.1 Using population pharmacokinetic models to optimize dosing regimens 
The work in this thesis describes the population of pharmacokinetics of rifampicin, 
pyrazinamide and isoniazid when dosed in children. Limited studies which have 
evaluated the pharmacokinetics of these drugs in children raised concern of under-
dosing. The WHO recommended increased doses based on these studies, but it was 
necessary to evaluate the adequacy of doses of rifampicin, isoniazid and pyrazinamide in 
children using the revised doses currently recommended by WHO, and dosed in weight 
bands suited to FDCs. The key finding in this thesis, following simulations based on the 
final pharmacokinetic models, predicted that the newly recommended weight band-based 
doses following WHO guidelines for children would result in rifampicin exposures in 
similar to those in adults. When these children are dosed in pragmatic weight bands, 
there is wider variability in rifampicin exposures. The doses of pyrazinamide and 
isoniazid will give lower exposures than those in an ethnically similar adult population. 
If similar findings are confirmed in other studies, dose adjustment may be warranted 
especially when children are dosed using FDCs according to weight bands. The 
pharmacokinetic models incorporated factors like maturation of drug transporters and/or 
metabolising enzymes, pharmacogenetic factors, and total body weight which was 
implemented through allometric scaling. These models could be used to simulate the 
optimal doses for children across different weight and/or age bands. The results from the 
patient population studied in this thesis could be generalized across African populations. 
It was surprising that dose-dependent non-linearity in pharmacokinetics of rifampicin 
was not identified, which is different to described in adults (Pargal & Rani 2001). This 
limits the application of the pharmacokinetic models in simulating optimal doses where 
higher doses are considered. In children, variability in rifampicin exposures was higher 
than those for the reference adult population, partly due to physiological differences 
153 
 
between adults and children, and possibly also the severity of the disease in the 
hospitalized cohort of children. Based on this high variability, there is a need for further 
studies to evaluate such sources of variability; formulation was reported to alter 
bioavailability of drugs (Agrawal et al. 2004, McIlleron et al. 2006) and its effect was 
not identified this analysis. Another important consideration will be evaluation of 
pharmacokinetic and pharmacogenetic correlates. The differences in the distribution of 
NAT2 polymorphisms (Fuselli et al. 2007, Sabbagh et al. 2011) may also limit generality 
of application these models. Further studies which identify more sources of variability in 
children are warranted factors such as proper anthropometric measurements and 
reference values derived in for a specific population, and association between 
pharmacokinetics, efficacy and toxicity. 
Other factors which alter drug pharmacokinetics include meal effects. The analysis 
described in this thesis showed that food intake results in a substantial increase 
bioavailability of rifapentine and consequently its metabolite, which supports previous 
findings by Chan et al. (Chan et al. 1994).  The most important contribution of the 
analysis described in this thesis was different categorization of meals which may help 
policy makers in tuberculosis control programs in selecting the meals, which may be 
relevant in the clinical program and setting.  In addition, this finding is important 
because high doses of rifapentine (1200 mg) are being investigated in clinical trials 
which may impact on patient safety. The limitation of this study was that the extent of 
meal effect was only investigated in healthy volunteers. When rifapentine is dosed daily 
and for longer durations, autoinduction effects would be more marked (Dooley et al. 
2008), and an interaction between the food effect and autoinduction cannot be ruled out. 
Furthermore, dose nonlinearity in rifapentine exposures have been reported, where doses 
above 900 mg are administered with decreased bioavailability (Savic et al. 2011), a fact 
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which the model in this thesis did not account for. Because higher doses of rifapentine 
give enhanced therapeutic effect, further studies investigating meal effect in combination 
with dose nonlinearity and indexed against safety are recommended. 
Another important contribution of work is that high-dose intermittent rifapentine 
increased the CL/F of moxifloxacin by only 8%, which is clinically insignificant. The 
change in AUC0-∞ had the same magnitude. This means that the RIFAQUIN study was 
better designed to reduce the magnitude of effect of rifapentine on the pharmacokinetics 
of moxifloxacin. This finding is very important for future trials investigating the 
combination of moxifloxacin and rifapentine. Even though there is a marginal decrease 
in AUC0-∞ of moxifloxacin, similar results cannot be assumed to circumstances where 
the drugs are administered more frequently, for example daily. The extent of rifapentine 
induction potential was reported in doses of 10 to 20 mg/kg, where rifapentine in these 
doses is as potent an inducer of CYP3A as rifampin (Bliven-Sizemore et al. 2011), a 
comparison made when the drugs are dosed daily. Also, results from study 29X where 
patients were given daily rifapentine had CL values of rifapentine being doubled by end 
of 2
nd
 week of daily dosing  (Savic et al. 2011). Therefore, rifapentine effect on 
moxifloxacin exposure may be higher than what was observed in this work. However, 
the magnitude of effect should be evaluated in larger sample sizes and consideration of 
efficacy and safety are also warranted.  
10.2 Understanding what drives efficacy 
The work in this thesis showed that pharmacokinetics variables had no conclusive effect as 
predictors of relapse. This is probably due partly to the very small number of patients who 
relapsed in the 4-month and 6-month arms. Out of 18 patients who relapsed, only 5 were 
from 6-month arm. It is unclear what contributed towards more relapses in 4-month arm. The 
differences between the arms were dose, dosing frequency and treatment duration. In 
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addition, most of the pharmacokinetic summary variables were significantly higher in the 6-
month arm. Given the failure to separate which factor contributed towards relapse, the 
observed effect could be a result of overall impact of all pharmacokinetic summary variables 
and duration of treatment. The results of this analysis showed that the exposure to rifapentine 
in the RIFAQUIN trial was significantly higher than those observed in the TBTC study 29X. 
Importantly, it is reasonable to assume that the difference between the two studies might be 
attributable to auto-induction and type of food administered. In the study 29X, patients were 
given high fat food while patients in the RIFAQUIN study had 2 boiled eggs and bread 
before rifapentine was administered. Hence eggs in the RIFAQUIN probably have enhanced 
rifapentine absorption. Eggs were has been shown to increase the bioavailability of 
rifapentine (Chan et al. 1994). However, there were quite a lot of limitations in the study 
which may have led to lack of pharmacokinetic variables effect. However future studies 
aiming at evaluating the PKPD should consider the limitation of the analysis which includes: 
choice of dose, dosing schedule and treatment duration. These factors could have confounded 
identification of factors or differences between arms that were associated with relapse. 
Further improvement in the study could be inclusion of data from all patients in the 
RIFAQUIN study such as including those who did not participate in population 
pharmacokinetic study. In addition, data on adherence patterns should evaluated in order to 
improve the analysis on top of data on actual number of doses. This will help in evaluation 
concentration and actual AUC profiles.   
10.3 How to improve treatment of drug resistant tuberculosis 
The main contribution of the work described in this thesis was that when using a target 
fAUC0-24/MIC ratio of >53, the CFR for 400 mg moxifloxacin was 98% versus 84% for 
800 mg ofloxacin in patients with MDR-TB. When a more stringent target of target ratio 
of >100 was considered, both regimens did not achieve a threshold of 90% CFR.  
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Importantly, simulation results showed that when the dose of moxifloxacin is doubled to 
800 mg, a CFR of 98% would be achieved same patients with MDR-TB when the target 
ratio of >100 is used. Hence the results of the analysis suggest that doubling the dose of 
moxifloxacin is beneficial. However, what is not known is the safety of moxifloxacin at 
these higher doses. Therefore further studies evaluating moxifloxacin efficacy at these 
higher doses should also evaluate toxicities. However, even though these results are 
encouraging, the limitation of the study was the MIC data used which may not represent 
the true distribution for some drug-resistance categories due to small sample size. 
Furthermore the PTA and CFR analyses may not be applicable to other populations 
outside the region, hence further studies where there are larger sample sizes of MICs will 
help in the application of these findings to other regions. Also, these future studies 
should consider free drug concentration in tissues, which would be more appropriate 
than plasma concentration used in this thesis. Lastly, there is need for validation of 




In summary, the population pharmacokinetics analysis in children demonstrated the 
utility of modeling and simulation in testing new guidelines based on expert opinion but 
not substantiated by evidence. The simulations showed that, even with the increased 
dosages, the majority of younger children would achieve relatively low exposures to 
pyrazinamide and isoniazid. Furthermore, intermediate and fast acetylators may be 
under-dosed with respect to isoniazid, if exposures in an ethnically similar population of 
adults are considered therapeutic. The models developed in this study could have been 
used to simulate optimal doses in children. However, if higher doses of pyrazinamide are 
157 
 
suggested, there could be potential overdosing in children on rifampicin and slow 
metabolisers of isoniazid when FDC are given. This study could also be tied up with 
other studies evaluating the pharmacokinetics in children at higher doses. Further 
recommended work could perform a meta-analysis of the all the studies in children 
evaluating higher doses, where the models developed in the study could also be 
employed to simulate the likely optimal doses in children. 
In terms of the population pharmacokinetics of rifapentine in healthy volunteers, the 
analysis showed that food increases the bioavailability and exposures of rifapentine. The 
high exposures found in the RIFAQUIN study compared to other studies could be due to 
eggs which were used. Even though highest exposures are desirable which could be 
achieved through the use meals as shown in health volunteers study, the immediate and 
reasonable dilemma is the use of these meals which may not be practical in Tuberculosis 
control programs especially in high burdened areas.  In terms of interaction between high 
dose rifapentine and moxifloxacin, these results in this thesis showed that rifapentine 
effect detectable was but clinically insignificant. This result cannot be assumed to be the 
same where rifapentine is used in combination with moxifloxacin dosed daily hence 
further studies will need to confirm this finding.  
The study of evaluation of efficacy between moxifloxacin and ofloxacin supports that 
moxifloxacin can be used instead of ofloxacin. The study also showed important benefit 
of higher doses of moxifloxacin.  However, further studies would need to evaluate the 
safety of moxifloxacin at higher doses.  In addition, the study demonstrates the 
successful application of pharmacometrics in comparison of 2 drugs against a pre-
defined pharmacodynamics target.  
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Furthermore, investigation of pharmacokinetic and PKPD variable suggest that the combined 
effect of longer treatment duration, higher rifapentine Cmax and AUCtotal is associated with 
better treatment response; the analysis is not conclusive regarding longer treatment duration 
as a main factor required to enhance successful treatment outcome. There was a noticeable 
impact of meal (eggs) effect which gave very high rifapentine AUC and Cmax values. 
Further studies may therefore use this strategy to boost the Cmax and AUC values of 
rifapentine. However this finding is based on a number of limitations which include small 
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Appendix  1- Rifampicin run record and control stream  
a) Rifampicin run record 
Model  Description a Commentb OFV 
1 One compartment, first-order absorption, 
first order elimination. IIV on CL, Vc, ka, 
F 
Base model 1035 
2 Add lag time to model 1 The model high imprecision on 
estimate of lag time, hence dropped 
1028 
3 Use transit absorption compartment on 
model 1 instead of lag time, IIV CL, Vc, 
F, MTT 
The model had good precision in 
parameter estimates, but IIV in ka 
was almost zero(0) and was dropped 
1023 
4 Add IOV in F on model 3. IIV CL, Vc, F, 
MTT 
Improvement in the fit but IIV in F 
dropped and had high RSE.  
988 
5 Add IOV in CL on model 4 Improvement in fit.  980 
6 Add IOV in MTT on model  4, IIV in CL, 
Vc, IOV in CL, MTT and F 
Improvement in the fit but IIV in 
MTT dropped and had high RSE 
967 
7 Add IOV in V on model 5 No significant improvement in fit 961 
8 Add IOV in ka on model 6 No significant improvement in fit 960 
9 Run 6 plus covariance between IIV for CL 
and Vc 
Improvement in fit 963 
10 Run 9 plus dose-nonlinearity Very high RSE on estimates of CL, 
Vc 
958 
11 Run 9 plus saturable clearance Imprecision in estimates of Km and 
Vmax 
962 
12  Run 9  and add weight as linear covariate 
on CL 
Huge improvement in fit 898 
13 Run 12 plus add weight as covariate on 
Vc  
improvement in fit 891 
14 Run 9 plus allometric scaling with weight 
on CL and Vc. Therefore selected. IIV in 
CL, Vc, IOV in CL, MTT and F 
Improvement in fit. This run was 
preferred than run13 based on well-
established principles (Anderson & 
Holford 2008) and  parsimony 
893 
15 Run 9 plus allometric scaling with fat free 
mass on CL and Vc 
Was worse than run 14 898 
16 Run 9 plus allometric scaling with fat 
mass mass on CL and Vc 
Was than run 14 901 
17 Run 14 plus test HIV on F Slight improvement in fit compared 
with run 14 
891 
18 Run 14 plus HIV on CL No improvement in fit compared with 
run 14 
892 
19 Run 14 plus HIV on Vc No improvement in fit compared with 
run 14 
893 
20 Run 14 plus SEX on F No improvement in fit compared with 
run 14 
890 
21 Run 14 plus SEX on CL No improvement in fit compared with 
run 14 
890 
22 Run 14 plus SEX on Vc Improvement in fit compared with 
run 14, but was dropped because it 
was being confounded with 
kwashiorkor status. Females 17% had 
higher Vc and estimates had high 
RSE 
888 
23 Run 14 plus albumin on Vc No improvement in fit compared with 
run 14 
893 
24 Run 14 plus maturation of CL Improvement in fit and better RSE 874 
25 Run 14 plus maturation on Vc No improvement in fit 880 
26 Run 14 pus maturation on MTT Improvement in fit and better RSE 875 
27 Combine maturation effect in MTT and 
CL 
Improvement in fit 870 
28 Add hill factor on run 26 Final model 866 
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aCL and Vc are oral clearance and apparent volume of distribution in plasma, respectively. MTT, absorption mean 
transit time, value at full maturation; NN, number of transit compartments; F, relative bioavailability; Hill, steepness 
of the maturation function; IIV, inter-individual variability; IOV, inter-occasional variability. bRSE, relative standard 





b) Rifampicin run record 
$PROBLEM  RIF PAEDIATRICS  
$ABBREVIATED COMRES=2 
$INPUT ID OCC TIME DVO=DROP DV AMT DOSE AGE KWS HIV WT EVID SEX HT PRB SITE BLQ 
$DATA simba_rif_2013_09_20.csv IGNORE=# IGNORE=(PRB.EQ.1) 
$SUBROUTINE ADVAN13 TOL=8 
 
$MODEL NCOMPARTMENTS=1  
COMP=(CENTRAL DEFDOSE DEFOBSERVATION)  
 
$PK 






IF (TIME<72.AND.TIME>71) TAD=TIME-72 ; Fix the TAD for pre-doses 
 
; Maturation 
HILL   = THETA(9) 
TM50   = THETA(8) 
 








IF(OCC.EQ.1) OC1 =1 
IF(OCC.EQ.2) OC2 =1 
IF(OCC.EQ.3) OC3 =1 
IF(OCC.EQ.4) OC4 =1 
 
IOVBIO  = OC1*(ETA(3)) + OC2*(ETA(4))+ OC3*(ETA(5)) + OC4*(ETA(6)) 
IOVCL   = OC1*(ETA(7)) + OC2*(ETA(8))+ OC3*(ETA(9)) + OC4*(ETA(10)) 





 TVCL  = THETA(1)*((WT/12.5)**0.75)*FMAT   
 CL    = TVCL *EXP(BSVCL+IOVCL)          
  
 TVV  = THETA(2) *(WT/12.5)        
 V    = TVV*EXP(BSVV2) 
  
 TVMTT  = THETA(3)*FMAT                 
 MTT    = TVMTT*EXP(IOVMTT)  
  
 TVBIO  = THETA(4)                  
 BIO    = TVBIO*EXP(IOVBIO)    
  
 TVNN   =THETA(5)                    




F1=0 ; set bioavailability in compartment 1 to 0 when using transit compartment 
 
KTR = (NN+1)/MTT 
 
IF (NEWIND.NE.2.OR.EVID.GE.3) THEN  



















IF (NEWIND.LE.1.OR.EVID.GE.3) THEN ; assign negative Cmax Tmax for the new subject  
 COM(1)=-1 ; holder of Cmax  














;------CMAX AND TMAX 
CT=A(1)/V  
IF(CT.GT.COM(1)) THEN  
 COM(1)=CT  





PROP  =THETA(6)*IPRED 
ADD   =THETA(7) 
IF (SITE==2) ADD=THETA(10) 
 
 
W = SQRT(PROP**2+ADD**2) 
IF (W.LE.0.0001) W=0.0001 
IF(BLQ==1.AND.SITE==1) W = 0.05 
IF(BLQ==1.AND.SITE==2) W = 0.375 
 
IRES  = DV-IPRED 
IWRES = IRES/W 
Y     = IPRED+W*EPS(1) 
 
 
IF (ICALL==4.AND.SITE==1.AND.Y.LE.0.1) Y = 0.05 
IF (ICALL==4.AND.SITE==2.AND.Y.LE.0.75) Y = 0.375 
 
AUC  = BIO*AMT/CL 
CMAX = COM(1)  




;-------initial estimates_ theta 
$THETA  (0,8.14633,20) ; 1_TVCL 
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$THETA  (0,16.238,30) ; 2_TVV2 
$THETA  (0,1.03838,3) ; 3_TVMTT 
$THETA  1 FIX ; 4_BIO 
$THETA  (0,8.04401,30) ; 5_NN 
$THETA  (0,0.233525,0.5) ; 6_PROP 
$THETA  (0,0.121799,1) ; 7_ADD 
$THETA  (0,1.12139,5) ; 8_TM50 
$THETA  (0,2.2141,5) ; 9_HILL 
$THETA  (0,0.629802,1) ; 10_ADD2 
$OMEGA  BLOCK(2) 
 0.106349  ;   1_IIV_CL 
 0.125873 0.188156  ;    2_IIV_V 
 
$OMEGA  BLOCK(1)  0.230832   
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1)  0.0631686  
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) 0.160309  
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$SIGMA  1  FIX 
$ESTIMATION MAXEVAL=9999 PRINT=1 SIGDIG=3 SIGL=9 POSTHOC METH=COND INTER NOABORT 
MSFO=msf1020 ATOL=4 
$COVARIANCE PRINT=E MATRIX=S ATOL=4 
 
$TABLE FILE=sdtab1020 ID CMAX OCC TIME TAD DV IPRED PRED IWRES WRES CWRES NPDE AA1 NOPRINT 
ONEHEADER NOAPPEND ESAMPLE=1000 FORMAT=,  
$TABLE FILE=patab1020 ID OCC CL V BIO BSVCL BSVV2 IOVCL IOVBIO NOPRINT ONEHEADER NOAPPEND 
FORMAT=, 
$TABLE FILE=cotab1020 ID OCC WT AGE NOPRINT ONEHEADER NOAPPEND FORMAT=, 
$TABLE FILE=catab1020 ID OCC KWS HIV SEX SITE NOPRINT ONEHEADER NOAPPEND FORMAT=, 
$TABLE FILE=mytab1020 ID CMAX OCC TIME TAD DV IPRED PRED IWRES WRES CWRES NPDE AA1  
CL V BIO BSVCL BSVV2 IOVCL IOVBIO 
WT AGE KWS HIV SEX SITE CMAX TMAX AUC NOPRINT ONEHEADER NOAPPEND FORMAT=,  
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Appendix  2- Pyrazinamide run record and control stream  
 
a) Pyrazinamide run record 
Model  Description a Commentb OFV 
1 One compartment, first-order absorption, 
first order elimination. IIV on CL, Vc, ka, 
F 
Base model 2030 
2 Add lag time to model 1 No improvement in fit 2030 
3 Use transit absorption compartment on 
model 1 instead of lag time, IIV CL, Vc, 
F, MTT, ka 
Improvement in fit 2022 
4 Add IOV in F on model 3. IIV CL, Vc, F, 
MTT 
Improvement in the fit but 
IIV in F and Vc zeros 
2002 
5 Add IOV in CL on model 4 Improvement in fit.  1992 
6 Add IOV in MTT on model  5 Improvement in the fit but 
IIV in MTT zeros 
1985 
7 Add IOV in V on model 6 No improvement in fit 1983 
8 Add IOV in ka on model 6 Improvement in fit 1974 
9 Run 8 plus covariance between IIV for CL 
and Vc 
No improvement in fit 1974 
10 Run 8 plus dose-nonlinearity Very RSE on estimates of 
CL, Vc 
1973 
11 Run 8 plus saturable clearance Imprecision in estimates of 
Km and Vmax 
1971 
12  Run 8  and add weight as linear covariate 
on CL 
Improvement in fit 1965 
13 Run 12 plus add weight as covariate on 
Vc  
improvement in fit, but not 
significant 
1963 
14 Run 8 plus allometric scaling with weight 
on CL and Vc. Therefore selected. IIV in 
CL, IOV in CL, MTT , F, ka 
Improvement in fit. This run 
was preferred than run13 
based on well-established 
principles (Anderson & 




15 Run 8 plus allometric scaling with fat free 
mass on CL and Vc 
Worse fit 1969 
16 Test allometric scaling with fat mass mass 
on CL and Vc 
Worse fit 1967 
17 Run 14 plus test HIV on F Not significant 1958 
18 Run 14 plus HIV on CL Not significant 1959 
19 Run 14 plus HIV on Vc Not significant 1959 
20 Run 14 plus SEX on F High RSE in estimate of  sex 
effect  
1955 
21 Run 14 plus SEX on CL Not significant 1960 
22 Run 14 plus SEX on Vc Not significant 1960 
23 Run 14 plus albumin on Vc Not significant 1960 
aCL and Vc are oral clearance and apparent volume of distribution in plasma, respectively. MTT, absorption mean 
transit time, value at full maturation; NN, number of transit compartments; F, relative bioavailability; IIV, inter-





b) Pyrazinamide run record 
$PROBLEM  PZA  pediatrics  
$INPUT ID OCC TIME ORG_DV=DROP DV AMT MDV EVID AGE KWS HIV WT SEXM PRB SITE BLQ 
 
$DATA PZA_2013-09-20.csv IGNORE=@ IGNORE=(PRB.EQ.1) 
 
$ABBREVIATED COMRES=2 
$SUBROUTINE ADVAN13 TOL=9 
$MODEL NCOMP=2 










































TVCL = THETA(1)*ALLMCL        
CL   = TVCL*EXP(BSVCL+IOVCL)          
 
TVV2 = THETA(2)*ALLMV        
V2    = TVV2*EXP(BSVV2)                    
  
TVKA = THETA(3)                           
KA   = TVKA*EXP(IOVKA) 
 
TVBIO =1 
BIO   =TVBIO*EXP(IOVF) 
 
TVMTT  = THETA(6)                   




TVNN   =THETA(7)                    
NN     =TVNN 
 
 
K    = CL/V2 
F1=0  
KTR = (NN+1)/MTT 
 
IF (NEWIND.NE.2.OR.EVID.GE.3) THEN 
 TNXD=TIME  











LNGAM = NN*LOG(NN)-NN+LOG(NN*(1+4*NN*(1+2*NN)))/6+0.572364942  
PIZZA=LOG(BIO*PD*KTR+0.00001)-LNGAM  
 
IF(NEWIND.NE.2.OR.EVID.GE.3) THEN  
 COM(1)=-1 ; holder of Cmax  













DADT(2) = KA*A(1)-K*A(2)     
 
CT=A(2)/V2  
IF(CT.GT.COM(1)) THEN  
 COM(1)=CT  




IPRED = A(2)/V2  
PROP = THETA(4)*IPRED 
ADD = THETA(5) 
IF (SITE==2) PROP = THETA(8)*IPRED 
 
W =SQRT(PROP**2+ADD**2) 
IF (W.LT.0.001) W = 0.001 
IF (BLQ==1.AND.SITE==1.AND.ICALL.EQ.2) W=0.05   




Y = IPRED + W*EPS(1) 
 
IF (ICALL==4.AND.SITE==1.AND.Y.LE.0.1) Y = 0.05 
IF (ICALL==4.AND.SITE==2.AND.Y.LE.0.5) Y = 0.25 
 
CMAX = COM(1)  
TMAX = COM(2)  
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AUC  = BIO*AMT/CL 
 
$THETA  (0,1.08297,5) ; 1_CL 
$THETA  (0,9.64465,20) ; 2_V 
$THETA  (0,4.48056,10) ; 3_KA 
$THETA  (0,0.0999155,0.5) ; 4_PROP_RUV_SITE1 
$THETA  0 FIX ; 5_ADD_RUV 
$THETA  (0,0.095077,2) ; 6_MTT 
$THETA  (0,3.93896,50) ; 7_NN 
$THETA  (0,0.0553184,0.5) ; 8_PROP_RUV_SITE2 
$OMEGA  0.0733772  ;    1 IIVCL 
$OMEGA  0  FIX  ;     2 IIVV 
 
$OMEGA  BLOCK(1)  0.0647795  ;    3 IOVCL 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1)  0.0610214  ;     7 IOVF 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1)  0.745937  ;   11 IOVKA 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1)  1.25559  ;  15 IOVMTT 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$SIGMA  1  FIX 
$ESTIMATION MSFO=msf129 MAXEVAL=9999 PRINT=1 SIGDIG=3 SIGL=9 POSTHOC METH=COND ATOL=4 
INTER NOABORT  
$COVARIANCE ATOL=4 PRINT=E MATRIX=S 
 
$TABLE FILE=sdtab129 ID CMAX OCC TIME TAD DV IPRED PRED IWRES WRES CWRES NPDE AA1 AA2 
NOPRINT ONEHEADER NOAPPEND ESAMPLE=1000 FORMAT=,  
$TABLE FILE=patab129 ID OCC CL V2 KA F1 BSVCL BSVV2 IOVCL IOVKA IOVF NOPRINT ONEHEADER 
NOAPPEND FORMAT=, 
$TABLE FILE=cotab129 ID OCC WT AGE NOPRINT ONEHEADER NOAPPEND FORMAT=, 
$TABLE FILE=catab129 ID OCC KWS HIV SEXM SITE NOPRINT ONEHEADER NOAPPEND FORMAT=, 
$TABLE FILE=mytab129 ID CMAX OCC TIME TAD DV IPRED PRED IWRES WRES CWRES NPDE AA1 AA2 CL 
V2 KA F1  
 BSVCL BSVV2 IOVCL IOVKA IOVF WT AGE KWS HIV SEXM SITE CMAX TMAX AUC NOPRINT 
ONEHEADER NOAPPEND FORMAT=,  
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Appendix  3 - Isoniazid run record and control stream  
a) Isoniazid run record 
Model  Description a Commentb OFV 
1 One compartment, first-order absorption, 
first order elimination. IIV on CL, Vc, ka, 
F 
Base model -90 
2 Add lag time to model 1 High RSE on lag time -98 
3 Use transit absorption compartment on 
model 1 instead of lag time, IIV CL, Vc, 
F, MTT,ka 
Better than run 2 in term of 
fit and diagnostics 
-110 
4 Add IOV in F on model 3. IIV CL, MTT, 
ka 
Improvement in the fit but 
IIV in F was small while in 
Vc had high RSE.  
-125 
5 Add IOV in MTT on model 4 Improvement in fit. The IIV 
in MTT drops to zero (0). 
-135 
6 Add IOV in CL on model  5 No improvement in the fit  -138 
7 Add IOV in Vc on model 5 No significant improvement 
in fit 
-137 
8 Add IOV in ka on model 5.  Improvement in fit, IIV in ka 
zeros 
-150 
9 Run 6 plus covariance between IIV for CL 
and Vc 
No improvement in fit. 
Estimates of RSE increased 
-152 
10 Run 8 plus dose-nonlinearity Very high RSE on estimates 
of CL, Vc 
-146 
11 Run 8plus saturable clearance Imprecision in estimates of 
Km and Vmax 
-146 
12  Run 8 and add weight as linear covariate 
on CL 
Huge improvement in fit -188 
13 Run 12 plus add weight as covariate on 
Vc  
improvement in fit -200 
14 Run 8 plus allometric scaling with weight 
on CL and Vc. Therefore selected. IIV in 
CL, Vc, IOV in CL, MTT and F 
Improvement in fit. This run 
was preferred than run13 
based on well-established 
principles (Anderson & 
Holford 2008) and  
parsimony 
-200 
15 Run 8 plus allometric scaling with fat free 
mass on CL and Vc 
Was worse than run 14 -195 
16 Run 8 scaling with fat mass mass on CL 
and Vc 
Was better than run 14 -185 
17 Run 14 plus genotype on CL Huge improvement in fit. 
The genenotypes were fast, 
intermediate and slow 
acetylators. 
-246 
18 Run 14 plus test HIV on F Slight improvement in fit 
compared with run 14 
-248 
18 Run 14 plus HIV on CL insignificant -248 
19 Run 14 plus HIV on Vc insignificant -247 
20 Run 14 plus SEX on F insignificant -246 
21 Run 14 plus SEX on CL insignificant -246 
22 Run 14 plus SEX on Vc insignificant -246 
23 Run 14 plus albumin on Vc insignificant -247 
24 Run 14 plus maturation of CL insignificant -251 
25 Run 14 plus maturation on Vc No improvement in fit -249 
26 Run 14 pus maturation on MTT insignificant -246 
27 Test different F on genotype significant -269 
28 Combine estimate of F for fast and 
intermediate acetylators. Final model 
(plus Hill) 
Significant. Final model -267 
aCL and Vc are oral clearance and apparent volume of distribution in plasma, respectively. MTT, absorption mean 
transit time, value at full maturation; NN, number of transit compartments; F, relative bioavailability; Hill, steepness 
of the maturation function; IIV, inter-individual variability; IOV, inter-occasional variability. bRSE, relative standard 




b) Isoniazid control stream  
  
$SIZES MAXFCN=100000000  
$PROBLEM PEDS INH  
 
$INPUT ID OCC TIME AMT DV AGE KWS HIV WT EVID SEX HT PRB SITE GENO MDV BLQ 
BLQ_VALUE=DROP 
$DATA  PEDS_INH_2013-09-20.csv IGNORE=# IGNORE=(PRB.EQ.1) 
 
$ABBREVIATED COMRES=2 
$SUBROUTINE ADVAN13 TOL=6 
 
$MODEL NCOMPARTMENTS=3  
COMP=(ABSORB DEFDOSE)      
COMP=(CENTRAL DEFOBS)  
COMP=(PERI) 
 
$THETA  (0,4.43579) ; 1_CL_SLOW 
$THETA  (0,8.9373) ; 2_CL_INT 
$THETA  (0,11.3482) ; 3_CL_FAST 
$THETA  (0,11.035) ; 4_TVV2 
$THETA  (0,2.46631) ; 5_TVKA 
$THETA  (0,5.02587) ; 6_V3 
$THETA  (0,1.99841) ; 7_Q 
$THETA  (0,0.205733) ; 8_PROP 
$THETA  0 FIX ; 9_ADD 
$THETA  (0,0.179338) ; 10_MTT 
$THETA  (0,0.942572) ; 11_TM50 
$THETA  (0,2.19) ; 12_HILL 
$THETA  (-0.99,-0.228087,1) ; 13_F_INTER&FAST 
$THETA  0.402777778 FIX ; 14_P1_SLOW 
$THETA  0.402777778 FIX ; 15_P2_INTER 
$THETA  0.194444444 FIX ; 16_P3_FAST 
$THETA  4 FIX ; 17_NN 
$THETA  (0,0.0699578,0.5) ; 18_PROP2 
 
$OMEGA  0.0630975  ;    1_IIVCL 
$OMEGA  0  FIX  ;    2 DUMMY 
 
$OMEGA  BLOCK(1)  0.157738  ;     3_IOVF 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1)  0.378515  ;    5_IOVKA 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME  
 
$OMEGA  BLOCK(1)  0.882379  ;  11_IOVMTT 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME  
$OMEGA  BLOCK(1) SAME 
 










IF (TIME<72.AND.TIME>71) TAD=TIME-72 ; Fix the TAD for pre-doses 
 
HILL   = THETA(12) 
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TM50   = THETA(11) 
PMA     = AGE + (9/12) 







IF(OCC.EQ.1) OC1 =1 
IF(OCC.EQ.2) OC2 =1 
IF(OCC.EQ.3) OC3 =1 
IF(OCC.EQ.4) OC4 =1 
 
IOVBIO   = ETA(3)*OC1 + ETA(4)*OC2 + ETA(5)*OC3 + ETA(6)*OC4 
IOVKA  = ETA(7)*OC1 + ETA(8)*OC2 + ETA(9)*OC3 + ETA(10)*OC4 




IF (GENO.NE.-99) THEN 
 GENOME=GENO 
ELSE  
 IF (MIXNUM.EQ.1) GENOME=0 
 IF (MIXNUM.EQ.2) GENOME=1 





 TVCL  = THETA(1)*((WT/12.5)**0.75)*FMAT   ;SLOW 





 TVCL  = THETA(2)*((WT/12.5)**0.75)*FMAT     ;INTER 





 TVCL  = THETA(3)*((WT/12.5)**0.75)*FMAT     ;FAST 
 TVBIO  = 1+THETA(13)        
ENDIF 
 
  BSVCL  = ETA(1) 
  CL     = TVCL*EXP(BSVCL) 
  BIO    = TVBIO*EXP(IOVBIO) 
 
 TVV2   = THETA(4)*(WT/12.5)    ;volume of the central compartment     
 V2     = TVV2                 
  
 TVKA   = THETA(5)         
 KA     = TVKA*EXP(IOVKA) 
  
  
TVV3    = THETA(6)*(WT/12.5)                  ;4_V3 
V3      = TVV3 
 
TVQ     = THETA(7)*((WT/12.5)**0.75)          ;5_Q 
Q       = TVQ 
 
TVMTT   = THETA(10) 
MTT     = TVMTT*EXP(ETA(2)+IOVMTT)  
 





 S2   = V2 
 K  = CL/V2 
 K23  = Q/V2 
 K32  = Q/V3 
 




KTR = (NN+1)/MTT 
 
IF (NEWIND.NE.2.OR.EVID.GE.3)  
 TNXD=TIME  











LNGAM = NN*LOG(NN)-NN+LOG(NN*(1+4*NN*(1+2*NN)))/6+0.572364942 ; approximation of log of gamma(n), 
0.572364942 is LOG(PI)/2 
PIZZA=LOG(BIO*PD*KTR+0.00001)-LNGAM ; without +0.00001, it won't work with ETAs in bioavailability 
 
   IF(NEWIND.LE.1.OR.EVID.GE.3) THEN ; assign negative Cmax Tmax for the new subject  
      COM(1)=-1 ; holder of Cmax  
      COM(2)=-1 ; holder of Tmax  




        NSPOP=3 
        P(1)=THETA(14) 
        P(2)=THETA(15) 
     P(3)=THETA(16) 
 
$DES 
TEMPO=T-TDOS ; this is time after dose, it should always be >= 0 
KTT=0 







DADT(2) =  K32*A(3)- K23*A(2) + KA*A(1)-K*A(2) 
DADT(3) =  K23*A(2)-K32*A(3) 
 
;------CMAX AND TMAX 
CT=A(2)/V2 ; (or other expression for concentration)  
IF(CT.GT.COM(1)) THEN  
 COM(1)=CT  
 COM(2)=T  
ENDIF  
 














IF(W.LT.0.0001) W = 0.0001 
 
IF(BLQ==1.AND.SITE==1) W = 0.05 
IF(BLQ==1.AND.SITE==2) W = 0.5 
 










$ESTIMATION MSFO=run1601.msf MAXEVAL=9999 PRINT=1 SIGDIG=2 SIGL=8 POSTHOC METH=COND INTER 
NOABORT  
 
$COVARIANCE PRINT=E MATRIX=S 
 
$TABLE FILE=sdtab1601 ID OCC TIME TAD IPRED PRED IWRES WRES CWRES NPDE NOPRINT NOAPPEND 
ONEHEADER  
$TABLE FILE=patab1601 ID OCC CL V2 KA Q V3 BIO MTT BSVCL IOVBIO IOVKA IOVMTT NOPRINT 
NOAPPEND ONEHEADER  
$TABLE FILE=cotab1601 ID OCC WT AGE HT NOPRINT NOAPPEND ONEHEADER     
$TABLE FILE=catab1601 ID OCC HIV SEX GENO GENOME SITE NOPRINT NOAPPEND ONEHEADER                                            
$TABLE FILE=mytab1601 ID OCC TIME TAD IPRED PRED IWRES WRES CWRES NPDE CL V2 KA Q V3 BIO MTT  
BSVCL IOVBIO IOVKA IOVMTT WT AGE HT HIV SEX GENO GENOME SITE NOPRINT NOAPPEND 
ONEHEADER   
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Appendix  4- Rifapentine and 25-desacetyl rifapentine in healthy volunteer run record and control stream  
a) Rifapentine and 25-desacetyl rifapentine run record 
Model  Description a Commentb OFV 
Rifapentine 
1 One compartment, first-order absorption, 
first order elimination. IIV on CL, Vc, ka, 
F 
Base model 6087 
2 Add lag time to model 1 No improvement in fit 6066 
3 Use transit absorption compartment on 
model 1 instead of lag time, IIV CL, Vc, 
F, MTT, ka 
Improvement in fit 6011 
4 Add IOV in F on model 3. IIV CL, Vc, F, 
MTT 
IIV if F zeros 5084 
5 Add IOV in CL on model 4 Improvement in fit.  5077 
6 Add IOV in MTT on model  5 Improvement in the fit but 
IIV in MTT zeros 
5060 
7 Add IOV in V on model 6 No improvement in fit 5058 
8 Add IOV in ka on model 6 Improvement in fit 5060 
9 Run 6 plus covariance between IIV for CL 
and Vc 
No improvement in fit 5060 
10 Run 6 plus dose-nonlinearity All the estimates had high 
RSE and estimate of CL 
increased 10 times 
5054 
11 Run 6 plus saturable clearance Significant improvement in 
fit 
5054 
12  Run 6  and add weight as linear covariate 
on CL 
No improvement in fit 5057 
13 Run 6 plus weight as covariate on Vc  improvement in fit, but not 
significant 
5060 
14 Run 6 plus allometric scaling with body 
weight 
No significant improvement 
in fit 
5057 
15 Run 6 plus allometric scaling with fat free 
mass on CL and Vc 
Worse fit 5064 
16 Run6 plus allometric scaling with fat mass 
mass on CL and Vc 
Worse fit 5063 
17 Run 6 plus time varying clearance  Better than run 11, and had 
improved goodness of fit 
plots 
5040 
18 Run 17 plus Meal effect of F Significant covariate 5020 
19 Run 18 plus meal effect on MTT  insignificant 5018 
20 Run 18 plus meal effect on ka  Insignificant and high RSE 5019 
Rifapentine plus 25-desacetyl rifapentine 
run 21 Fix estimate from run 20 then first order 
elimination of rifapentine to form 
metabolite, IIV on CLm of metabolite 
(one compartment) 
 9377 
run 22 Run 21 plus IIV Vm of metabolite Insignificant improvement in 
fit 
1974 
Run 22 Two compartment model for metabolite 
plus IIV CLm, Vm 
Improvement in fit 1969 
Run23 Run22 plus IIV Qm Insignificant improvement in 
fit 
1968 
Run24 Run22 plus IIV Vpm Insignificant improvement in 
fit 
1969 
Run 25  Run22 plus IOV CLm Improvement in fit 1953 
Run 26 Run 25 plus IOV Vm Insignificant improvement in 
fit 
 
Run27 Run 22 plus time-varying clearance of 
metabolite 
Improvement in fit. Final 
model 
1947 
aCL and Vc are oral clearance and apparent volume of distribution in plasma, respectively. MTT, absorption mean 
transit time; NN, number of transit compartments; F, relative bioavailability; IIV, inter-individual variability; IOV, 
inter-occasional variability; Vm, volume of metabolite in plasma; Vpm, volume of metabolite on peripheral 
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compartment; CLm, clearance of metabolite; Qm, intercompartmental clearance of metabolite. bRSE, relative standard 
error.    
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b) Rifapentine and 25-desacetyl rifapentine control stream (healthy volunteer study) 
$PROBLEM    RIFAPENTINE SINGLE-DOS FIVE WAY CROSSOVER 
$INPUT     ID PTIM=DROP TIME TAD=DROP DV AMT DOSE EVID OCC MDV AGE WT HT RACE RX
 EXID=DROP CMT FLAG 
$DATA Final_par_met2.csv IGNORE=# 
 
 
$SUBROUTINE ADVAN6 TRANS1 TOL=6 





RXBIO = 0  ; reference meal 
IF(RX.EQ.4) RXBIO = THETA(9) 
IF(RX.EQ.3) RXBIO = THETA(10) 
IF(RX.EQ.2) RXBIO = THETA(11) 














IIVCL1 = ETA(1) 
IIVMTT = ETA(2) 
IIVBIO = ETA(3) 
BOVCL  = ETA(4)*OCC1+ ETA(5)*OCC2+ ETA(6)*OCC3+ ETA(7)*OCC4+ ETA(8)*OCC5 
BOVBIO = ETA(9)*OCC1+ ETA(10)*OCC2+ETA(11)*OCC3+ETA(12)*OCC4+ETA(13)*OCC5 
BOVMTT = ETA(14)*OCC1+ETA(15)*OCC2+ETA(16)*OCC3+ETA(17)*OCC4+ETA(18)*OCC5 
IIVCLM = ETA(19) 
 




;------changing CL, typical values  
MTIME(1)= THETA(13) ;*EXP(IMTM)             
TVCL1   = THETA(1)*EXP(IIVCL1+BOVCL)            
TVCL2   = THETA(14)*EXP(IIVCL1+BOVCL)         
CL      = TVCL1*(1-MPAST(1))+TVCL2*(MPAST(1))   
 
TVV2    = THETA(2)   
TVKA    = THETA(3) 
TVMTT   = THETA(5) 
TVBIO   = THETA(4)*(1+RXBIO) 
 
V2     = TVV2  
KA     = TVKA      
BIO    = TVBIO*EXP(IIVBIO+BOVBIO)  
MTT    = TVMTT*EXP(IIVMTT+BOVMTT) 
TVNN   = THETA(6)                     
NN     = TVNN 
 
 
KTR = (NN+1)/MTT                        








MTIME(2)= THETA(21) ;*EXP(IMTM)   
TVCLM1  = THETA(15) 
TVCLM2  = THETA(22) 
           
CLM1   = TVCLM1*EXP(IIVCLM+BOVCLM)            
CLM2   = TVCLM2*EXP(IIVCLM+BOVCLM)        
CLM    = CLM1*(1-MPAST(2))+CLM2*(MPAST(2))  
TVV3   = THETA(16) 
TVQM   = THETA(19) 
TVVPM  = THETA(20) 
 
 
V3   = TVV3 
QM   = TVQM 
VPM  = TVVPM 
 
 
KMET = CLM/V3 
S3   = V3   
K34  =QM/V3 









A_0(1) = 0 
A_0(2) = 0 












IPREDP = CP2 ; parent 
IPREDM = CP3 ; metabolite 
IF(FLAG.EQ.2)IPRED = IPREDP   ; parent 







IRES = DV - IPRED 
IF(FLAG.EQ.2)W2 = SQRT(PROPP**2 + ADDP**2)   ; RUV parent--corrected paranthesis 
IF(FLAG.EQ.3)W3 = SQRT(PROPM**2 + ADDM**2) ; RUV metabolite 
IF(W2.EQ.0) W2 = 1 
IF(W3.EQ.0) W3 = 1 
 
IF(FLAG.EQ.2)IWRES = IRES/W2 
IF(FLAG.EQ.3)IWRES = IRES/W3 
IF(FLAG.EQ.2)Y = IPREDP + W2*EPS(1)  ; parent 







STRT = 0 
;--parent 
IF(FLAG.EQ.2.AND.RX.EQ.1)STRT = 1 
IF(FLAG.EQ.2.AND.RX.EQ.2)STRT = 2 
IF(FLAG.EQ.2.AND.RX.EQ.3)STRT = 3 
IF(FLAG.EQ.2.AND.RX.EQ.4)STRT = 4 
IF(FLAG.EQ.2.AND.RX.EQ.5)STRT = 5 
 
;--metabolite 
IF(FLAG.EQ.3.AND.RX.EQ.1)STRT = 6 
IF(FLAG.EQ.3.AND.RX.EQ.2)STRT = 7 
IF(FLAG.EQ.3.AND.RX.EQ.3)STRT = 8 
IF(FLAG.EQ.3.AND.RX.EQ.4)STRT = 9 
IF(FLAG.EQ.3.AND.RX.EQ.5)STRT = 10 
 
 
$THETA  2.14 FIX ; 1 POP_CL 
$THETA  60.6 FIX ; 2 POP_V 
$THETA  1.66 FIX ; 3  POP_KA 
$THETA  1 FIX ; 4 POP_BIO 
$THETA  1.45 FIX ; 5 POP_MTT 
$THETA  10.9 FIX ; 6 POP_NN number of transit compartments 
$THETA  0.106 FIX ; 7 PROPP RUV 
$THETA  0.206 FIX ; 8 ADDP RUV 
$THETA  .489 FIX ; 9 Meal = 4 on BIO - bioavailability 
$THETA  .457 FIX ; 10 Meal = 3 on bio 
$THETA  .327 FIX ; 11  Meal = 2 on bio 
$THETA  .857 FIX ; 12 Meal = 1 on bio 
;-------CL2 
$THETA  43 FIX ; 13_change_point_time 
$THETA  3.22 FIX ; 14_POP_CL 
;--metabolite 
$THETA  (0,1.810000) ; 15_CLM 
$THETA  (1,6.360000) ; 16_V3 
$THETA  (0,0.191000) ; 17 PROPM RUV 
$THETA  (0,0.211000) ; 18 ADDM RUV 
$THETA  (0,4.400000) ; 19_TVQ3 
$THETA  (0,22.10000) ; 20_TVVPM 
$THETA  (0,46.80000) ; 21_T2_CLM 
$THETA  (0,4.630000) ; 22_CLM2 
;------- 
$OMEGA  0.0367  FIX  ; 1 BETWEEN SUBJECT VARIABILITY BSVCL 
$OMEGA  0.00904  FIX  ; 2 BETWEEN SUBJECT VARIABILITY BSVMTT 
$OMEGA  0.0458  FIX  ; 3 BETWEEN SUBJECT VARIABILITY BSVBIO 
 
$OMEGA  BLOCK(1) FIX  0.015  ; 4 BOVCL OCC=1 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) FIX 0.0586  ; 9  BOV_BIO OCC =1 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) FIX  0.0839  ; 14 BOVMTT OCC=1 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  0.056900  ;  19_IIVCLM 
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$OMEGA  BLOCK(1)  0.091200  ; 4 BOVCLM OCC=1 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$SIGMA  1  FIX 
$SIGMA  1  FIX 
$ESTIMATION METHOD=1 INTER MAXEVAL=9999 PRINT=1 POSTHOC    NOABORT                                                     
MSFO=run30.msf 
$COVARIANCE  PRINT=E MATRIX=S 
$TABLE ID TIME DV DAMT PRED OCC STRT ETA19 ETA20 CL TVCLM1 TVCLM2 QM K43 K34 VPM V2 K MTT 
KTR NN BIO BOVCL BOVMTT BOVBIO  
                                                       CMT  RXBIO AGE WT HT RACE RX IPRED IRES IWRES               NOPRINT 
ONEHEADER FILE=sdtab30 
$TABLE ID TIME CL V2 K MTT NN QM K43 K34 VPM ETA19 ETA20 BIO KTR BOVCL BOVMTT BOVBIO PRED 
IPRED IRES IWRES        NOPRINT ONEHEADER FILE=patab30 
$TABLE ID TIME AGE WT HT PRED IPRED IRES IWRES                                                                     NOPRINT 
ONEHEADER FILE=cotab30 
$TABLE ID TIME RACE RX OCC PRED IPRED IRES IWRES                                                                   NOPRINT 
ONEHEADER FILE=catab30  
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Appendix  5- Moxifloxacin run records and control streams  
a) Moxifloxacin run records 
Model  Description a Commentb OFV 
Moxifloxacin in 28 patients from RIFAQUIN study 
1 One compartment, first-order absorption, 
first order elimination. IIV on CL, Vc, 
ka, F 
Base model -720 
2 Add lag time to model 1 No improvement in fit -730 
3 Use transit absorption compartment on 
model 1 instead of lag time, IIV CL, Vc, 
F, MTT, ka 
Improvement in fit -795 
4 Run 3 plus two compartment model Improvement in fit -894 
5 Run 4 plus IOV in F  IIV in V and F zeros -936 
6 Run 5  plus IOV MTT Significant improvement in 
fit, IIV in MTT zeros 
-954 
7 Run 6 plus IOV in CL No improvement if fit -958 
8 Run6 plus IOV in  Vc No improvement if fit -955 
9 Run 6 plus IOV in Vp No improvement if fit -955 
10 Run 6 plus IOV in ka Significant improvement in 
fit, IIV in had high RSE 
(120%) 
-960 
11 Run 10 plus allometric scaling scaling 
with body weight on Clearance and 
Volume  terms 
insignificant -962 
12  Run 10 plus allometric scaling scaling 
with fat-free mass on Clearance and 
Volume  terms, IIV on CL and IOV F, 
MTT, ka 
significant -966 
13 Run 10 plus allometric scaling scaling 
with fat mass on Clearance and Volume  
terms 
Significant but scaling with 
fat-free mass was better 
-964 
14 Run 12 plus rifapentine effect on CL Significant  and Final model -995 
 
Continues on next page 
Model  Description a Commentb OFV 
Moxifloxacin in 241 patients from RIFAQUIN study 
50 Run 12 structural model plus IIV in 
CL, ka, F, MTT 
The model had one occasion -1137 
52 Run 50 plus IIV in Q significant -1144 
53 Run 52 plus allometric scaling with total 
body weight  
Worse fit -1125 
54 Scaling with fat-free mass on CL, Vc, Q 
and fat mass on Q 
Improved fit -1148 
55 Run 54 plus HIV on CL insignificant -1151 
56 Run 54 plus HIV on Vc insignificant -1148 
57 Run 54 plus HIV  on Vp insignificant -1148 
58 Run 54 plus HIV on CL insignificant -1148 
59 Run 54 plus HIV on Vc insignificant -1148 
60 Run 54 plus HIV  on Vc insignificant -1148 
61 Run 54 plus HIV on F insignificant -1148 
62 Run 54 plus ARM on CL insignificant -1148 
63 Run 54 plus ARM on Vc insignificant -1148 
64 Run 54 plus ARM  on Vp insignificant -1148 
65 Run 54 plus ARM on CL insignificant -1148 
66 Run 54 plus ARM on Vc insignificant -1148 
67 Run 54 plus ARM  on F insignificant -1148 
68 Run 54 plus sex on CL insignificant -1151 
69 Run 54 plus sex on Vc insignificant -1148 
70 Run 54 plus sex  on Vp insignificant -1148 
71 Run 54 plus sex on CL insignificant -1148 
72 Run 54 plus sex on Vc insignificant -1148 
73 Run 54 plus sex  on F insignificant -1148 
74 Run 54 plus age on CL insignificant -1148 
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75 Run 54 plus age on Vc insignificant -1148 
76 Run 54 plus age on Vp insignificant -1148 
77 Run 54 plus age on CL insignificant -1148 
78 Run 54 plus age on Vc insignificant -1148 
79 Run 54 plus age  on F insignificant -1148 
80 Run 54 estimated using LAPLACE 
method 
The method was used when 
fitting data which was 
below lower limit of 
quantification 
-832 
aCL and Vc are oral clearance and apparent volume of distribution in plasma, respectively. MTT, absorption mean transit 
time; NN, number of transit compartments; F, relative bioavailability; IIV, inter-individual variability; IOV, inter-occasional 
variability; Vp, volume of distribution in peripheral compartment; Q, intercompartmental clearance. bRSE, relative standard 




b) Moxifloxacin control stream (241 Patients) 
$PROBLEM    ;FINAL M3 method 
$ABBREVIATED COMRES=2 
$INPUT      ID RFP=DROP SID DV1=DROP DVO=DROP DATE=DROP TIME 
            ATIME=DROP EVID MDV OCC SS II BLQ DAY ARM HT WT AGE HIV 
            SEX PROB_RPT PSID=DROP DV AMT PROB SPARSE   
    
$DATA       MXF20130529M3.csv IGNORE=@ IGNORE=(PROB.EQ.1) 
$SUBROUTINE ADVAN13 TOL=9 
$MODEL      NCOMPARTMENTS=4 COMP=(ABS DEFDOSE) ; Actually the dose won't go there. F1=0 
            COMP=(CENTRAL DEFOBSERVATION) COMP=(PERI) COMP=(AUC) 
$PK 
IF(SEX.EQ.0) THEN    ;females in my dataset 
WHSMAX = 37.99 
WHS50  = 35.98 
  ELSE  ;            ;males in my dataset 
WHSMAX = 42.98 












IF(OCC.EQ.1) OC1 =1 
IF(OCC.EQ.2) OC2 =1 
IOVF   = OC1*(ETA(7))  + OC2*(ETA(8)) 
IOVMTT = OC1*(ETA(9))  + OC2*(ETA(10)) 








 TVCL   = THETA(1) *(FFMC**0.75)     
  CL    = TVCL*EXP(BSVCL) 
   
 TVV2   = THETA(2) *FFMC    ;volume of the central compartment     
 V2     = TVV2*EXP(BSVV2)                  
  
 TVKA   = THETA(3)         
 KA     = TVKA*EXP(IOVKA+ETA(3))  
  
TVV3   = THETA(4) *FATV3 ;FFMC                  ;4_V3 
V3     = TVV3*EXP(BSVV3) 
 
TVQ   = THETA(5) *(FFMC**0.75)             ;5_Q 
Q     = TVQ*EXP(BSVQ) 
  
TVMTT = THETA(8) 
  MTT = TVMTT*EXP(IOVMTT+ETA(5)) 
   
TVNN  = THETA(9) 
  NN  = TVNN 
  
 S2   = V2 
 K    = CL/V2 
 K2T3 = Q/V2 
 K3T2 = Q/V3 





TVBIO =THETA(10)  
BIO  =TVBIO*EXP(IOVF+ETA(6))  
 
LNGAM = NN*LOG(NN)-NN+LOG(NN*(1+4*NN*(1+2*NN)))/6+0.572364942  
 
IF (NEWIND.NE.2.OR.EVID.GE.3) THEN  
 TNXD=TIME  












    
   IF(NEWIND.LE.1.OR.EVID.GE.3) THEN  
      COM(1)=-1 ; holder of Cmax  
      COM(2)=-1 ; holder of Tmax  





TEMPO=T-TDOS ; this is time after dose, it should always be >= 0 
 





DADT(2) = KA*A(1)-K*A(2) - K2T3*A(2) + K3T2*A(3) 




;------CMAX AND TMAX 
   CT=A(2)/S2 ; (or other expression for concentration)  
   IF(CT.GT.COM(1)) THEN  
         COM(1)=CT  
         COM(2)=T  
   ENDIF  
    
    
;-------AUC 0-50 





















;-------M3 METHOD FOR BLQ DATA--------------  
 
LOQ    = 0.063           ;  
DUM    = (LOQ - IPRED) / W 
CUMD   = PHI(DUM) 
 
; TREAT DV AS AN OBSERVATION BY DEFAULT 
Y = IPRED + W*EPS(1) 
; !!! CAREFUL TO IGNORE BLQ==-1 WHICH ARE SUSPICIOUS SAMPLES !!! 
 
;Sim_start 
IF (BLQ>0) THEN           ; TREAT DV AS A LIKELIHOOD 
 F_FLAG = 1 
 Y = CUMD 
ENDIF 
;IF (ICALL==4.AND.Y.LE.0.0315) THEN  






AUC50 = A(4) 
AUCINF= BIO*AMT/CL 
CMAX = COM(1)  
TMAX = COM(2)  
 
$THETA  (0,10.6) ; 1_CL 
$THETA  (0,114) ; 2_V 
$THETA  (0,1.5) ; 3_KA 
$THETA  (0,89.8) ; 4_V3 
$THETA  (0,2.14) ; 5_Q 
$THETA  (0,0.0785) ; 6_PROP 
$THETA  0 FIX ; 7_ADD 
$THETA  (0,0.723) ; 8_MTT 
$THETA  (0,11.6) ; 9_NN 
$THETA  1 FIX ; 10_TVBIO 
$OMEGA  0.0351  ;    1_IIVCL 
$OMEGA  0  FIX  ;     2_IIVV 
$OMEGA  0  FIX  ;    3_IIVKA 
$OMEGA  0  FIX  ;    4_IIVV3 
$OMEGA  0  FIX  ;   5_IIVMTT 
$OMEGA  0  FIX  ;   6_IIVBIO 
$OMEGA  BLOCK(1) 
 0.0314  ;     7_IOVF 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) 
 0.539  ;   9_IOVMTT 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) 
 0.489  ;   11_IOVKA 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  0.108  ;   13 BSV Q 
$SIGMA  1  FIX 
;Sim_start 
$ESTIMATION MAXEVAL=9999 PRINT=1 SIGDIG=3 SIGL=8 POSTHOC METHOD=1 
            ATOL=4 INTER LAPLACE NUMERICAL SLOW NOABORT 
            MSFO=run145.msf 
$COVARIANCE PRINT=E MATRIX=S ATOL=4 
;$SIMULATION (12345) ONLYSIMULATION 
$TABLE      ID TIME DV AUCINF AUC50 CMAX TMAX FAT TAD OCC ARM WT HT 
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            FFM MTT NN CL V2 KA Q V3 BSVCL BSVV2 BSVQ BSVV3 IOVF W 
            IOVMTT IOVKA WT CWRES NPDE PRED IPRED PREDI RESI WRESI 
            IPRED IWRES NOPRINT ONEHEADER FILE=sdtab145 
$TABLE      ID TIME TAD OCC CL V2 KA Q V3 MTT NN BSVCL BSVV2 BSVQ 
            BSVV3 IOVF IOVKA IOVMTT PRED CWRES NPDE IPRED PREDI RESI 
            WRESI NOPRINT ONEHEADER FILE=patab145 
$TABLE      ID FAT HT WT FFM AGE NOPRINT ONEHEADER FILE=cotab145 
$TABLE      ID ARM SEX HIV SID NOPRINT ONEHEADER FILE=catab145 
$TABLE      ID TIME DV W AUCINF AUC50 CMAX FAT FFM TMAX OCC WT TAD 
            IOVF IOVMTT IOVKA ARM HT CL V2 KA Q V3 MTT NN BSVCL BSVV2 
            BSVQ BSVV3 CWRES PRED IPRED PREDI RESI WRESI NOPRINT 
            ONEHEADER FILE=mytab145 
; $TABLE FILE=simtab144 ID OCC TIME DV AMT MDV EVID IPRED PRED IWRES WRES CWRES NPDE  
; CL V2 KA MTT NN BIO Q V3 BSVBIO BSVCL BSVV BSVQ BSVV3  




c) Moxifloxacin control stream (28 Patients) 
$PROBLEM   ;Moxifloxacin 28 patients  
$INPUT      ID AMT TIM=DROP TIME PTIM=DROP DV MDV ARM OCC WT AGE 
            HT HIV  SEX EVID PRB SS=DROP II=DROP RFP GRP FFM  
$DATA       MOXI_02062011.csv IGNORE=@ 





$SUBROUTINE ADVAN13 TOL=9 
$MODEL      NCOMPARTMENTS=4  
                     COMP=(ABS DEFDOSE) ; Actually the dose won't go there. F1=0 
                     COMP=(CENTRAL DEFOBSERVATION)  
          COMP=(PERI) 
                     COMP=(AUC) 
 
$PK 
IF(RFP.EQ.1) CLRFP = 1  ; presence of rifapentine  






IF(OCC.EQ.1) OC1 =1 
IF(OCC.EQ.2) OC2 =1 
IOVF   = OC1*(ETA(4))  + OC2*(ETA(5)) 
IOVMTT = OC1*(ETA(6))  + OC2*(ETA(7)) 
IOVKA  = OC1*(ETA(8)) + OC2*(ETA(9)) 
 
 
 TVCL   = THETA(1)*((FFM/44.784)**0.75)     
TVCL = CLCOV*TVCL 
  CL    = TVCL*EXP(ETA(1)) 
 
 TVV2   = THETA(2)*(FFM/44.784)         
 V2     = TVV2*EXP(ETA(2))                  
  
 TVKA   = THETA(3)         
 KA     = TVKA*EXP(IOVKA)  
  
TVV3   = THETA(4)*(FFM/44.784)                  ;4_V3 
 
TVV3 = V3COV*TVV3 
V3     = TVV3*EXP(ETA(3)) 
 
TVQ   = THETA(5)*((FFM/44.784)**0.75)             ;5_Q 
Q     = TVQ 
  
TVMTT = THETA(8) 
  MTT = TVMTT*EXP(IOVMTT) 
   
TVNN  = THETA(9) 
  NN  = TVNN 
  
 S2   = V2 
 K    = CL/V2 
 K2T3 = Q/V2 
 K3T2 = Q/V3 
 KTR  = (NN+1)/MTT 
  
F1=0  
TVBIO =THETA(10)  
 
TVBIO = BIOCOV*TVBIO 
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BIO  =TVBIO*EXP(IOVF)  
 
LNGAM = NN*LOG(NN)-NN+LOG(NN*(1+4*NN*(1+2*NN)))/6+0.572364942  
 
IF (NEWIND.NE.2.OR.EVID.GE.3) THEN  
 TNXD=TIME  










PIZZA=LOG(BIO*PD*KTR+0.00000001)-LNGAM    
   IF(NEWIND.LE.1.OR.EVID.GE.3) THEN  
      COM(1)=-1 ; holder of Cmax  
      COM(2)=-1 ; holder of Tmax  











DADT(2) = KA*A(1)-K*A(2) - K2T3*A(2) + K3T2*A(3) 




;------CMAX AND TMAX 
   CT=A(2)/S2 ; (or other expression for concentration)  
   IF(CT.GT.COM(1)) THEN  
         COM(1)=CT  
         COM(2)=T  
   ENDIF    
    
;-------AUC 0-50 











Y = IPRED + W*EPS(1) 
IF(ICALL.EQ.4.AND.Y.LT.0.04) Y=0.04 
 
AUC50 = A(4) 
AUCINF= BIO*AMT/CL 
CMAX = COM(1)  
TMAX = COM(2)  
 
$THETA  (0,10.6449) ; 1_CL 
$THETA  (0,114.162) ; 2_V 
$THETA  (0,1.85084) ; 3_KA 
$THETA  (0,41.5755) ; 4_V3 
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$THETA  (0,2.89708) ; 5_Q 
$THETA  (0,0.0894374) ; 6_PROP 
$THETA  (0,0.0189204) ; 7_ADD 
$THETA  (0,0.482942) ; 8_MTT 
$THETA  (0,22.4926) ; 9_NN 
$THETA  1 FIX ; 10_TVBIO 
$THETA  (-1,-0.0802717,5) ;11CLRFP1 
 
$OMEGA  0.0158083  ;    1_IIVCL 
$OMEGA  0  FIX  ;     2_IIVV 
$OMEGA  0  FIX  ;    3_IIVV3 
 
$OMEGA  BLOCK(1)  0.0306359  
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 0.495098  
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 0.557799   
$OMEGA  BLOCK(1) SAME 
 
$SIGMA  1  FIX 
$ESTIMATION MAXEVAL=9999 PRINT=1 SIGDIG=3 SIGL=9 POSTHOC METH=COND  INTER NOABORT 
MSFO=run69.msf 
$COVARIANCE PRINT=E MATRIX=S 
$TABLE  ID TIME DV AUCINF AUC50 CMAX TMAX  OCC SEX ARM AGE HIV WT HT MTT NN CL V2 KA Q V3 
ETA1 ETA2 ETA3 IOVF W IOVMTT IOVKA  WT HIV CWRES NPDE  PRED IPRED PREDI RESI WRESI IPRED 
IWRES   NOPRINT ONEHEADER FILE=sdtab69 
$TABLE  ID TIME CL V2 KA Q V3 MTT NN ETA1 ETA2 ETA3  IOVF  IOVMTT IOVKA PRED CWRES NPDE 
IPRED PREDI RESI WRESI           NOPRINT ONEHEADER FILE=patab69 
$TABLE  ID TIME PRED WT AGE HT  NOPRINT ONEHEADER FILE=cotab69 
$TABLE  ID TIME PRED HIV SEX ARM     NOPRINT ONEHEADER FILE=catab69 
$TABLE  ID TIME DV W RFP AUCINF AUC50 CMAX TMAX OCC HIV SEX WT IOVF IOVMTT IOVKA ARM  
AGE HT CL V2 KA Q V3 MTT NN ETA1 ETA2 ETA3  CWRES PRED IPRED PREDI RESI WRESI NOPRINT 
ONEHEADER FILE=mytab69.tab69  
203 
 
Appendix  6- Rifapentine run records and control streams (RIFAQUIN study) 
 
a) Rifapentine run records 
Model  Description a Commentb OFV 
Rifapentine 
1 Run 16  from Health volunteer study only 
IIV in CL, Vc, ka, MTT,  
 3855 
2 Run 1 plus covariance on  CL and Vc  3847 
3 Two compartment model Estimate of V3 has 120% 
RSE 
3845 
4 run 2 plus allometric scaling with body 
weight 
 3807 
5 run 2 plus allometric scaling with fat-free 
mass 
 3810 
SCM Run 4 was used for SCM run   
540 IIV on  CL, Vc, ka, MTT plus effect of 
HIV on F, and significant covariates on 
CL were regimen an Sex effects 
HIV positive patients had 
lower F, females had lower 
CL than males, and patients 




b) Rifapentine SCM log file. 
Model directory /home/simba/RFPUCSF/scm_dir1/m1 
 
MODEL            TEST     BASE OFV     NEW OFV         TEST OFV (DROP)    GOAL     dDF    SIGNIFICANT PVAL 
BIOAGE-2         PVAL   3807.32200  3805.93600              1.38600  >   3.84150    1              0.239080  
BIOARM-2         PVAL   3807.32200  3806.87900              0.44300  >   3.84150    1              0.505680  
BIOHIV-2         PVAL   3807.32200  3753.58800             53.73400  >   3.84150    1        YES!  2.30e-13  
BIOSEX-2         PVAL   3807.32200  3807.05100              0.27100  >   3.84150    1              0.602660  
CLAGE-2          PVAL   3807.32200  3807.25400              0.06800  >   3.84150    1              0.794270  
CLARM-2          PVAL   3807.32200  3798.04200              9.28000  >   3.84150    1        YES!  0.002317  
CLHIV-2          PVAL   3807.32200  3796.03200             11.29000  >   3.84150    1        YES!  0.000779  
CLSEX-2          PVAL   3807.32200  3792.79100             14.53100  >   3.84150    1        YES!  0.000138  
KAAGE-2          PVAL   3807.32200  3803.48700              3.83500  >   3.84150    1              0.050193  
KAARM-2          PVAL   3807.32200  3807.26500              0.05700  >   3.84150    1              0.811300  
KAHIV-2          PVAL   3807.32200  3795.02800             12.29400  >   3.84150    1        YES!  0.000454  
KASEX-2          PVAL   3807.32200  3800.85000              6.47200  >   3.84150    1        YES!  0.010959  
MTTAGE-2         PVAL   3807.32200  3801.93800              5.38400  >   3.84150    1        YES!  0.020322  
MTTARM-2         PVAL   3807.32200  3803.15900              4.16300  >   3.84150    1        YES!  0.041316  
MTTHIV-2         PVAL   3807.32200  3806.09800              1.22400  >   3.84150    1              0.268580  
MTTSEX-2         PVAL   3807.32200  3804.65800              2.66400  >   3.84150    1              0.102640  
V2AGE-2          PVAL   3807.32200  3805.57900              1.74300  >   3.84150    1              0.186760  
V2ARM-2          PVAL   3807.32200  3803.26100              4.06100  >   3.84150    1        YES!  0.043885  
V2HIV-2          PVAL   3807.32200  3791.62400             15.69800  >   3.84150    1        YES!  0.000074  
V2SEX-2          PVAL   3807.32200  3799.38200              7.94000  >   3.84150    1        YES!  0.004835  
 
Parameter-covariate relation chosen in this forward step: BIO-HIV-2 
CRITERION              PVAL < 0.05 
BASE_MODEL_OFV        3807.32200 
CHOSEN_MODEL_OFV      3753.58800 
Relations included after this step: 
BIO     HIV-2    
CL       
KA       
MTT      
V2       
-------------------- 
 
Model directory /home/simba/RFPUCSF/scm_dir1/forward_scm_dir1/m1 
 
MODEL            TEST     BASE OFV     NEW OFV         TEST OFV (DROP)    GOAL     dDF    SIGNIFICANT PVAL 
BIOAGE-2         PVAL   3753.58800  3751.26100              2.32700  >   3.84150    1              0.127150  
BIOARM-2         PVAL   3753.58800  3753.38600              0.20200  >   3.84150    1              0.653110  
BIOSEX-2         PVAL   3753.58800  3750.54200              3.04600  >   3.84150    1              0.080936  
CLAGE-2          PVAL   3753.58800  3753.60800             -0.02000  >   3.84150    1                   
9999 
CLARM-2          PVAL   3753.58800  3747.30300              6.28500  >   3.84150    1        YES!  0.012176  
CLHIV-2          PVAL   3753.58800  3753.28100              0.30700  >   3.84150    1              0.579530  
CLSEX-2          PVAL   3753.58800  3735.40800             18.18000  >   3.84150    1        YES!  0.000020  
KAAGE-2          PVAL   3753.58800  3749.35300              4.23500  >   3.84150    1        YES!  0.039599  
KAARM-2          PVAL   3753.58800  3753.58200              0.00600  >   3.84150    1              0.938260  
KAHIV-2          PVAL   3753.58800  3752.63200              0.95600  >   3.84150    1              0.328200  
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KASEX-2          PVAL   3753.58800  3748.93500              4.65300  >   3.84150    1        YES!  0.030999  
MTTAGE-2         PVAL   3753.58800  3748.09100              5.49700  >   3.84150    1        YES!  0.019049  
MTTARM-2         PVAL   3753.58800  3749.47400              4.11400  >   3.84150    1        YES!  0.042530  
MTTHIV-2         PVAL   3753.58800  3752.37300              1.21500  >   3.84150    1              0.270340  
MTTSEX-2         PVAL   3753.58800  3750.65600              2.93200  >   3.84150    1              0.086840  
V2AGE-2          PVAL   3753.58800  3751.04500              2.54300  >   3.84150    1              0.110780  
V2ARM-2          PVAL   3753.58800  3746.69300              6.89500  >   3.84150    1        YES!  0.008644  
V2HIV-2          PVAL   3753.58800  3753.26900              0.31900  >   3.84150    1              0.572210  
V2SEX-2          PVAL   3753.58800  3749.79600              3.79200  >   3.84150    1              0.051498  
 
Parameter-covariate relation chosen in this forward step: CL-SEX-2 
CRITERION              PVAL < 0.05 
BASE_MODEL_OFV        3753.58800 
CHOSEN_MODEL_OFV      3735.40800 
Relations included after this step: 
BIO     HIV-2    
CL      SEX-2    
KA       
MTT      
V2       
-------------------- 
 
Model directory /home/simba/RFPUCSF/scm_dir1/forward_scm_dir1/scm_dir1/m1 
 
MODEL            TEST     BASE OFV     NEW OFV         TEST OFV (DROP)    GOAL     dDF    SIGNIFICANT PVAL 
BIOAGE-2         PVAL   3735.40800  3732.58200              2.82600  >   3.84150    1              0.092749  
BIOARM-2         PVAL   3735.40800  3735.26800              0.14000  >   3.84150    1              0.708280  
BIOSEX-2         PVAL   3735.40800  3735.32600              0.08200  >   3.84150    1              0.774600  
CLAGE-2          PVAL   3735.40800  3735.34900              0.05900  >   3.84150    1              0.808080  
CLARM-2          PVAL   3735.40800  3726.97500              8.43300  >   3.84150    1        YES!  0.003685  
CLHIV-2          PVAL   3735.40800  3734.13700              1.27100  >   3.84150    1              0.259580  
KAAGE-2          PVAL   3735.40800  3731.23400              4.17400  >   3.84150    1        YES!  0.041049  
KAARM-2          PVAL   3735.40800  3735.41800             -0.01000  >   3.84150    1                   
9999 
KAHIV-2          PVAL   3735.40800  3734.74900              0.65900  >   3.84150    1              0.416910  
KASEX-2          PVAL   3735.40800  3733.53700              1.87100  >   3.84150    1              0.171360  
MTTAGE-2         PVAL   3735.40800  3729.78300              5.62500  >   3.84150    1        YES!  0.017706  
MTTARM-2         PVAL   3735.40800  3731.36500              4.04300  >   3.84150    1        YES!  0.044355  
MTTHIV-2         PVAL   3735.40800  3734.14900              1.25900  >   3.84150    1              0.261840  
MTTSEX-2         PVAL   3735.40800  3732.61100              2.79700  >   3.84150    1              0.094441  
V2AGE-2          PVAL   3735.40800  3732.91400              2.49400  >   3.84150    1              0.114280  
V2ARM-2          PVAL   3735.40800  3727.58800              7.82000  >   3.84150    1        YES!  0.005167  
V2HIV-2          PVAL   3735.40800  3734.11500              1.29300  >   3.84150    1              0.255500  
V2SEX-2          PVAL   3735.40800  3735.36300              0.04500  >   3.84150    1              0.832000  
 
Parameter-covariate relation chosen in this forward step: CL-ARM-2 
CRITERION              PVAL < 0.05 
BASE_MODEL_OFV        3735.40800 
CHOSEN_MODEL_OFV      3726.97500 
Relations included after this step: 
BIO     HIV-2    
CL      ARM-2   SEX-2    
KA       
MTT      
V2       
-------------------- 
 
Model directory /home/simba/RFPUCSF/scm_dir1/forward_scm_dir1/scm_dir1/scm_dir1/m1 
 
MODEL            TEST     BASE OFV     NEW OFV         TEST OFV (DROP)    GOAL     dDF    SIGNIFICANT PVAL 
BIOAGE-2         PVAL   3726.97500  3724.75000              2.22500  >   3.84150    1              0.135790  
BIOARM-2         PVAL   3726.97500  3724.48900              2.48600  >   3.84150    1              0.114860  
BIOSEX-2         PVAL   3726.97500  3726.97700             -0.00200  >   3.84150    1                   
9999 
CLAGE-2          PVAL   3726.97500  3726.88600              0.08900  >   3.84150    1              0.765450  
CLHIV-2          PVAL   3726.97500  3726.50000              0.47500  >   3.84150    1              0.490700  
KAAGE-2          PVAL   3726.97500  3722.68500              4.29000  >   3.84150    1        YES!  0.038337  
KAARM-2          PVAL   3726.97500  3726.70200              0.27300  >   3.84150    1              0.601330  
KAHIV-2          PVAL   3726.97500  3726.18000              0.79500  >   3.84150    1              0.372590  
KASEX-2          PVAL   3726.97500  3725.18800              1.78700  >   3.84150    1              0.181290  
MTTAGE-2         PVAL   3726.97500  3721.51000              5.46500  >   3.84150    1        YES!  0.019401  
MTTARM-2         PVAL   3726.97500  3722.67700              4.29800  >   3.84150    1        YES!  0.038157  
MTTHIV-2         PVAL   3726.97500  3725.78600              1.18900  >   3.84150    1              0.275530  
MTTSEX-2         PVAL   3726.97500  3724.29200              2.68300  >   3.84150    1              0.101420  
V2AGE-2          PVAL   3726.97500  3724.08600              2.88900  >   3.84150    1              0.089186  
V2ARM-2          PVAL   3726.97500  3724.48100              2.49400  >   3.84150    1              0.114280  
V2HIV-2          PVAL   3726.97500  3726.49700              0.47800  >   3.84150    1              0.489330  
V2SEX-2          PVAL   3726.97500  3726.96900              0.00600  >   3.84150    1              0.938260  
 
Parameter-covariate relation chosen in this forward step: MTT-AGE-2 
CRITERION              PVAL < 0.05 
BASE_MODEL_OFV        3726.97500 
CHOSEN_MODEL_OFV      3721.51000 
Relations included after this step: 
BIO     HIV-2    
CL      ARM-2   SEX-2    
KA       
MTT     AGE-2    
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V2       
-------------------- 
 
Model directory /home/simba/RFPUCSF/scm_dir1/forward_scm_dir1/scm_dir1/scm_dir1/scm_dir1/m1 
 
MODEL            TEST     BASE OFV     NEW OFV         TEST OFV (DROP)    GOAL     dDF    SIGNIFICANT PVAL 
BIOAGE-2         PVAL   3721.51000  3719.25400              2.25600  >   3.84150    1              0.133100  
BIOARM-2         PVAL   3721.51000  3718.97400              2.53600  >   3.84150    1              0.111280  
BIOSEX-2         PVAL   3721.51000  3721.62000             -0.11000  >   3.84150    1                   
9999 
CLAGE-2          PVAL   3721.51000  3721.37000              0.14000  >   3.84150    1              0.708280  
CLHIV-2          PVAL   3721.51000  3720.98800              0.52200  >   3.84150    1              0.469990  
KAAGE-2          PVAL   3721.51000  3720.40000              1.11000  >   3.84150    1              0.292080  
KAARM-2          PVAL   3721.51000  3721.31300              0.19700  >   3.84150    1              0.657150  
KAHIV-2          PVAL   3721.51000  3720.56100              0.94900  >   3.84150    1              0.329970  
KASEX-2          PVAL   3721.51000  3719.68500              1.82500  >   3.84150    1              0.176720  
MTTAGE-3         PVAL   3721.51000  3717.70700              3.80300  >   3.84150    1              0.051161  
MTTARM-2         PVAL   3721.51000  3717.78500              3.72500  >   3.84150    1              0.053604  
MTTHIV-2         PVAL   3721.51000  3719.98500              1.52500  >   3.84150    1              0.216860  
MTTSEX-2         PVAL   3721.51000  3719.13400              2.37600  >   3.84150    1              0.123210  
V2AGE-2          PVAL   3721.51000  3718.98900              2.52100  >   3.84150    1              0.112340  
V2ARM-2          PVAL   3721.51000  3718.92600              2.58400  >   3.84150    1              0.107950  
V2HIV-2          PVAL   3721.51000  3721.00700              0.50300  >   3.84150    1              0.478190  
V2SEX-2          PVAL   3721.51000  3721.46400              0.04600  >   3.84150    1              0.830180  
 
Parameter-covariate relation chosen in this forward step: -- 
CRITERION              PVAL < 0.05 
-------------------- 
-------------------- 
Forward search done. Starting backward search inside forward top level directory 
Model directory /home/simba/RFPUCSF/scm_dir1/backward_scm_dir1/m1 
 
MODEL            TEST     BASE OFV     NEW OFV         TEST OFV (DROP)    GOAL     dDF  INSIGNIFICANT PVAL 
BIOHIV-1         PVAL   3721.51000  3775.95200            -54.44200  >  -6.63490   -1              1.60e-13  
CLARM-1          PVAL   3721.51000  3729.70700             -8.19700  >  -6.63490   -1              0.004196  
CLSEX-1          PVAL   3721.51000  3741.56700            -20.05700  >  -6.63490   -1              0.000008  
MTTAGE-1         PVAL   3721.51000  3727.04800             -5.53800  >  -6.63490   -1        YES!  0.018608  
 
Parameter-covariate relation chosen in this backward step: MTT-AGE-1 
CRITERION              PVAL > 0.01 
BASE_MODEL_OFV        3721.51000 
CHOSEN_MODEL_OFV      3727.04800 
Relations included after this step: 
BIO     HIV-2    
CL      ARM-2   SEX-2    
KA       
V2       
-------------------- 
 
Model directory /home/simba/RFPUCSF/scm_dir1/backward_scm_dir1/scm_dir1/m1 
 
MODEL            TEST     BASE OFV     NEW OFV         TEST OFV (DROP)    GOAL     dDF  INSIGNIFICANT PVAL 
BIOHIV-1         PVAL   3727.04800  3781.25800            -54.21000  >  -6.63490   -1              1.80e-13  
CLARM-1          PVAL   3727.04800  3735.39100             -8.34300  >  -6.63490   -1              0.003872  
CLSEX-1          PVAL   3727.04800  3747.14100            -20.09300  >  -6.63490   -1              0.000007  
 
Parameter-covariate relation chosen in this backward step: -- 
 
c) Rifapentine Control stream (RIFAQUIN study) 
$PROBLEM   ;RIFAPENTINE 
 
$ABBREVIATED COMRES=2 
$INPUT      ID AMT SID DV DVO=DROP DATE=DROP TIME ATIM=DROP EVID  
            MDV OCC SS=DROP II=DROP BQL DAY=DROP ARM HT WT AGE HIV
 SEX PROB  
   PSID=DROP MXF=DROP DOSM=DROP PROB_MXF=DROP
 SPARSE 
$DATA       20131003RFP.csv IGNORE=# 
$DATA       IGNORE=(PROB.EQ.1) 
$SUBROUTINE ADVAN13 TOL=9 
$MODEL      NCOMPARTMENTS=4 COMP=(ABS DEFDOSE) 
                                    COMP=(CENTRAL DEFOBSERVATION) 
   COMP=(TBMIC) 




IF(SEX.EQ.1) CLSEX = 1  ; Males 
IF(SEX.EQ.0) CLSEX = ( 1 + THETA(11)) 
IF(ARM.EQ.6) CLARM = 1  ; Most common 
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IF(HIV.EQ.0) BIOHIV = 1  ; Most common 
IF(HIV.EQ.1) BIOHIV = ( 1 + THETA(9)) 
 
BIOCOV=BIOHIV 
   
     
TVCL    = THETA(1)*((WT/55.2)**0.75)     
 
TVCL = CLCOV*TVCL 
CL      = TVCL*EXP(ETA(1)) 
 
TVV2   = THETA(2)*(WT/55.2)             
 V2     = TVV2*EXP(ETA(2))                  
  
TVKA   = THETA(3)         
 KA     = TVKA*EXP(ETA(3))   
  
TVMTT = THETA(4) 
  MTT = TVMTT*EXP(ETA(4))  
   
F1=0 ; 
TVBIO = THETA(5)  
 
TVBIO = BIOCOV*TVBIO 
BIO   = TVBIO*EXP(ETA(5))   
 
TVNN  = THETA(6) 
  NN  = TVNN 
  
 S2   = V2 
 K    = CL/V2 
 KTR  = (NN+1)/MTT 
  
 
LNGAM = NN*LOG(NN)-NN+LOG(NN*(1+4*NN*(1+2*NN)))/6+0.572364942  
 
IF (NEWIND.NE.2.OR.EVID.GE.3) THEN  
 TNXD=TIME  













IF(NEWIND.LE.1.OR.EVID.GE.3) THEN  
      COM(1)=-1 ; holder of Cmax  
      COM(2)=-1 ; holder of Tmax  













DADT(2) = KA*A(1)-K*A(2) 
 
   CT=A(2)/S2 ; (or other expression for concentration)  
   IF(CT.GT.COM(1)) THEN  
         COM(1)=CT  
         COM(2)=T  
   ENDIF       
 
   MIC=6 ; MIC adjusted for protein binding 
   BMIC=0  
   AMIC=0 
   IF(CT.LT.MIC) BMIC=1 
   IF(CT.GE.MIC) AMIC=1 
   DADT(3)=BMIC ; time below threshold  
   DADT(4)=AMIC ;cumulative time above MIC  











IF(BQL.EQ.0) THEN  















AUC    = BIO*AMT/CL 
CMAX   = COM(1)  
TMAX   = COM(2)  
TBMIC  =A(3)  ;cumulative time below MIC 
TAMIC  =A(4)  ;cumulative above below MIC 
AUCMIC =A(3)*A(2)/S2 
 
$THETA  (0,1.07616) ; 1 POP_CL 
$THETA  (0,24.4966) ; 2 POP_V 
$THETA  (0,0.8851) ; 3  POP_KA 
$THETA  (0,1.45013) ; 4 POP_MTT 
$THETA  1 FIX ; 4 POP_BIO 
$THETA  (0,8.41091) ; 6 POP_NN number of transit compartments 
$THETA  (0,0.107836) ; 7 PROPP RUV 
$THETA  (0,0.462632) ; 8 ADDP RUV 
$THETA  (-1,-0.276084,5) ; BIOHIV1 
$THETA  (-1,0.103575,5) ; CLARM1 
$THETA  (-1,-0.151606,5) ; CLSEX1 
 
$OMEGA  BLOCK(2) 
 0.0818678  ;     1BSVCL 
 0.0403007 0.0551038  ;      2BSVV 
$OMEGA  0.192439  ;     3BSVKA 
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$OMEGA  0.14761  ;    4BSVMTT 
$OMEGA  0  FIX  ;    5BSVBIO 
 
$OMEGA  BLOCK(1) FIX 
 0  ;     6_IOVF 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) FIX 
 0  ;   8_IOVMTT 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) FIX 
 0  ;   10_IOVKA 
$OMEGA  BLOCK(1) SAME 
 
$SIGMA  1  FIX 
$ESTIMATION MAXEVAL=9999 PRINT=1 SIGDIG=3 SIGL=9 POSTHOC METH=COND 
 ATOL=4 INTER NOABORT                                                                                                                          
MSFO=run540.msf 
$COVARIANCE PRINT=E MATRIX=S ATOL=4 
$TABLE  ID TIME DV CL V2 KA MTT NN BIO ETA1 ETA2 ETA4 ETA5 ETA5 TAD SID TMAX CMAX TBMIC 
TAMIC AUCMIC AUC   
CWRES NPDE  PRED IPRED PREDI RESI WRESI IPRED IWRES                                                                   NOPRINT 
ONEHEADER FILE=sdtab540 
$TABLE  ID TIME CL V2 KA MTT NN TAD BIO ETA1 ETA2 ETA3 ETA4 ETA5 ETA5 PRED CWRES NPDE IPRED 
PREDI RESI WRESI          NOPRINT ONEHEADER FILE=patab540 
$TABLE  ID TIME PRED WT  HT AGE                                                                                       NOPRINT ONEHEADER 
FILE=cotab540 
$TABLE  ID TIME PRED ARM HIV SEX                                                                                      NOPRINT ONEHEADER 
FILE=catab540 
$TABLE  ID TIME DV CL V2 KA MTT NN TAD TMAX CMAX TBMIC TAMIC AUCMIC AUC SID BIO  
AGE HIV SEX  ETA1 ETA2 ETA3 ETA4 ETA5 ETA5 WT ARM HT CWRES PRED IPRED PREDI RESI WRESI                                   
NOPRINT ONEHEADER FILE=mytab540  
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Appendix  7- Parametric hazard modeling   
a) Control stream of final model 
$PROB Time To Event data ; TIME VARYING HAZARD SAME 
 
$INPUT ID CAV SEX WEIGHT RACE=DROP CD4=DROP SMOKED SMOKER MITT_STATUS TTE_MITT
 PP_STATUS TTE_PP TMAXRFP=DROP CMAXRFP AUCRFP CMAXMX TMAXMX AUCMX 
CMAXWTMXF TMAXWTMXF=DROP AUCWTMX AUCMICMX1=DROP AUCMICMX2=DROPAUCMICRFP 
CMAXMICMX1=DROP CMAXMICMX2=DROP CMAXMICRFP AUCMICWTMX1 AUCMICWTMX2 
CMAXMICWTMX1 CMAXMICWTMX2 IDENTIFIER HIV SITE ARM AUCRFP_WT CMAXRFP_WT 
AUCMXF_WT CMAXMXF_WT  TIME MARKER1 DVONE MARKER2 DV AGE  EVID
 MARKER TOTAL_AUCRFP RFP_AUCMIC CMAXRFP_MIC TAMIC_RFP MXFAUCT 
MXFAUC_MIC CMAXMXF_MIC TAMICMXF 
 
 
$DATA TWO_ARMS.csv  IGNORE=@  ACCEPT=(TIME==0)  ACEPT=(MARKER1==1) 
 





IF(ARM.EQ.2) COVDUR = 1  ; Males 
IF(ARM.EQ.1) COVDUR = ( 1 + THETA(3)) 
 
IF(NEWIND.NE.2) TP=0 
  TVLAM = THETA(1)*COVDUR 
  TVSHP = THETA(2) ; shape (FIXED TO 1) 
 
  LAM=TVLAM*EXP(ETA(1))  ;the ETA is a placeholder here 
  SHP=TVSHP 
   
$DES 
  DEL=1E-6 




  IF(NEWIND.NE.2) OLDCHZ=0  ;reset the cumulative hazard 
  CHZ = A(1)-OLDCHZ         ;cumulative hazard  
                            ;from previous time point 
                            ;in data set 
  OLDCHZ = A(1)             ;rename old cumulative hazard 
  SUR = EXP(-CHZ)           ;survival probability 
  DELX = 1E-6 
  HAZNOW=LAM*SHP*(TIME-TP+DELX)**(SHP-1) 
                            ;rate of event 
                            ;NB: update with each new model 
 
  IF(DV.EQ.0)   Y=SUR   ;censored event (prob of survival) 
  IF(DV.NE.0)   Y=SUR*HAZNOW  ;prob of event at time=TIME 
 
 
$THETA  (0,0.000102896) ; 1.BASE 
$THETA  1 FIX ; 2.ALPHA 
$THETA  (0,1.87119) ; 3.COVDUR 
$OMEGA  0  FIX 
$ESTIM MAXEVAL=9990 METHOD=0 LIKE PRINT=1 NOABORT MSFO=msfb34 
$COV PRINT=E 
 
$TABLE ID TIME EVID SUR NOPRINT ONEHEADER FILE=sdtab34 
$TABLE ID NOPRINT ONEHEADER FILE=patab34 
$TABLE ID    NOPRINT ONEHEADER FILE=cotab34 
$TABLE ID CAV SEX HIV SMOKED SMOKER ARM  SITE PP_STATUS  NOPRINT ONEHEADER 
FILE=catab34 
 
___________________________END OF THESIS__________________________ 
